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Figure 1.1: The life cycle of Streptomyces coelicolor A3(2). Spore germination results in 
the formation of germ tubes, which extend and branch to produce the substrate mycelium. 
Hyphae subsequently grow into the air to generate the aerial mycelium, which develops 
and matures into long chains of spores. Spores are then released to start a new cycle.  
Figure 1.2: Selected bioactive compounds produced by Streptomyces, including 
antibacterials (1-3), insecticides (4), herbicides (5), anticancer agents (6), 
immunosuppressants (7) and antifungals (8) 
Figure 1.3: Streptomyces coelicolor specialised metabolites, discovered prior to the 
availability of the genome sequence through a classical bioassay-guided approach  
Figure 1.4: Selected Streptomyces coelicolor specialised metabolites, discovered through 
a genomics-driven approach 
Figure 1.5: The organisation of the 59 kb-long cpk gene cluster directing coelimycin 
biosynthesis in Streptomyces coelicolor M145. The proposed functions of the proteins 
encoded by the genes are as follows: Purple: precursor supply; red: PKS component; blue: 
post-PKS tailoring; green: regulatory; gold: export; and grey: hypothetical.  
Figure 1.6: Structures of the characterised shunt metabolite, coelimycin P1 18, and the 
putative true metabolite, coelimycin A 19, of the cpk biosynthetic pathway 
Figure 1.7: The structures of riboflavin, FMN and FAD. The isoalloxazine ring and 
ribityl side chain are highlighted in purple and blue, respectively. 
Figure 1.8: The different oxidation states of flavin, in protonated (top) and unprotonated 
(bottom) forms 
Figure 1.9: The structure of NADH (R = H) and NADPH (R = PO3
2–). The nicotinamide 
and ADP ribose groups are highlighted in purple and blue, respectively. 
Figure 1.10: Regulation of coelimycin biosynthesis, involving S. coelicolor butenolide 
(SCB) signalling molecules and interactions with receptors and ligands from other 
pathways (grey). Activatory and inhibitory steps are indicated by arrows or lines ending 
with a bar, respectively. Additional binding sites of ScbR2 (intergenic regions of acca1‒
scF, cpkA‒cpkD, cpkI‒cpkJ and the promoter of cpkN) have been omitted for clarity. 
Adapted from Liu and coworkers.  
Figure 1.11: Structures of polyketide alkaloids from Actinobacteria 
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Figure 2.1: (A) Nickel affinity purification of His6-CpkG. L1: Molecular weight marker; 
L2: elution with 20 mM imidazole; L3: elution with 50 mM imidazole; L4: elution with 
100 mM imidazole; L5: elution with 200 mM imidazole; L6: elution with 300 mM 
imidazole; L7: flow through from column; L8: soluble protein; L9: insoluble protein. (B) 
Deconvoluted mass spectrum of His6-CpkG. The measured and calculated molecular 
weights of His6-CpkG are 60648 Da and 60646 Da, respectively.  
Figure 2.2: UV/Vis spectra and structures of PLP (light grey) and the aldimine adduct of 
PLP with CpkG (dark grey). The λmax values of the two peaks are 410 nm and 418 nm, 
respectively. 
Figure 2.3: Amino donor and acceptor specificities of CpkG as determined by the 
CuSO4/MeOH staining method. The specificities for the different substrate combinations 
are shown relative to the specificity of CpkG for octylamine and pyruvate as amino donor 
and acceptor. Data are represented as means ± 1 standard deviation from triplicate 
experiments. 
Figure 2.4: Extracted ion chromatograms at m/z = 232.1366 ± 0.005 (corresponding to 
the [M+H]+ ion of the D-cysteine derivative of octanal) from LC-MS analyses of the 
CpkG-catalysed reaction of octylamine with pyruvate. From top to bottom: enzymatic 
reaction; control from which the enzyme was omitted; and authentic standard. 
Figure 2.5: Extracted ion chromatograms at m/z = 342.1044 ± 0.005 (corresponding to 
the [M+H]+ ion of Marfey’s-derivatised alanine) from LC-MS analyses of the 
CpkG-catalysed reaction of octylamine with pyruvate. From top to bottom: Marfey’s 
derivatisation of the product of the reaction; Marfey’s derivatisation of the control 
reaction from which enzyme was omitted; Marfey’s derivatisation of an L-alanine 
standard; Marfey’s derivatisation of a D-alanine standard. 
Figure 2.6: (A) Detection of pyruvate formation from L-alanine using a coupled assay 
with LDH and NADH. The consumption of NADH was determined by monitoring the 
decrease in absorbance at 340 nm after CpkG addition (dark grey) and without CpkG 
addition (light grey). (B) Extracted ion chromatograms at m/z = 130.1590 ± 0.005 
(corresponding to the [M+H]+ ion for octylamine) from LC-MS analyses of the 
CpkG-catalysed reaction of octanal with L-alanine. From top to bottom: enzymatic 
reaction; control reaction from which the enzyme was omitted; and authentic standard. 
Figure 2.7: (A) Extracted ion chromatograms at m/z = 202.2165 ± 0.005 (corresponding 
to the [M+H]+ ion for 1-aminododecan-5-ol) from LC-MS analyses of the 
CpkG-catalysed reaction of 5-hydroxydodecanal with L-alanine. From top to bottom: 
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enzymatic reaction; control reaction from which the enzyme was omitted; and authentic 
standard. (B) Extracted ion chromatograms at m/z = 304.1941 ± 0.005 (corresponding to 
the [M+H]+ ion for D-cysteine-derivatised 5-hydroxydodecanal) from LC-MS analyses of 
the CpkG-catalysed reaction of 1-aminododecan-5-ol with pyruvate. From top to bottom: 
enzymatic reaction; control reaction from which the enzyme was omitted; and authentic 
standard. 
Figure 2.8: A crystal obtained from a PACT premierTM screen 
Figure 2.9: (A) A cartoon display of the CpkG homodimer. Monomer units are 
highlighted in violet and teal, while PMP ligands are depicted as spheres. (B) A cartoon 
display of the domain architecture of a CpkG monomer. The large domain, small domain 
and additional domain are highlighted in blue, green and magenta, respectively, while the 
PMP ligand is depicted as sticks in CPK colouring. (C) The predicted substrate binding 
tunnel positioned behind the primary amino group of PMP, displayed in surface view. 
Figure 2.10: (A) Polar interactions of PMP with surrounding residues. (B) Face-to-edge 
π−π stacking interaction of PMP with Phe209. The carbon chains of PMP and residues 
are depicted in grey and teal, respectively, while other atoms are shown in CPK colouring. 
Figure 2.11: (A) Polar interactions of PLP with surrounding residues. (B) An overlay of 
CpkG_ala (teal) with CpkG_ala_lactol (violet). Residues that have undergone significant 
conformational alternations are depicted. Nitrogen, oxygen and phosphorous atoms are 
shown in CPK colours. 
Figure 2.12: (A) SDS-PAGE analysis of His6-CpkC-TR (L2) and His6-CpkG (L3), 
relative to a protein molecular weight marker (L1). The molecular weights of 
His6-CpkC-TR and His6-CpkG are 46.0 and 60.6 kDa, respectively. (B) Native-PAGE 
analysis of His6-CpkC-TR (L1), His6-CpkG (L2) and a 1:1 mixture of His6-CpkC-TR and 
His6-CpkG (L3).  
Figure 2.13: Left: SDS-PAGE analysis of (A) CpkG and (B) CpkC-TR, following 
cleavage of hexahistidine tags with TEV protease. L1: Protein molecular weight marker; 
L2: His6-tagged protein standard; L3: Protein collected from wash fraction (20 mM 
imidazole); L4: Protein collected from elution fraction (300 mM imidazole). Right: 
SDS-PAGE analysis of fractions collected from pull-down assays, following incubation 
of (C) His6-CpkC-TR with CpkG, and (D) His6-CpkG with CpkC-TR. L1: Protein 
molecular weight marker; L2: protein collected from wash fraction; L3: protein collected 
from elution fraction.  
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Figure 2.14: A partial display of a multiple sequence alignment of CpkG and homologues 
encoded within putative polyketide alkaloid biosynthetic gene clusters, produced using 
T-Coffee and BoxShade software. Darker regions indicate higher levels of homology 
between proteins. The additional domain of CpkG (residues 142-189) appears to contain 
fewer amino acids, which may have been necessary for interactions with CpkC-TR. 
Figure 2.15: Overview of gene clusters harbouring PKS genes and homologues of 
cpkC-TR and cpkG  
Figure 2.16: Base peak chromatograms from LC-MS analyses of S. cyaneofuscatus 
metabolites extracted from ISP2 (top), R3 (middle) and R5 (bottom) agar  
Figure 2.17: Plasmid map of pOSV556t. An integrase gene (int_pSAM2), origins of 
replication (ColE1) and transfer (oriT), ampicillin and hygromycin resistance genes (ampr 
and hygr) and restriction sites (XhoI and HindIII) used for cloning are highlighted. 
Figure 2.18: (A) Gel from agarose electrophoresis following PCR amplification of 
IF17_RS0112435; (B) plasmid map with restriction sites used for analysis displayed; (C) 
gel from agarose electrophoresis following restriction digest with HindIII and XhoI; and 
(D) gel from agarose electrophoresis following restriction digest with NotI. 
Figure 2.19: Plasmid map of pKC1132. The lacZα gene, an apramycin resistance gene 
(amR), origins of replication (reppUC) and transfer (oriT) and restriction sites used for 
cloning (HindIII and XbaI) are highlighted. 
Figure 2.20: (A) Gel from agarose electrophoresis following PCR amplification of 
IF17_RS0112385; (B) plasmid map with restriction sites used for analysis displayed; (C) 
gel from agarose electrophoresis following restriction digest with HindIII and XbaI; and 
(D) gel from agarose electrophoresis following restriction digest with SmaI. 
Figure 2.21: Base peak chromatograms from LC-MS analyses of S. cyaneofuscatus 
metabolites extracted from R3 agar. Black trace: wild-type S. cyaneofuscatus; red trace: 
S. cyaneofuscatusPKS::am; green trace: S. cyaneofuscatus::SARP; blue trace: 
S. cyaneofuscatus::SARP-PKS::am. 
Figure 2.22: (A) Characterised (64 and 65) and predicted (67) structures of 
S. cyaneofuscatus::SARP metabolite fragments; and (B) structure of valinomycin 66 with 
isolated and predicted fragments highlighted. 
Figure 2.23: Comparison of predicted (top) and known (bottom) valinomycin 
biosynthetic gene clusters in Streptomyces cyaneofuscatus NRRL B-2570 and 
Streptomyces tsusimaensis ATCC 15141, respectively (Dr. Emmanuel de los Santos, 
University of Warwick). Homologous genes are coloured similarly, and are proposed to 
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encode a type II thioesterase (green), NRPS modules 1 and 2 (blue), NRPS modules 3 
and 4 (purple) and a transposase (pink). 
Figure 2.24: (A) Base peak chromatograms from LC-MS analyses of S. cyaneofuscatus 
metabolites extracted from AM1 liquid media. Black trace: wild-type S. cyaneofuscatus; 
green trace: S. cyaneofuscatus::SARP. (B) Observed [M+Na]+ for metabolite eluting at 
26.5 min, likely corresponding to valinomycin (calculated [M+Na]+ = 1133.6204).  
Figure 2.25: The organisation of a gene cluster within Streptomyces abikoensis DSM 
40831, predicted to direct the biosynthesis of latumcidin 35. The proposed functions of 
the proteins encoded by the genes are as follows. Purple: precursor supply; red: PKS 
component (with TR domain highlighted in yellow); blue: post-PKS tailoring; green: 
regulatory; grey: hypothetical. 
Figure 2.26: Structures of the predicted polyketide aldehyde 68 and latumcidin 35, with 
carbon atoms numbered accordingly 
 
Figure 3.1: Map of the pET151/D-TOPO vector used for the assembly of protein 
expression constructs. Key features (clockwise): T7 promoter; lac operator (lacO); 
ribosome binding site (RBS); start codon (ATG); N-terminal His6-tag; V5 epitope; TEV 
recognition site; TOPO® cloning site; SacI restriction site; T7 transcription termination 
region; ampicillin resistance gene (β-lactamase); pBR322 origin of replication (ori); ROP 
gene; and lacI gene. 
Figure 3.2: Gels from agarose electrophoresis following PCR amplifications of (A) cpkI; 
and (B) cpkE, at selected annealing temperatures. The expected sizes of the PCR products 
are labelled. 
Figure 3.3: (A) Plasmid maps with restriction sites used for analysis; and (B) gels from 
agarose electrophoresis following restriction digests, of pET151::cpkI (top) and 
pET151::cpkE (bottom). The expected sizes of the DNA fragments are labelled. 
Figure 3.4: SDS-PAGE analysis of purified His6-CpkI (L2) and His6-CpkE (L3) 
alongside a protein molecular weight marker (L1) 
Figure 3.5: Measured (left) and deconvoluted (right) mass spectra of His6-CpkI (top) and 
His6-CpkE (bottom). The calculated molecular weights of the proteins are 31214 and 
34813 Da, respectively. 
Figure 3.6: (A) Extracted ion chromatograms at m/z = 304.1941 ± 0.05 (corresponding 
to the [M+H]+ ion for (4S)-2-(4-hydroxyhexyl)thiazolidine-4-carboxylic acid). From top 
to bottom: reaction of His6-CpkI with dodecane-1,5-diol and NAD+; reaction of His6-CpkI 
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with dodecane-1,5-diol and NADP+; and D-cysteine derivatised authentic standard. (B) 
Extracted ion chromatograms at m/z = 230.1751 ± 0.05 (corresponding to the [M+H]+ ion 
for tris-derivatised octenal). From top to bottom: reaction of trans-octen-2-al with 
His6-CpkE and tris; control reaction from which the enzyme has been omitted; and 
authentic standard of tris-derivatised cis-octen-3-al. Experiments were performed in 
duplicate. 
Figure 3.7: (A) Gels from agarose electrophoresis following PCR amplifications at 
selected annealing temperatures; (B) plasmid maps with restriction sites used for analysis; 
and (C) gels from agarose electrophoresis following restriction digests of pET151 
constructs harbouring cpkD (top), scF (middle) and cpkH (bottom). The expected sizes 
of the DNA fragments are labelled. 
Figure 3.8: SDS-PAGE analysis of purified His6-CpkD (L2), His6-ScF (L3) and 
His6-CpkH (L4) alongside a protein molecular weight marker (L1) 
Figure 3.9: UV/Vis spectra of flavoproteins: (A) His6-CpkD; (B) His6-ScF; and 
(C) His6-CpkH 
Figure 3.10: Measured (top) and deconvoluted (bottom) mass spectra of (A) His6-CpkD; 
(B) His6-ScF; and (C) His6-CpkH. The calculated protein molecular weights are 51807 
Da, 60363 Da (+ FAD = 61148 Da) and 58827 Da (+ FAD = 59611 Da), respectively. 
Figure 3.11: Extracted ion chromatograms at m/z = 784.1499 ± 0.05 (top trace, 
corresponding to the [M-H]− ion of FAD) and m/z = 455.0973 ± 0.05 (bottom trace, 
corresponding to the [M-H]− ion of FMN) 
Figure 3.12: Amino acid residues involved in the covalent binding of FAD to TamL. 
Note: Only the isoalloxazine moiety of FAD is shown.  
Figure 3.13: A partial view of a multiple sequence alignment of TamL, ScF and CpkH, 
produced using T-Coffee and BoxShade software. Darker regions indicate higher levels 
of homology. Residues implicated in covalent FAD binding are highlighted with a purple 
box.  
Figure 3.14: UV/Vis monitoring at A340 to detect the oxidation of NADH (dark grey) or 
NADPH (light grey), by (A) His6-CpkD; (B) His6-ScF; and (C) His6-CpkH  
Figure 3.15: Proposed substrate mimic of 31 
Figure 3.16: (A) Extracted ion chromatograms at m/z = 182.1903 ± 0.05 (corresponding 
to the [M+H]+ ion for 6-heptyl-2,3,4,5-tetrahydropyridine). From top to bottom: reaction 
of 1-aminododecan-5-ol with CpkD, ScF, CpkH and without enzyme. (B) Measured m/z 
and predicted molecular formula for the compound eluting at 15.4 min. 
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Figure 3.17: Extracted ion chromatograms at m/z = 182.1903 ± 0.05 (corresponding to 
the [M+H]+ ion for 6-heptyl-2,3,4,5-tetrahydro-pyridine). From top to bottom: reaction 
of 1-aminododecan-5-ol with CpkH; control reaction from which the enzyme was 
omitted; and authentic standard.  
Figure 3.18: Two different representations of (A) the (R,R)-diastereomer; (B) the 
(R,S)-diastereomer; (C) the (S,R)-diastereomer; and (D) the (S,S)-diastereomer of 
Mosher’s-derivatised 95, adapted from Hoye and coworkers. The shielding effect exerted 
by the phenyl group is indicated with a purple arrow. 
Figure 3.19: Structure of 96 with protons labelled 
Figure 3.20: A comparison of 1H NMR spectra from 4.2–5.8 ppm of (A) (R,R)-96; (B) 
(R,S)-96; (C) (S,R)-96; and (D) (S,S)-96. Protons 3, 4, 5 and 7 in spectra (B) and (C) are 
shifted upfield compared to those of (A) and (D). 
Figure 3.21: Extracted ion chromatograms at m/z = 182.1903 ± 0.05 (corresponding to 
the [M+H]+ ion for 6-heptyl-2,3,4,5-tetrahydropyridine). From top to bottom: reaction of 
(R)-1-aminododecan-5-ol with His6-CpkH (ion count = 45640 a.u.); reaction of (S)-1-
aminododecan-5-ol with His6-CpkH (ion count = 1864 a.u.); control reaction from which 
the enzyme was omitted; and authentic standard. Independent experiments were 
performed in triplicate. 
Figure 3.22: Proposed substrate mimic of 29 
Figure 3.23: Extracted ion chromatograms at (A) m/z = 324.1240 ± 0.05 (corresponding 
to the [M+Na]+ ion for the NAC-derivatised mono-epoxide) and (B) 340.1189 ± 0.05 
(corresponding to the [M+Na]+ ion for the NAC-derivatised bis-epoxide), Brown trace: 
reaction with His6-ScF; blue trace: reaction with His6-CpkD; purple trace: reaction with 
His6-CpkD, supplemented with additional FAD; green trace: reaction with His6-CpkD, 
supplemented with additional FMN. Independent experiments were performed in 
triplicate. 
Figure 3.24: Possible structures of a NAC ring-opened mono-epoxide (A) and 
bis-epoxide (B). Other structures may include regioisomers (e.g. epoxidation at carbons 
6-7 and NAC addition at carbon 7), Michael-addition products (e.g. epoxidation at 
carbons 4-5 and NAC addition at carbon 9) and related diastereomers. 
Figure 3.25: Extracted ion chromatograms at (A) m/z = 324.1240 ± 0.05 (corresponding 
to the [M+Na]+ ion for the NAC-derivatised mono-epoxide) and (B) 340.1189 ± 0.05 
(corresponding to the [M+Na]+ ion for the NAC-derivatised bis-epoxide) arising from the 
incubation of His6-CpkD with triene ester 99, FMN, NADH and NAC. From top to 
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bottom: reaction without substrate; reaction without NAC; reaction without His6-CpkD; 
reaction with boiled His6-CpkD; and reaction without NADH. Independent experiments 
were performed in triplicate. 
Figure 3.26: CD spectra of non-denatured (grey) and boiled (orange) His6-CpkD 
Figure 3.27: Extracted ion chromatograms at m/z = 259.0545 ± 0.005 (corresponding to 
the [M+Na]+ ion for diNAC). Green trace: incubation of His6-CpkD with triene ester 99, 
FMN, NADH and NAC; purple trace: control reaction from which FMN was omitted; 
and brown trace: control reaction from which NAC was omitted. 
Figure 3.28: Extracted ion chromatograms from LC-MS analysis of reactions of CpkD, 
FMN, triene ester 99 and NAC, in air (A) and under 18O2 (B). The extracted ion 
chromatograms at m/z = 324.1240 ± 0.05 (green) and m/z = 326.1240 ± 0.05 (purple) 
correspond to the 16O and 18O isotopes of the mono-epoxide, respectively. Independent 
assays were performed in duplicate. 
Figure 3.29: Extracted ion chromatograms from LC-MS analysis of reactions of CpkD, 
FMN, triene ester 99 and NAC, in air (A) and under 18O2 (B). The extracted ion 
chromatograms at m/z = 340.1189 ± 0.05 (green), m/z = 342.1189 ± 0.05 (purple) and m/z 
= 344.1189 ± 0.05 (brown) correspond to the 16O, 18O1 and 18O2 isotopes of the 
bis-epoxide, respectively. Independent assays were performed in duplicate. 
Figure 3.30: Histograms depicting the relative contributions of isotopes to the A+2, B+2 
and B+4 peaks, following reaction of triene ester 99 with His6-CpkD, FMN and NAC 
under an 18O2-enriched atmosphere. For simplicity, contributions of naturally occurring 
isotopes are annotated as 13C2 and 
13C4 responses. Calculations and data display are 
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Scheme 1.1: The organisation of the DEBS system, responsible for the assembly of 
6-deoxyerythronolide B 20. Subsequent modification by post-PKS tailoring enzymes 
affords erythromycin A 21. 
Scheme 1.2: Mechanism of reaction of apo-ACP with coenzyme A to form holo-ACP. 
B = general base. 
Scheme 1.3: Mechanism of reaction of an AT domain with a starter unit (e.g. 
propionyl-CoA, R = H) or extender unit (e.g. methylmalonyl-CoA, R = CO2
−), and the 
subsequent transfer to a downstream holo-ACP. The catalytic histidine residue is 
indicated. Mx = module x. 
Scheme 1.4: Mechanism of reaction of a KS domain with an upstream acyl-ACP, 
followed by a decarboxylative Claisen condensation with a methylmalonyl unit tethered 
to a downstream ACP. Catalytic histidine residues are indicated. R = polyketide chain; 
Mx = module x. 
Scheme 1.5: Mechanisms of (A) reduction; and (B) epimerisation of a β-ketothioester, 
catalysed by a KR domain. The serine, tyrosine and lysine residues within the catalytic 
triad are indicated. R = polyketide chain; A = general acid; B = general base; Mx = 
module x. 
Scheme 1.6: Mechanism of dehydration of a β-hydroxythioester, catalysed by a DH 
domain. Catalytic histidine and aspartate residues are indicated. R = polyketide chain; Mx 
= module x. 
Scheme 1.7: Mechanism of reduction of an α,β-unsaturated thioester, catalysed by an ER 
domain. R = polyketide chain; A = general acid; Mx = module x. 
Scheme 1.8: Mechanisms of chain release of a fully assembled polyketide chain by a TE 
domain, to yield a carboxylic acid (top) or macrolactone (bottom). The serine, histidine 
and aspartate residues within the catalytic triad are indicated. 
Scheme 1.9: The PKS module and domain organisation of CpkABC and the proposed 
structures of ACP-bound intermediates. The cross indicates that the DH domain in 
module 4 is likely inactive. 
Scheme 1.10: Mechanism of NADH-mediated reductive chain release of 22 by 
CpkC-TR. A = general acid. 




Scheme 1.11: The conversion of pyruvate 25 to malonyl-CoA 27, catalysed by a 
pyruvate-dependent ferredoxin reductase and an acetyl-CoA carboxylase. Relevant 
cofactors are highlighted.  
Scheme 1.12: Catalytic cycle of a TA. The amino donor (top left) transfers an amino 
group to enzyme-bound pyridoxal-5’-phosphate (E-PLP), and the newly-formed 
enzyme-bound pyridixamine-5’-phosphate (E-PMP) transfers it on to the amino acceptor 
(bottom right). For α-TAs, R1 = RIII = CO2H. For ω-TAs, if R1 = CO2H, then RIII ≠ CO2H.  
Scheme 1.13: Reaction mechanism of a TA. In the first half of the reaction, an amino 
group is transferred from an α-amino acid to enzyme-bound PLP, to form an α-keto acid 
and PMP. In the second half of the reaction, the amino group is transferred from PMP to 
an aldehyde, to form a primary amine and enzyme-bound PLP. Note: reactions are 
reversible, but arrows are unidirectional for clarity. 
Scheme 1.14: The catalytic cycle of flavoenzymes  
Scheme 1.15: The oxidation of an alcohol by a flavin-dependent oxidase via a direct 
hydride transfer. The oxidised-form of the cofactor is subsequently regenerated by 
molecular oxygen (or an alternative electron acceptor in the case of a dehydrogenase). 
A = general acid; B = general base.  
Scheme 1.16: The epoxidation of an alkene by a flavin-dependent monooxygenase. The 
C(4a)-hydroperoxy species is formed by reaction of reduced flavin with molecular 
oxygen. Nucleophilic attack of an alkene at the electrophilic oxygen yields the epoxide 
product, and a C(4a)-hydroxyflavin adduct which eliminates water to form oxidised 
flavin. The reduced cofactor is subsequently regenerated by direct hydride transfer from 
NAD(P)H. A = general acid; B = general base.  
Scheme 1.17: The dehydrogenation of an alcohol by a short-chain dehydrogenase, using 
NAD(P)+ as a cofactor  
Scheme 1.18: The isomerisation of trans-2-decenoic acid to cis-3-decenoic acid by 
β-hydroxydecanoyl thioester isomerase. A = general acid. Revised from Bugg, Schwab 
and Klassen.  
Scheme 1.19: The proposed biosynthesis of coelimycin A 19 and coelimycin P1 18 
Scheme 1.20: The biosynthesis of S. coelicolor butenolides (SCBs, 13) 1-8. An ACP-
bound β-ketothioester from a fatty acid synthase (FAS) is condensed with 
dihydroxyacetone phosphate (DHAP) by ScbA and the double bond reduced by ScbB. A 
dephosphorylation (by an unknown enzyme) and reduction of the keto group by ScbC 
afford the SCBs. 





Scheme 2.1: Proposed reaction catalysed by CpkG in coelimycin biosynthesis 
Scheme 2.2: The general transamination reaction catalysed by CpkG. 
Scheme 2.3: Assay employed to detect amino acids produced during the transamination 
reaction. Amines (10 mM, 45-49) and α-keto acids (10 mM, 25 and 50) tested as substrates 
for CpkG (20 μM) are shown. 
Scheme 2.4: Assay employed for the detection and derivatisation of octanal 57 with 
D-cysteine (400 μM), following reaction of pyruvate 25 (200 μM) and octylamine 49 
(200 μM) with CpkG (90 μM).  
Scheme 2.5: Assay employed to establish the stereochemistry of alanine 51 produced, 
following reaction of octylamine 49 (10 mM) and pyruvate 25 (10 mM) with CpkG 
(20 μM). 
Scheme 2.6: Assay employed to detect octylamine 49 and pyruvate 25 production, 
following reaction of octanal 57 (200 μM) and alanine 51 (200 μM) with CpkG (90 μM). 
Octylamine was observed by LC-MS comparison to an authentic standard, while pyruvate 
was detected by monitoring the decrease in absorbance at 340 nm after addition of LDH 
(1 μM) and NADH (200 μM). 
Scheme 2.7: Left: Synthesis of 5-hydroxydodecanal 59 by reduction of δ-dodecalactone 
61 (1.0 eq.) with DIBAL-H (1.0 eq.). Right: Synthesis of 1-aminododecan-5-ol 60 by 
reaction of 59 (1.0 eq.) with benzylamine (1.3 eq.), Pd/C (catalytic) and H2 (1 atm). 
Scheme 2.8: General assay for the detection of 1-aminododecan-5-ol 60 (forward 
reaction) or 5-hydroxydodecanal 59 (reverse reaction), from incubation of the appropriate 
substrates (200 μM) with CpkG (90 μM). For the reverse reaction, 59 was derivatised with 
D-cysteine (400 μM) prior to LC-MS analysis. 
Scheme 2.9: Possible biosynthetic pathways leading to the formation of the amine 
intermediate. Grey: original proposed pathway; black: alternative pathway in which 
CpkC-TR and CpkG interact with one another, resulting in the direct conversion of the 
aldehyde to the amine. Note: the postulated isomerisation catalysed by CpkE has been 
omitted for clarity. 
Scheme 2.10: Proposed universal biosynthesis of actinobacterial polyketide alkaloids 
Scheme 2.11: Proposed biosynthesis of polyketide alkaloid intermediates in Streptomyces 
cyaneofuscatus NRRL B-2570 




Scheme 2.12: A proposed biosynthesis of latumcidin 35, based on the predicted functions 
of genes within cluster 43 of Streptomyces abikoensis DSM 40831 and the pathways 
proposed for streptazone E 42 and coelimycin P1 18 biosynthesis  
 
Scheme 3.1: Proposed reactions catalysed by CpkI and CpkE in coelimycin biosynthesis 
Scheme 3.2: Synthesis of dodecane-1,5-diol 76 by reduction of δ-dodecalactone 61 
(1.0 eq.) with LiAlH4 (1.5 eq.) 
Scheme 3.3: Assay employed to probe the possible oxidation of dodecane-1,5-diol 76 
(200 μM) by CpkI (90 μM) and NAD(P)+ (200 μM), followed by derivatisation with 
D-cysteine (400 μM) 
Scheme 3.4: Assay employed to probe the possible isomerisation of trans-octen-2-al 78 
(200 μm) by CpkE (100 μM), and derivatisation with tris (20 mM) 
Scheme 3.5: Synthesis of cis-octen-3-al 79 by oxidation of cis-octen-3-ol 80 (1.0 eq.) 
with DMP (1.3 eq.) 
Scheme 3.6: Proposed reactions catalysed by CpkD, CpkH and ScF in coelimycin 
biosynthesis 
Scheme 3.7: Proposed oxidation reaction catalysed by CpkD, CpkH or ScF  
Scheme 3.8: Assay employed to probe flavin-dependent dehydrogenase activity, by 
incubation of 1-aminododecane-5-ol (200 μM) with CpkD, ScF or CpkH (20 μM) 
Scheme 3.9: Synthesis of 6-heptyl-2,3,4,5-tetrahydropyridine 81 from 1-amino-
dodecan-5-ol 60; 18 % yield over 5 steps from δ-dodecalactone 61 
Scheme 3.10: Proposed CpkH-catalysed oxidation of (R)-84 or (S)-84 
Scheme 3.11: Synthetic routes to (R)-84 and (S)-84. a) CDI, monomethyl malonate 
potassium salt, MgCl2, THF, r.t., o/n; b) [Ru(OAc)2((R)-BINAP)] or 
[Ru(OAc)2((S)-BINAP)], MeOH, HCl, H2 (49 atm), 50 °C, o/n; c) tert-butyldimethylsilyl 
chloride, imidazole, DMF, 0 °C → r.t., o/n; d) DIBAL-H, DCM, -78 °C, 1 h; e) 
ethyl(triphenylphosphoranylidene)acetate, THF, r.t., o/n; f) DIBAL-H, DCM, -78 °C, 3 h; 
g) (R)-enantiomer: triphenylphosphine, N-chlorosuccinamide, THF, r.t., 3.5 h; (S)-
enantiomer: triethylamine, tosyl chloride, DCM, 0 °C → r.t., o/n; h) potassium 
phthalimide, DMF, r.t., 72 h; i) (1S)-(+)-10-camphorsulfonic acid, MeOH, DCM, r.t., 1.5 
h; j) 40 % aq. MeNH2, EtOH, r.t, 2 h. 
Scheme 3.12: Catalytic cycle for the asymmetric hydrogenation of β-keto esters by 
[Ru(Cl)2BINAP)], generated in situ from [Ru(OAc)2BINAP)] and methanolic HCl. In the 
first step, the active RuII monohydride complex is formed from reaction of the dichloride 




precatalyst with H2. The β-keto ester substrate then chelates to the complex, displacing 
two solvent ligands. The keto oxygen is then protonated, increasing the electrophilicity at 
the carbonyl carbon and thereby facilitating intramolecular hydride transfer. The chiral 
β-hydroxy ester product is then displaced by incoming solvent ligands. The ruthenium 
complex then reacts with H2 to regenerate the monohydride, thus completing the catalytic 
cycle. L = solvent; PᴖP = BINAP.  
Scheme 3.13: Enantio-determining transition states during reaction of a β-keto ester with 
[RuCl2(R)-BINAP] and H2, adapted from Noyori et al. The phenyl rings projecting 
forward and backward are depicted as shaded and colourless hexagons, respectively. 
BINAP rings have been omitted for clarity. In TSR, the R group occupies an open quadrant 
within the chiral template. In TSS, there is a significant nonbonding repulsion between 
the R group and the equatorial phenyl ring, indicated by the double-headed arrow. Thus, 
TSR, and therefore the (R)-β-hydroxy-ester product, are favoured.  
Scheme 3.14: Reaction of aldehyde 90 with ethyl(triphenylphosphoranylidene)acetate to 
form (E)-91 as the major product. Unfavourable 1,2-steric interactions between the R 
group and the ester moiety are minimised in the trans-oxaphosphetane transition state.  
Scheme 3.15: Reaction of vinyl alcohol (S)-92 with TsCl and Et3N to form a tosylate 
intermediate. The leaving group is subsequently displaced by a chloride ion to afford 
(S)-93. 
Scheme 3.16: Synthesis of Mosher’s esters of (R)- and (S)-95. Reaction conditions: (R)- 
or (S)-95 (1.0 eq.), (R)- or (S)-Mosher’s acid (MTPA: α-methoxy-α-trifluoromethyl-
phenylacetic acid, 1.1 eq.), EDC (1.1 eq.), DMAP (0.1 eq.), DCM, r.t.. 
Scheme 3.17: Assays employed to investigate the hypothetical conversion of (R,E)- or 
(S,E)-1-aminododec-2-en-5-ol 84 (200 μM) to 6-heptyl-2,3-dihydropyridine 97 or 6-
heptyl-2,3,4,5-tetrahydropyridine 81, catalysed by CpkH (20 μM) and either CpkE 
(20 μM) or CpkI (20 μM), respectively.  
Scheme 3.18: Left: Reduction of (R,E)- and (S,E)-95 (1.0 eq.) with Pd/C (catalytic) and 
H2 (1 atm), to form (R)- and (S)-98. Right: Deprotection of (R)- and (S)-98 (1.0 eq.) with 
MeNH2 (excess), to form (R)- and (S)-60. 
Scheme 3.19: Assay employed to investigate the oxidation of (R)- or (S)-60 (200 μM), 
catalysed by CpkH (20 μM) 
Scheme 3.20: Proposed epoxidation reactions catalysed by CpkD and/or ScF  
Scheme 3.21: Attempts to synthesise ethyl (2E,4E,6E)-octa-2,4,6-trienoate 99 from 
trans,trans-2,4-hexadienal 100 




Scheme 3.22: Putative epoxidation of 99 (200 μM) by CpkD/ScF (20 μM), FMN/FAD 
(40 μM) and NADH (40 μM), followed by trapping with NAC (400 μM) 
Scheme 3.23: Mechanism of FMN reduction by NADH (A) and NAC (B) 
Scheme 3.24: Putative epoxidation of 99 (200 μM) by CpkD (20 μM) and FMN (40 μM), 
followed by derivatisation with NAC (400 μM), to yield NAC-adducts of a mono- and 
bis-epoxide (possible structures are shown). Under an 18O2-atmosphere, one or two atoms 
of 18O would be expected to be incorporated into the mono and bis-epoxide derivatives, 
respectively, resulting in an increase in intensity of peaks of 326 and 344 Da. 
 
Scheme 4.1: Updated proposed biosynthesis of coelimycin A 19 and coelimycin P1 18. 
[O] represents an unknown dehydrogenase.  
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°C Degrees Celsius 
ACP Acyl carrier protein 
ADP Adenosine diphosphate 
AM1 Alkaloid medium 1 
AT Acyltransferase (domain) 
ATP Adenosine triphosphate 
BINAP 2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl 
bp Base pairs 
Bn Benzyl 
CD Circular dichromism 
CDI 1'-carbonyldiimidazole 
CoA Coenzyme A 
COSY Correlation spectroscopy 
CSA Camphorsulfonic acid 
DCM Dichloromethane 
DH Dehydratase (domain) 
DHAP Dihydroxyacetone phosphate 
DIBAL-H Diisobutylaluminium hydride 
DMAP 4-Dimethylaminopyridine 
DMF N,N-Dimethylformamide 
DMP Dess-Martin periodinane 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
dNTP Deoxynucleotide triphosphate 
EDC 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
EDTA Ethylenediaminetetraacetic acid 
EIC Extracted ion chromatogram 
ER Enoyl reductase (domain) 
ESI Electrospray ionisation 
Et Ethyl 
eq Equivalents 




FA Formic acid 
FAD Flavin adenine dinucleotide 
FAS Fatty acid synthase 
Fd Ferredoxin 
FMN Flavin mononucleotide 
FPLC Fast protein liquid chromatography 
HEPES 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid 
HMBC Heteronuclear multiple bond coherence 
HMQC Heteronuclear single quantum coherence 
HPLC High performance liquid chromatography 
HRMS High resolution mass spectrometry 
IMAC Immobilised metal-affinity chromatography 
IPTG Isopropyl-β-D-thiogalactoside 
ISP2/4 International Streptomyces project medium 2/4 
KR Ketoreductase (domain) 
KS Ketosynthase (domain) 
LB Luria-Bertani (medium) 
LC-MS Liquid chromatography-mass spectrometry 
LDH Lactate dehydrogenase 
LRMS Low resolution mass spectrometry 
Me Methyl 
MS Mass spectrometry 
MTPA α-Methoxy-α-trifluoromethylphenylacetic acid 
m/z Mass to charge ratio 
NAC N-acetyl cysteamine 
NAD+ / NADH β-Nicotinamide adenine dinucleotide (ox/red) 
NADP+ / NADPH β-Nicotinamide adenine dinucleotide 2′-phosphate (ox/red) 
NMR Nuclear magnetic resonance 
NRPS Non-ribosomal peptide synthetase 
NTA Nitriloacetic acid 
OAT Ornithine aminotransferase 
OD Optical density 
PAGE Polyacrylamide gel electrophoresis 




PCR Polymerase chain reaction 
Phth Phthalimide 
PKS Polyketide synthase 
PLP Pyridoxal 5'-phosphate  
PMP Pyridoxamine 5'-phosphate  
PMSF Phenylmethylsulfonyl fluoride 
PVDF Polyvinylidene fluoride 
rt Room temperature 
SARP Streptomyces antibiotic regulatory protein 
SCB Streptomyces coelicolor butenolide 
SDH Short-chain dehydrogenase 
SDS Sodium dodecyl sulfate 
SFM Soya flour mannitol (medium) 
SMM Supplemented minimal medium 
STE Sodium chloride-TRIS-EDTA (buffer) 
TA Transaminase 
TAT Twin arginine translocase 
TBAF Tetrabutylammonium fluoride 




TFA Trifluoroacetic acid 
THF Tetrahydrofuran 
TLC Thin layer chromatography 
TMS Trimethyl silyl 
TPP Thiamine pyrophosphate 
TR Thioester reductase (domain) 
Tris Tris(hydroxymethyl)aminomethane 










Coelimycin P1 is a yellow-pigmented alkaloid with a unique 1,5-oxathiocane ring, 
produced by Streptomyces coelicolor M145. Recently, it was demonstrated that a type I 
modular polyketide synthase (PKS) with a C-terminal thioester reductase (TR) domain is 
involved in its assembly. Due to its unusual biosynthetic origin, unprecedented structure 
and the antibiotic activity likely associated with coelimycin A, its biosynthesis is of great 
interest.  
 
To investigate the roles of the putative post-PKS tailoring enzymes (CpkG, CpkH, CpkD, 
ScF, CpkE and CpkI), the recombinant proteins were overproduced in E. coli, purified 
and incubated with various commercial and synthetic substrates. CpkG was characterised 
as an (S)-selective ω-transaminase with a broad substrate tolerance, responsible for the 
incorporation of nitrogen into the six-membered ring of coelimycin P1. Crystal structures 
of CpkG revealed a rare tri-domain architecture, key active site residues and provided 
insight into the transamination mechanism. CpkH, CpkD and ScF were all subsequently 
characterised as flavoproteins. Specifically, CpkH was demonstrated to catalyse an 
(R)-specific FAD-dependent dehydrogenation, while CpkD was shown to catalyse two 
FMN-dependent epoxidations. The roles of ScF, CpkE and CpkI in coelimycin 
biosynthesis remain to be elucidated.  
 
 
Scheme 1: The revised proposed biosynthesis of coelimycin A and coelimycin P1 
 
Bioinformatics searches identified 22 additional actinobacterial gene clusters, which also 
encode modular PKSs with a TR domain and a homologue of CpkG. These have been 
predicted to direct the biosynthesis of both known and novel polyketide alkaloids, suggesting 
that reductive chain release and transamination constitute a conserved mechanism for the 
biosynthesis of such metabolites. 











Streptomyces are a class of GC-rich, Gram-positive bacteria, with a filamentous form 
resembling that of fungi. Together, they constitute the largest genus of Actinobacteria.1 
They are ubiquitous in the soil, with their characteristic earthy odour emanating from the 
production of the volatile metabolite, geosmin.2 They are also widespread in marine and 
freshwater sediments, and in decaying vegetation. Streptomyces are essential in these 
environments due to their involvement in a range of metabolic processes and 
biotransformations, including the decomposition of biological polymers. Consequently, 
these bacteria play a fundamental role in carbon and nitrogen cycling.3  
 
Streptomyces have a complex developmental life cycle, which begins with a free spore. 
Under favourable germination conditions, one or two germ tubes can emerge and grow 
through tip extension and branching to form a network of multigenomic hyphae, known 
as the substrate mycelium. This stage often coincides with the onset of specialised 
metabolite production.4 Due to nutrient limitation and other stress signals, aerial hyphae 
can form and grow into the air, then differentiate into long chains of unigenomic pre-
spore compartments. Following septation, the pre-spores can undergo further maturation, 
involving cell-wall thickening and the production of a grey spore pigment. The dormant 
spores are then ready for dispersal at the end of the cycle (figure 1.1).5,6 
 
 
Figure 1.1: The life cycle of Streptomyces coelicolor A3(2).5 Spore germination results in the formation of 
germ tubes, which extend and branch to produce the substrate mycelium. Hyphae subsequently grow into 
the air to generate the aerial mycelium, which develops and matures into long chains of spores. Spores are 
then released to start a new cycle.  




Perhaps most importantly, Streptomyces are prolific producers of specialised metabolites. 
Approximately two-thirds of naturally-occurring antibiotics have been isolated from the 
genus, including many clinically-approved drugs such as daptomycin 1, chloramphenicol 
2 and tetracycline 3.7,8 In addition to antibiotics, Streptomyces produce a diverse array of 
other bioactive compounds with enormous medicinal and agrochemical potential. 
Renowned examples include the insecticide avermectin B1b 4, the herbicide bialaphos 5, 
the anticancer agent daunorubicin 6, the immunosuppressant tacrolimus 7 and the 




Figure 1.2: Selected bioactive compounds produced by Streptomyces, including antibacterials (1-3), 
insecticides (4), herbicides (5), anticancer agents (6), immunosuppressants (7) and antifungals (8) 
 




1.2 Streptomyces coelicolor A3(2) 
 
Streptomyces coelicolor A3(2) is a particular strain of Streptomyces that is considered to 
be a model representative of the genus.9 This is due to its genetic tractability and aptitude 
to produce strongly pigmented antibiotics, such as the actinorhodins 9 (blue) and 




Figure 1.3: Streptomyces coelicolor specialised metabolites, discovered prior to the availability of the 
genome sequence through a classical bioassay-guided approach  




In the early 2000s, the complete genome sequence of S. coelicolor A3(2) was 
published.7,12,13 It is comprised of an 8.7 Mb-long linear chromosome, a 356 kb linear 
plasmid, SCP1, and a 31 kb circular plasmid, SCP2. Before this, gene clusters for only 
six groups of specialised metabolites had been characterised: the actinorhodins 9, 
prodiginines 10-11, methylenomycins 12, γ-butyrolactones 13, calcium-dependent 
antibiotics 14 (figure 1.3) and grey spore pigment.14,15,16,17,18,19 Detailed bioinformatic 
analysis of the genome sequence unveiled a further 16 gene clusters, encoding proteins 
normally associated with complex natural product biosynthesis, whose metabolic 
products were unknown.20 This prompted the investigation of these cryptic gene clusters, 
and thereafter the discovery of several novel metabolites, including germicidin C 15, 
coelichelin 16 and methylenomycin furan 1 17 (figure 1.4).21,22,23 In addition, a wealth of 
information regarding biosynthetic mechanisms was revealed; for example, 
unprecedented type III polyketide synthase (PKS) enzymology and atypical non-





Figure 1.4: Selected Streptomyces coelicolor specialised metabolites, discovered through a genomics-
driven approach 
 
1.3 Discovery of coelimycin P1 
 
Another cryptic gene cluster uncovered through the S. coelicolor A3(2) genome 
sequencing project was predicted to encode a type I modular PKS.7 It was thereafter 
named the cpk (coelicolor polyketide) biosynthetic gene cluster (figure 1.5, also see 
appendix 1). DNA fragments encoding acyltransferase (AT) and ketosynthase (KS) 
domains within the PKS were first identified in the mid-1990s by Kuczek and co-workers, 








Figure 1.5: The organisation of the 59 kb-long cpk gene cluster directing coelimycin biosynthesis in 
Streptomyces coelicolor M145. The proposed functions of the proteins encoded by the genes are as follows: 
Purple: precursor supply; red: PKS component; blue: post-PKS tailoring; green: regulatory; gold: export; 
and grey: hypothetical.  
 
In 2010, Gottelt and Pawlik independently reported the polyketide product to be a 
diffusible yellow pigment, although no structural information was provided.26,27 Gottelt 
also observed that production of the pigment was associated with antibiotic activity.26  
 
In 2012, Gomez-Escribano and coworkers attempted to increase the metabolic flux 
through the cpk pathway using two genetic engineering strategies. Firstly, gene clusters 
responsible for the production of three classes of antibiotics (the actinorhodins 9, 
prodiginines 10-11 and calcium-dependent antibiotics 14) were deleted from S. coelicolor 
M145, a derivative of A3(2) lacking its two plasmids, to reduce competition for 
biosynthetic precursors. Secondly, spontaneous mutations in rpoB, encoding the 
β-subunit of RNA polymerase (RNAP), were selected for with rifampicin. These 
mutations are known to trigger antibiotic production, presumably because the resulting 
RNAP mutant has an altered confirmation resembling that of a guanosine tetraphosphate 
(ppGpp)-bound state, which promotes the transcription of specialised metabolite gene 
clusters.28,29 One rifampicin-resistant strain, named Streptomyces coelicolor M1157, 
produced large quantities of the yellow pigment. 
 
Comparative metabolic profiling of S. coelicolor M1157 with a functionally equivalent 
strain harbouring a different rpoB mutation (S. coelicolor M1152) resulted in the 
identification of a compound with an absorbance maximum at 360 nm and a molecular 
formula of C17H20N2O4S. Structural elucidation of the compound by NMR revealed that 
it was an alkaloid containing an unprecedented 1,5-oxathiocane ring (figure 1.6).30  
 





Figure 1.6: Structures of the characterised shunt metabolite, coelimycin P1 18, and the putative true 
metabolite, coelimycin A 19, of the cpk biosynthetic pathway 
 
Interestingly, while the culture supernatants possessed antibiotic activity, the purified 
compound, named coelimycin P1 18, did not. It was therefore suggested that coelimycin 
P1 18 may be a shunt metabolite of the pathway, derived from reaction of the putative 
antibacterial metabolic product, coelimycin A 19 (figure 1.6), with N-acetylcysteine in 
the culture medium. 
 
Notably, the yellow pigment observed by Gottelt and coworkers26 was overproduced in 
glutamate-supplemented medium, and had a different molecular formula (C17H22N2O6) 
corresponding to a putative glutamate adduct of coelimycin A 19. It was later named 
coelimycin P2.30  
 
1.3.1 Type I modular PKSs 
 
Type I modular PKS assembly lines catalyse a series of condensations and subsequent 
modifications of acyl-CoA thioesters to form diverse polyketide scaffolds.31,32 Type I 
PKSs differ from their type II and III counterparts, in that they are multifunctional 
polypeptide complexes harbouring different catalytic domains. Type II PKSs are 
dissociable complexes containing discrete, monofunctional, iteratively-acting enzymes, 
while type III PKSs are smaller, homodimeric enzymes with a single active site and an 
acyl carrier protein (ACP)-independent mechanism.33,34  
 
Type I PKSs can be further subdivided depending on whether they act in an iterative or 
modular fashion. Type I iterative PKSs have their catalytic domains housed within a 
single module, meaning that each domain is used repeatedly during polyketide chain 




assembly. In contrast, modular PKSs have their catalytic domains organised within 
several sequential modules, with each module usually associated with a single round of 
chain elongation and β-carbon processing.35 In these systems, accurate predictions of the 
polyketide product can be made, based on knowledge of the module and domain order. 
However, non-canonical examples of modular PKSs have also been reported, in which 
modules can be bypassed (e.g. in mupirocin biosynthesis)36 or used more than once (e.g. 
in borrelidin biosynthesis)37. These events have been termed ‘module skipping’ and 
‘module stuttering’, respectively, and result in a loss of the co-linearity normally 
associated with these enzymes. 
 
 
Scheme 1.1: The organisation of the DEBS system, responsible for the assembly of 6-deoxyerythronolide B 
20. Subsequent modification by post-PKS tailoring enzymes affords erythromycin A 21. 
 
The majority of type I modular PKSs contain three minimal catalytic domains within their 
chain extension modules: the acyl carrier protein (ACP), acyltransferase (AT), and 
ketosynthase (KS), which result in the incorporation of one acyl-CoA thioester building 
block into the nascent polyketide chain. Some chain extension modules also contain 




accessory domains, such as the ketoreductase (KR), dehydratase (DH) and enoyl 
reductase (ER), which are involved in β-carbon processing. A terminal thioesterase (TE) 
is usually employed for the release of the full-length polyketide, via hydrolysis or 
macrolactonisation.38 The 6-deoxyerythronolide B synthase (DEBS) is the prototypical 
example of a type I modular PKS, comprised of three proteins and seven modules. In this 
system, one propionyl-CoA starter unit and six methylmalonyl-CoA extender units are 
condensed, processed and released to yield 6-deoxyerythronolide B 20, the precursor to 
the antibiotic erythromycin A 21 (scheme 1.1).39  
 
1.3.1.1 Minimal catalytic domains 
 
The ACP domain is a small, four-helical bundle, located at the C-terminus of each 
module. Before polyketide chain assembly can occur, a conserved serine residue within 
the ACP must first be post-translationally modified by reaction with coenzyme A, 
catalysed by a phosphopantetheinyl transferase (scheme 1.2). This converts the inactive 
apo-form of ACP to its active holo-form, in which the newly-attached, flexible, 
phosphopantetheinyl arm can shuttle growing polyketide chains between active sites of 
the PKS, through the formation of thioester bonds.40 
 
 
Scheme 1.2: Mechanism of reaction of apo-ACP with coenzyme A to form holo-ACP. B = general base. 
 




The AT domain is responsible for catalysing the transfer of particular starter and extender 
units to the downstream ACPs with high specificity, and is thus often referred to as the 
gatekeeper domain.41 Typical starter units include acetyl- and propionyl-CoA, while 
extender units comprise their carboxylated analogues: malonyl- and methylmalonyl-CoA, 
respectively (see section 1.3.2). However, many additional starter and extender units have 
been identified, including branched, hydroxylated, chlorinated, cyclic and aromatic 
derivatives, in addition to amino acids, as part of PKS/NRPS hybrid systems.42,43  
 
The transacylation reaction occurs by a ping-pong mechanism, in which the catalytic 
serine, activated by a neighbouring histidine residue, first attacks the thioester of a CoA-
derivatised building block (e.g. propionyl- or methylmalonyl-CoA).44 The AT-tethered 
intermediate is then transferred to the phosphopantetheinyl arm of a downstream holo-
ACP (scheme 1.3), prior to being processed by the subsequent module.41  
 
 
Scheme 1.3: Mechanism of reaction of an AT domain with a starter unit (e.g. propionyl-CoA, R = H) or 
extender unit (e.g. methylmalonyl-CoA, R = CO2−), and the subsequent transfer to a downstream holo-
ACP. The catalytic histidine residue is indicated. Mx = module x. 
 
While most PKS assembly lines contain AT domains that are integrated within modules 
(cis-AT PKSs), other AT domains are encoded by discrete genes and expressed as stand-
alone polypeptides (trans-AT PKSs). In these systems, the AT is capable of acting 
iteratively, and transferring extender units to multiple ACP domains within the PKS.45 
 
The KS domain is responsible for catalysing intermodular translocation and extension of 
the polyketide chain, through the formation of carbon-carbon bonds. Initially, the 
conserved nucleophilic cysteine residue attacks the upstream ACP-bound thioester to 
form a KS-bound thioester. The downstream ACP, loaded with an extender unit, then 
docks to the acylated KS, and a decarboxylative Claisen condensation ensues, resulting 




in the elongation of the polyketide backbone by two carbon units (scheme 1.4). Two 
conserved histidine residues have recently been reported to mediate these reactions 
through general acid and base catalysis.46  
 
 
Scheme 1.4: Mechanism of reaction of a KS domain with an upstream acyl-ACP, followed by a 
decarboxylative Claisen condensation with a methylmalonyl unit tethered to a downstream ACP. Catalytic 
histidine residues are indicated. R = polyketide chain; Mx = module x. 
 
Sometimes, modular PKSs have a modified KS domain in the loading module, which 
contains a mutation of the active site cysteine to a glutamine. In these loading modules, 
the AT domain recruits a malonyl-CoA, rather than an acetyl-CoA, and the so-called KSQ 
solely catalyses its decarboxylation.47 
 
1.3.1.2 Accessory catalytic domains 
 
A number of accessory domains can then act to modify the nascent polyketide chain. The 
KR domain is responsible for reducing the β-keto group of the ACP-bound thioester to a 
β-hydroxyl group, and controlling the configuration at both the α- and β-stereogenic 
centres. During catalysis, a conserved tyrosine and serine residue activate the β-keto 
group to receive the pro-(4S) hydride of a nicotinamide adenine dinucleotide phosphate 
(NADPH) cofactor. The oxygen anion then abstracts a proton from the same catalytic 
tyrosine residue, which is stabilised by a neighbouring lysine (scheme 1.5a). Based on 
their activity and stereospecificity, KR domains can be labelled as one of three types: A- 
and B-type KRs produce a β-hydroxyl group with (S)- or (R)-stereochemistry, 
respectively (according to polyketide convention in which the α-substituent is given 
higher priority than the γ-substituent), while C-type KRs are reductase-inactive. In 
addition, KRs may be selective for substrates with either an (S)- or (R)-configured α-
substituent, or may catalyse an epimerisation at that position (scheme 1.5b).48,40 





Scheme 1.5: Mechanisms of (A) reduction; and (B) epimerisation of a β-ketothioester, catalysed by a KR 
domain. The serine, tyrosine and lysine residues within the catalytic triad are indicated. R = polyketide 
chain; A = general acid; B = general base; Mx = module x. 
 
After reduction of the β-ketothioester to a β-hydroxythioester, a DH domain can catalyse 
a dehydration reaction to generate a double bond between the α- and β-carbons. A 
catalytic histidine and aspartate have been proposed to abstract the α-proton, and 
protonate the β-hydroxyl group, respectively, to promote the syn elimination of water 
(scheme 1.6). This converts (R)- or (S)-configured β-hydroxyl groups to the 
corresponding trans- or cis-α,β-unsaturated thioesters.40,49 
 
Following the dehydration reaction, an ER domain can reduce the α,β-unsaturated double 
bond, setting the stereochemistry of α-substituents. During catalysis, a hydride is 
transferred from an NADPH cofactor and a proton is delivered to the resulting carbanion 
(scheme 1.7). Interestingly, the transfer of a pro-(4S) or pro-(4R) hydride appears to be 
organism-dependent.50,51 Active site residues involved in catalysis are as of yet unclear. 





Scheme 1.6: Mechanism of dehydration of a β-hydroxythioester, catalysed by a DH domain. Catalytic 
histidine and aspartate residues are indicated. R = polyketide chain; Mx = module x. 
 
 
Scheme 1.7: Mechanism of reduction of an α,β-unsaturated thioester, catalysed by an ER domain. 
R = polyketide chain; A = general acid; Mx = module x. 
 
Occasionally, O- and C-methyltransferase (MT) domains also reside within modules of 
type I PKSs.52,53,54,55 Rather than acting as “reductive” domains, they yield β-methoxy or 
α-alkylated products. 
 
1.3.1.3 Polyketide chain offloading 
 
Following the assembly of a full-length polyketide chain, the product is offloaded, usually 
by a TE domain. This can occur via hydrolysis or intramolecular cyclisation, to yield a 
linear carboxylic acid or macrolactone, respectively (scheme 1.8). 





Scheme 1.8: Mechanisms of chain release of a fully assembled polyketide chain by a TE domain, to yield 
a carboxylic acid (top) or macrolactone (bottom). The serine, histidine and aspartate residues within the 
catalytic triad are indicated. 
 
In both cases, a conserved histidine residue first deprotonates the nucleophilic serine, 
which then attacks the ACP-bound thioester. The tetrahedral intermediate then collapses 
with protonation of the phosphopantetheinyl leaving group by the same histidine residue, 
to yield a TE-bound ester. Subsequently, either a water molecule, or a hydroxyl moiety 
within the polyketide chain, can attack, through a similar addition-elimination 
mechanism.56 Other mechanisms of chain release are also prevalent, which result in the 
generation of different structural classes of specialised metabolites. For example, 
standalone N-acyltransferase (NAT), α-oxamine synthase (OAS) and KS domains can 
catalyse polyketide chain offloading to yield macrolactams, prodiginines and tetronates, 
respectively.57  




Commonly, PKS and NRPS gene clusters also encode a discrete type II thioesterase, 
which has a fundamental ‘editing’ role; incorrect starter units and non-reactive ACP-
bound acyl residues which would otherwise block the assembly line can be hydrolytically 
released. The responsible enzyme encoded within the cpk cluster is ScoT, which has been 
demonstrated to hydrolyse acetyl, propionyl and butyryl units.58 More recently, ScoT has 
been shown to be essential for coelimycin P2 production.59 
 
1.3.1.4 Predicted module and domain organisation of the coelimycin PKS  
 
The PKS involved in coelimycin biosynthesis is comprised of three proteins (CpkA, 




Scheme 1.9: The PKS module and domain organisation of CpkABC and the proposed structures of ACP-
bound intermediates. The cross indicates that the DH domain in module 4 is likely inactive. 




All chain extension modules are predicted to contain a KR and DH domain, in addition 
to the minimal catalytic domains. In contrast to the DEBS PKS (scheme 1.1), not all 
domains are active; the DH domain in module 4 is likely non-functional. Furthermore, no 
ER domains appear present, suggesting that the nascent polyketide chain is not fully 
reduced at any stage. One further difference is that all AT domains are predicted to recruit 
malonyl-CoA, rather than its methylated analogue. Assuming that the number of modules 
corresponds to the number of malonyl-CoA units used during chain assembly, a 
5-hydroxy-2,6,8,10-dodecatetraenoyl thioester 22 is likely assembled (scheme 1.9). 
 
Interestingly, the final PKS module contains a thioester reductase (TR) domain, rather 
than a TE domain, which has been proposed to catalyse reductive cleavage of the full-
length polyketide chain. To examine this hypothesis, purified recombinant CpkC-TR was 
incubated with octanoyl-CoA as a mimic of the proposed ACP-bound thioester 22, and 
either NADH or NADPH as a cofactor (Ruby Awodi, University of Warwick). UV-Vis 
and GC-MS analyses revealed that CpkC-TR is capable of catalysing two NADH-
mediated two-electron reductions of octanoyl-CoA to octanol.57 This suggests that 
CpkC-TR can fully reduce thioester 22 to alcohol 24 during coelimycin biosynthesis 
(scheme 1.10).  
 
 
Scheme 1.10: Mechanism of NADH-mediated reductive chain release of 22 by CpkC-TR. A = general acid. 




Notably, while several instances of TR-mediated reductive chain release have been 
reported within NRPSs, hybrid NRPS-PKSs, fatty acid synthases (FASs) and type I 
iterative PKSs,60,61,62,63 this is the first example within a type I modular PKS.30 
 
1.3.2 Precursor supply genes 
 
Four genes within the cpk cluster (cpkPα, cpkPβ, acca1 and cpkK) are proposed to encode 
enzymes which generate polyketide precursors. Typical precursors include acetyl- and 
propionyl-CoA, and their carboxylated equivalents, malonyl- and methylmalonyl-CoA. 
Six units of malonyl-CoA are predicted to be utilised by CpkA, CpkB and CpkC during 
the assembly of polyketide thioester 22. 
 
cpkPα and cpkPβ show sequence similarity to the α- and β-subunits of α-ketoacid-
dependent ferredoxin reductases. These are thiamine pyrophosphate (TPP)-, 
coenzyme A- and ferredoxin (Fd)-dependent enzymes which catalyse the oxidative 




Scheme 1.11: The conversion of pyruvate 25 to malonyl-CoA 27, catalysed by a pyruvate-dependent 
ferredoxin reductase and an acetyl-CoA carboxylase. Relevant cofactors are highlighted.  




acca1 and cpkK show sequence similarity to the α- and β-subunits of acyl-CoA 
carboxylases. These are biotin-dependent enzymes which catalyse a two-step reaction. 
Firstly, bicarbonate attacks adenosine triphosphate (ATP) to form CO2, which then reacts 
with biotin to afford carboxybiotin. Secondly, the carboxyl group is transferred from 
carboxybiotin to an acyl-CoA to yield a carboxylated derivative (e.g. acetyl-CoA 26 to 
malonyl-CoA 27, scheme 1.11).65  
 
1.3.3 Post-PKS tailoring genes 
 
Following the assembly and release of polyketide thioester 22, a series of transformations 
are necessary for its conversion to coelimycin P1 18. The responsible post-PKS tailoring 




cpkG has been demonstrated to encode a pyridoxal 5’-phosphate (PLP)-dependent 
enzyme with transaminase activity towards selected aldehydes and amines (Ruby Awodi, 
University of Warwick). Transaminases (TAs), also known as aminotransferases, are 
enzymes that mediate the transfer of an amino group between a suitable amino donor and 
acceptor. TAs that catalyse the transfer of amino groups at the α-carbon position with 
respect to a carboxylate moiety are given the prefix ‘α’, while TAs that perform the 
reaction at a β-, γ- or more distal position, or on substrates lacking a carboxylate moiety, 
are labelled as ‘ω’. Thus, in ω-TAs, at least one of the two substrates cannot be an α-amino 
acid or α-keto acid (scheme 1.12).66 
 
 
Scheme 1.12: Catalytic cycle of a TA. The amino donor (top left) transfers an amino group to enzyme-
bound pyridoxal-5’-phosphate (E-PLP), and the newly-formed enzyme-bound pyridixamine-5’-phosphate 
(E-PMP) transfers it on to the amino acceptor (bottom right). For α-TAs, R1 = RIII = CO2H. For ω-TAs, if 
R1 = CO2H, then RIII ≠ CO2H.  
 




TAs utilise PLP, a derivative of vitamin B6, as a cofactor, which acts as an effective 
molecular shuttle for protons, electrons and ammonia. The reaction catalysed by TAs can 
be divided into two halves: i) oxidative deamination of the amino donor and formation of 
pyridoxamine 5’-phosphate (PMP); and ii) reductive amination of the amino acceptor and 
reformation of PLP.67 This is often referred to as a ‘ping-pong bi-bi’ mechanism, as the 
second substrate cannot bind until the first product leaves.68 
 
 
Scheme 1.13: Reaction mechanism of a TA. In the first half of the reaction, an amino group is transferred 
from an α-amino acid to enzyme-bound PLP, to form an α-keto acid and PMP. In the second half of the 
reaction, the amino group is transferred from PMP to an aldehyde, to form a primary amine and enzyme-
bound PLP. Note: reactions are reversible, but arrows are unidirectional for clarity. 
 
 




In the catalytic cycle, PLP is initially tethered to an ε-amino group of a conserved lysine 
residue within the active site, through an internal aldimine linkage. The substrate amino 
donor (e.g. an α-amino acid) then displaces the lysine residue in a transaldimation 
reaction, forming an external aldimine. Deprotonation of the α-hydrogen by the same 
lysine residue affords a quinonoid intermediate, which is reprotonated near the pyridine 
ring to form a ketimine intermediate. Subsequent hydrolysis releases the corresponding 
carbonyl compound (e.g. an α-keto acid) and generates PMP (scheme 1.13).  
 
In the second half of the reaction, a reverse transamination occurs, in which the free amino 
group of PMP first attacks the amino acceptor (e.g. an aldehyde) to form a ketimine 
intermediate. Analogous isomerisations afford the quinonoid and external aldimine, 
which is subsequently displaced by the lysine residue, releasing the corresponding amine 
compound (e.g. a primary amine). At the same time, the PLP-form of the enzyme, or the 
internal aldimine, is regenerated (scheme 1.13).69,70  
 
Based on their 3D structures, ω-TAs can be further subdivided into fold type I or fold 
type IV classes. Members of these classes are typically selective for (S)- and (R)-
configured substrates, respectively.71 The highly stereoselective nature of ω-TAs makes 
them promising biocatalysts for the generation of chiral amines and unnatural amino 
acids, which are important synthons in pharmaceutical, fine chemical and agrochemical 
industries.72,73 
 
1.3.3.2 Flavin-dependent oxidases, dehydrogenases and monooxygenases 
 
cpkD, scF and cpkH are proposed to encode flavoenzymes. These are proteins that bind 
and utilise a form of flavin, usually flavin adenine dinucleotide (FAD), or flavin adenine 
mononucleotide (FMN). These cofactors are derivatives of riboflavin, or vitamin B2, and 
comprise a tricyclic isoalloxazine moiety attached to a ribityl chain at the N10 position 
(figure 1.7). Flavins are fundamental in many aspects of biology, including cell and drug 
metabolism, immune defence, DNA repair, cell signalling, protein folding and 
apoptosis.74,75  
 





Figure 1.7: The structures of riboflavin, FMN and FAD. The isoalloxazine ring and ribityl side chain are 
highlighted in purple and blue, respectively. 
 
Flavins are normally bound very tightly within the protein, and in approximately 11 % of 
cases, binding is covalent, with attachment of cysteine, histidine or tyrosine residues to 
the C-6 atom of the isoalloxazine ring and/or the 8α-methyl group.76 Flavins can exist in 
three oxidation states: oxidised (quinone), 1-electron reduced (semiquinone) or 2-electron 
reduced (hydroquinone), in both protonated and unprotonated forms (figure 1.8). As such, 
the cofactors are able to perform both 1- and 2-electron transfers. 
 
 
Figure 1.8: The different oxidation states of flavin, in protonated (top) and unprotonated (bottom) forms  
 
The reactions catalysed by flavoenzymes can be divided into reductive and oxidative half 
reactions. In the first half, a substrate reduces the oxidised cofactor, while in the second 
half, a separate substrate re-oxidises the reduced cofactor (scheme 1.14). In oxidases, this 




second substrate is molecular oxygen, which is converted to hydrogen peroxide. In 
dehydrogenases, an alternative electron acceptor is employed.77 
 
 
Scheme 1.14: The catalytic cycle of flavoenzymes  
 
Flavin-dependent oxidases and dehydrogenases can catalyse the oxidation of  α,β-carbon 
bonds in carboxylic acids or thioesters, and carbon-heteroatom bonds in substrates 
including alcohols, amines, amino acids and hydroxyacids.78,79 Mechanisms of oxidation 
of these substrates have been debated for several years, with proposals including: i) direct 
hydride transfer; ii) nucleophilic attack of a substrate at the C-4a position; ii) nucleophilic 
attack of a carbanion at the N-5 position; and iv) single electron transfer. However, it is 
generally accepted that the oxidation of alcohols and amines proceeds via a direct hydride 
transfer (scheme 1.15).80  
 
 
Scheme 1.15: The oxidation of an alcohol by a flavin-dependent oxidase via a direct hydride transfer. The 
oxidised-form of the cofactor is subsequently regenerated by molecular oxygen (or an alternative electron 
acceptor in the case of a dehydrogenase). A = general acid; B = general base.  
 




Flavin-dependent monooxygenases can catalyse a series of oxygenations, including 
hydroxylations, epoxidations, Baeyer-Villiger oxidations, halogenations and S- or 
N-oxidations. These enzymes transfer a single atom of molecular oxygen into the 
substrate, while the other atom is reduced to water.81 In the catalytic cycle, flavin is first 
reduced to its hydroquinone form by nicotinamide adenine dinucleotide (NADH) or its 
2’-phosphorylated analogue, NADPH (see section 1.3.3.3). Reaction with molecular 
oxygen then affords a C(4a)-hydroperoxy species, which donates an oxygen atom to the 
substrate. Elimination of water from the resulting C(4a)-hydroxyflavin adduct allows for 
the regeneration of oxidised flavin (scheme 1.16).82  
 
 
Scheme 1.16: The epoxidation of an alkene by a flavin-dependent monooxygenase. The C(4a)-hydroperoxy 
species is formed by reaction of reduced flavin with molecular oxygen. Nucleophilic attack of an alkene at 
the electrophilic oxygen yields the epoxide product, and a C(4a)-hydroxyflavin adduct which eliminates 
water to form oxidised flavin. The reduced cofactor is subsequently regenerated by direct hydride transfer 
from NAD(P)H. A = general acid; B = general base.  
  
Flavin-dependent monooxygenases can be categorised into eight groups, according to 
their fold, function, key sequence motifs and the electron donor. Groups A and B employ 
NAD(P)H as an external electron donor, while groups C–F require a flavin reductase 
partner protein instead. Groups G and H are mechanistically dissimilar, and directly 
utilise the substrate to reduce the flavin cofactor.83  
 




1.3.3.3 Short-chain dehydrogenases 
 
cpkI is proposed to encode a short-chain dehydrogenase (SDH). These are enzymes which 
catalyse a variety of catabolic and biosynthetic redox reactions, utilising NADH or 
NADPH as an electron carrier. These cofactors consist of an adenosine diphosphate 
(ADP) ribose group attached to a nicotinamide heterocyclic ring (figure 1.9). When 
oxidised to NAD(P)+, the 1,4-dihydropyridine moiety is converted to its pyridinium 
equivalent. In contrast to flavins, nicotinamide cofactors are exclusively bound non-
covalently and used in stoichiometric quantities.77 
 
 
Figure 1.9: The structure of NADH (R = H) and NADPH (R = PO32–). The nicotinamide and ADP ribose 
groups are highlighted in purple and blue, respectively. 
 
SDHs generally catalyse the oxidation or reduction of carbon-carbon, carbon-oxygen and 
carbon-nitrogen single- or double-bonds, respectively.84 Studies of SDHs from 
Drosophila, humans and bacteria indicate that a conserved tyrosine hydroxyl residue, 
activated by a nearby lysine, abstracts or donates a proton from/to the substrate, as 
appropriate (scheme 1.17).85,86,87,88 An asparagine residue also participates in the proton 
relay, while a conserved serine acts to stabilise and polarise the substrate. Contrary to 
medium-chain dehydrogenases (MDH), it is the pro-(4S) hydride that is transferred 
between the nicotinamide cofactor and the substrate.84 
 
 
Scheme 1.17: The dehydrogenation of an alcohol by a short-chain dehydrogenase, using NAD(P)+ as a 
cofactor  






cpkE is tentatively proposed to encode an isomerase. These are enzymes that catalyse 
intramolecular rearrangements, such as racemisations, epimerisations, tautomerisations 
and cis-trans isomerisations, often via a cofactor-independent mechanism.89 Examples 
include aspartate racemase, methylmalonyl-CoA epimerase, phosphoglucose isomerase 
and β-hydroxydecanoyl thioester isomerase.90,91,92,93 Such enzymes are biologically 
important in primary and secondary metabolism, particularly in transformations involving 
carbohydrates, terpenoids and polyketides.94 Isomerases generally operate via acid-base 
chemistry, in which a substrate is deprotonated at one position, and reprotonated at 
another (scheme 1.18). 
 
 
Scheme 1.18: The isomerisation of trans-2-decenoic acid to cis-3-decenoic acid by β-hydroxydecanoyl 
thioester isomerase. A = general acid. Revised from Bugg, Schwab and Klassen.89,93 
 
1.4 Proposed biosynthesis of coelimycin P1 
 
Based on the predicted functions of the enzymes encoded by the cpk cluster, a 
biosynthetic pathway was proposed by Gomez-Escribano and coworkers.30 
 
Initially, six units of malonyl-CoA 27, biosynthesised by CpkPα, CpkPβ, Acca1 and 
CpkK, are likely condensed together and processed by PKS enzymes CpkA, CpkB and 
CpkC to form thioester 22. This is then reductively cleaved by the TR domain of CpkC 
to afford aldehyde 23, which may be further reduced to the corresponding alcohol 24 and 
re-oxidised by CpkI. The E-configured 2,3-double bond of 23 may then be isomerised to 
a Z-configured 3,4-alkene by CpkE, to allow cyclisation to occur at a later stage. 
Subsequently, aldehyde 28 is hypothesised to undergo a CpkG-catalysed reductive 
amination to afford amine 29, which is then subject to a series of oxidative 
transformations by flavoenzymes CpkD, ScF and CpkH. These include epoxidations 




across the C-6/C-7 and C-8/C-9 double bonds to form mono- and bis-epoxides 30 and 31, 
respectively, and an oxidation of the C-4 hydroxyl group, to form ketone 32. Spontaneous 
intramolecular imine formation would then afford coelimycin A 19; the predicted true 
metabolic product of the cpk gene cluster. This is then likely attacked by N-acetyl cysteine 
(or glutamate, in the case of coelimycin P2) with loss of water to produce the 1,5-
oxathiocane skeleton. Oxidation of the C-9 hydroxyl group of 33 by molecular oxygen 




Scheme 1.19: The proposed biosynthesis of coelimycin A 19 and coelimycin P1 18 





Notably, CpkH and ScF are both substrates of the twin-arginine-translocase (TAT) 
secretion system,95 indicating that they are translocated across the cytoplasmic membrane 
in their folded states.96 Since they are secreted, this suggests that they may catalyse late-
stage biosynthetic reactions. CpkF, a putative transmembrane efflux protein, has been 
proposed to facilitate the export of intermediate 29 before it is further processed.  
 
Isotope incorporation experiments have provided some evidence for the proposed 
pathway. After culturing S. coelicolor M1157 in an 18O2 atmosphere, it was demonstrated 
that a single atom of labelled oxygen was specifically incorporated into the C-9 keto 
group of coelimycin P1 18, as anticipated. Furthermore, separate feeding experiments 
with N-(acetyl-d3)-cysteine enantiomers showed the incorporation of deuterium atoms 
(and therefore N-acetylcysteine) into coelimycin P1 in both instances. However, only 
(2R)-N-acetylcysteine had the same retention time as unlabelled coelimycin P1 from 
chiral LC-MS analysis, proving its stereochemistry at that position.30  
 
Moreover, in vivo gene knockouts of cpkD, scF and cpkH have provided insight into the 
roles of the oxidative enzymes and the order of pathway intermediates (Gomez-
Escribano, Song, Bibb and Challis, unpublished data). All mutants lost their ability to 
produce coelimycin P1, demonstrating that the corresponding enzymes are essential for 
its biosynthesis. Comparative metabolic profiling of S. coelicolor M1152ΔcpkH with the 
wild-type strain indicated that CpkH may catalyse the dehydrogenation of alcohol 31 to 
ketone 32; molecular ions corresponding to intermediates 23/28 and 29-31, but not 19, 
could be detected. From LC-MS analysis of S. coelicolor M1152ΔcpkD and S. coelicolor 
M1152ΔscF supernatants, ions consistent with the molecular masses of 30 or 31, 
respectively (and later stage intermediates), appeared absent, suggesting that CpkD and 
ScF may catalyse epoxidation reactions. However, further experiments are necessary to 
establish the structures represented by these ions.  
 
While preliminary studies are suggestive of the functions of some of the biosynthetic 
enzymes, further investigations are necessary for their full characterisation. Deciphering 
the biosynthesis of coelimycin P1 could allow for re-engineering of the pathway, for the 
generation of stable and novel analogues that may still retain antibiotic activity. 
 




1.5 Regulation of coelimycin P1 biosynthesis 
 
The expression of the cpk cluster is controlled by several regulatory genes (scbA, scbB, 
scbC, scbR, scbR2, cpkO, cpkN and cpkM). For example, scbA and scbB encode 
orthologues of AfsA and BprA from Streptomyces griseus, which function as a butenolide 
synthase and a butenolide phosphate reductase, respectively, while scbC encodes a 
homologue of an SDH (it is worth noting that scbB and scbC are sometimes named 
inversely).97,98 Together, these enzymes have been shown to be essential for the 
biosynthesis of γ-butyrolactone signalling molecules;17,99,98 ScbA and ScbB likely 
condense dihydroxyacetone phosphate (DHAP) with a β-ketothioester intermediate and 
reduce the resulting butenolide phosphate, respectively,100 while ScbC has been 
demonstrated to catalyse an NADPH-mediated reduction of the keto moiety (scheme 
1.20).98 At sufficiently high concentrations, these signalling molecules, termed 
S. coelicolor butenolides (SCBs, 13, scheme 1.20) bind to ScbR; a repressor protein with 
a TetR-like N-terminal helix-turn-helix domain.101 This likely causes a change in 
conformation of ScbR,102 resulting in the dissociation of the protein from its target DNA 
sites and leading to derepression of transcription (figure 1.10). The sites at which ScbR 
binds include the operator in the bidirectional scbA/scbR promoter and the promoters for 
cpkO and cpkM.103,104 Another repressor protein, ScbR2, also represses transcription of 
scbA, cpkO and cpkM, but does not bind SCBs.104,105,106 Deletion of ScbR2 was found to 
induce coelimycin P2 production.26 
 
 
Scheme 1.20: The biosynthesis of S. coelicolor butenolides (SCBs, 13) 1-8. An ACP-bound β-ketothioester 
from a fatty acid synthase (FAS) is condensed with dihydroxyacetone phosphate (DHAP) by ScbA and the 
double bond reduced by ScbB. A dephosphorylation (by an unknown enzyme) and reduction of the keto 
group by ScbC afford the SCBs.100,98 





Two further regulatory genes, cpkO and cpkN, encode Streptomyces Antibiotic 
Regulatory Proteins (SARPs); a family of transcriptional activators that recruit RNA 
polymerase to its target promoters.107 However, while cpkO is essential for coelimycin 
biosynthesis, cpkN is not.108,109 A final regulatory gene, cpkM, encodes a two-component 
histidine kinase. These proteins are usually involved in signal transduction in numerous 
cellular processes.110  
 
In addition to local regulatory effects, a range of global/pleiotropic regulators have been 
reported to bind to various promoters in the cpk cluster (figure 1.10), influencing the 
transcription of upstream genes. For example, the two-component systems DraR/K and 
AfsQ1/Q2 directly repress the transcription of cpkO and activate the transcription of 
cpkABC, respectively.111,112,113 Furthermore, DasR (involved in N-acetyl glucosamine 
metabolism),114 NdgR (involved in controlling nitrogen source-dependent growth)115 and 
PhoP (involved in phosphate metabolism)116 all bind to the scbA/scbR promoter region, 
suggesting a connection between primary and secondary metabolism through the SCB 
system.98 Another global regulator, ArgA (involved in mediating arginine biosynthesis), 
has also been implicated in the downregulation of several cpk genes, although its target 
DNA sites are not known.117 
 
 
Figure 1.10: Regulation of coelimycin biosynthesis, involving S. coelicolor butenolide (SCB) signalling 
molecules and interactions with receptors and ligands from other pathways (grey). Activatory and inhibitory 
steps are indicated by arrows or lines ending with a bar, respectively. Additional binding sites of ScbR2 
(intergenic regions of acca1‒scF, cpkA‒cpkD, cpkI‒cpkJ and the promoter of cpkN)104 have been omitted 
for clarity. Adapted from Liu and coworkers.108  
 




Further transcriptional regulation of the cpk cluster can occur via crosstalk with the act 
and red biosynthetic pathways. For instance, it has been demonstrated that actinorhodin 
9 and undecylprodigiosin 10 can bind ScbR2 and release it from its promoter (figure 
1.10), resulting in the derepression of transcription of cpkO.105 Likewise, addition of 
SCBs 13 or inactivation of scbA alters the expression of the act and red pathways.118,17 
 
1.6 Other polyketide alkaloids 
 
Coelimycin P1 18 was the first actinobacterial alkaloid to be conclusively characterised 
as the product of a type I modular PKS. Several other actinobacterial alkaloids also appear 
to be of polyketide origin, as demonstrated by incorporation experiments with isotope-
labelled acetate and propionate units. Examples include latumcidin 35 (also known as 
abikoviromycin), nigrifactin 36, pyrindicin 37, streptazolin 38 and cyclizidine 
39.119,120,121,122,123 The similarly-structured alkaloids JBIR-102 40, 4-hydroxy-(2-penta-
1,3-dienyl)piperidine 41, streptazone E 42, indolizomycin 43 and iminimycin A 44 may 
also derive from polyketide precursors (figure 1.11).124,125,126,127,128 Many of these 
metabolites display interesting biological properties, including antibacterial, antifungal, 
cytotoxic and beta-blocker activities.  
 
 
Figure 1.11: Structures of polyketide alkaloids from Actinobacteria 




At the start of this project, no genetic information was available to link these metabolites 
to polyketide clusters. Understanding their biosynthesis could uncover new enzymology 
and allow for the engineering or discovery of novel polyketide alkaloids with potentially 
wide-ranging activities.  
 
1.7 Aims of the project 
 
The main aim of this project was to investigate the biosynthetic reactions and enzymatic 
machinery involved in actinobacterial polyketide alkaloid formation, with primary focus 
on coelimycin P1. This would initially involve further investigations of CpkG, to 
determine factors such as the substrate scope, preference and stereospecificity of the 
transamination reaction, and to attempt to obtain a crystal structure of the protein. 
Following this, the aim was to clone the remaining post-PKS tailoring genes (cpkI, cpkE, 
cpkD, scF and cpkH) and purify the resulting recombinant enzymes. A range of putative 
substrates and standards would then be synthesised to establish the activities of the 
enzymes and to elucidate the cpk biosynthetic pathway in vitro.  
 
An additional aim was to explore the biosynthesis of further polyketide alkaloids through 
bioinformatics-guided and genomics-based approaches, in the hope of establishing 
whether general mechanistic principles underlie the assembly of this class of metabolite. 




2 RESULTS AND DISCUSSION I: Nitrogen incorporation 
in coelimycin and related polyketide alkaloids 








CpkG, a pyridoxal-5’-phosphate (PLP)-dependent ω-transaminase (TA), is proposed to 




Scheme 2.1: Proposed reaction catalysed by CpkG in coelimycin biosynthesis30 
 
CpkG has previously been shown to catalyse transamination reactions between selected 
aldehydes and amines (Ruby Awodi, University of Warwick). However, factors such as 
the substrate scope, preference and stereospecificity of the reaction remained to be 
investigated. Furthermore, CpkG had yet to be incubated with close structural analogues 
of 28 and 29 to establish its role in the proposed pathway.  
 
2.1.2 Overproduction, purification and characterisation of CpkG 
 
In order to probe the transaminase activity of CpkG in vitro, E. coli One Shot® BL21 
StarTM cells were first transformed with pET151::cpkG; a plasmid designed to 
overexpress cpkG from the IPTG-inducible T7 promoter as an N-terminal His6-fusion 
protein (engineered by Ruby Awodi). Following overnight induction of cpkG with IPTG, 
the cells were harvested and lysed. The recombinant protein was then purified from cell-
free extracts by immobilised metal-affinity chromatography (IMAC), using 
Ni-nitriloacetic acid (Ni-NTA) resin.  
 
SDS-PAGE analysis demonstrated that His6-CpkG was pure and of the expected 
molecular weight (figure 2.1a). The exact molecular weight of the protein was verified 
by high-resolution mass spectrometry (HRMS) (figure 2.1b; calculated m/z = 60646 Da, 
observed m/z = 60648 Da). Despite obtaining some insoluble protein, 10 mg/mL of 
soluble protein was recovered. 





Figure 2.1: (A) Nickel affinity purification of His6-CpkG. L1: Molecular weight marker; L2: elution with 
20 mM imidazole; L3: elution with 50 mM imidazole; L4: elution with 100 mM imidazole; L5: elution with 
200 mM imidazole; L6: elution with 300 mM imidazole; L7: flow through from column; L8: soluble protein; 
L9: insoluble protein. (B) Deconvoluted mass spectrum of His6-CpkG. The measured and calculated 
molecular weights of His6-CpkG are 60648 Da and 60646 Da, respectively.  
 
 
To investigate the ability of CpkG to covalently bind PLP, a UV/Vis absorption spectrum 
of the recombinant enzyme purified in the presence of the cofactor was compared to that 
of PLP alone. At pH 8.0, a characteristic λmax shift from 410 nm to 418 nm was observed, 
indicating that PLP forms an internal aldimine bond with CpkG (figure 2.2).129 Assuming 
that free PLP and the aldimine adduct have similar molar extinction coefficients, the 
concentration of bound PLP can be determined. The near-identical absorbance intensities 
at λmax are thus consistent with a 1:1 molar binding ratio. 
 
 
Figure 2.2: UV/Vis spectra and structures of PLP (light grey) and the aldimine adduct of PLP with CpkG 
(dark grey). The λmax values of the two peaks are 410 nm and 418 nm, respectively. 




2.1.3 In vitro assays 
 
The activity of CpkG was then investigated in vitro, by employing three different assays 
to detect the four components of the transamination reaction: the amino acid, 
aldehyde/ketone, α-keto acid and amine (scheme 2.2).57  
 
 
Scheme 2.2: The general transamination reaction catalysed by CpkG.  
 
2.1.3.1 Amino acid and aldehyde detection 
 
In collaboration with Dr. Joleen Masschelein, University of Warwick 
The activity and substrate specificity of CpkG were initially explored using a 
spectrophotometric assay designed to detect the production of amino acids via formation 
of a blue copper (II) complex (scheme 2.3).130  
 
 
Scheme 2.3: Assay employed to detect amino acids produced during the transamination reaction.130 Amines 
(10 mM, 45-49) and α-keto acids (10 mM, 25 and 50) tested as substrates for CpkG (20 μM) are shown.57 
 
His6-CpkG, supplemented with PLP during purification (herein referred to as holo-His6-
CpkG), was incubated with several amines and either pyruvate or α-ketoglutarate, to 
examine conversion to the corresponding aldehydes/ketones, and either alanine or 
glutamic acid, respectively. The absorbance at 595 nm was then measured relative to 
blank and control samples. 




All of the amines tested were found to stimulate conversion of the two α-keto acids to the 
corresponding amino acids, demonstrating that CpkG has a broad substrate tolerance 
(figure 2.3). No significant differences in relative specificities between benzylamine 45, 
cyclohexylamine 46, isobutylamine 47 and butylamine 48 were observed when using 
α-ketoglutarate 50 as a cosubstrate, suggesting that linear, branched, cyclic and aromatic 
amines can be similarly tolerated. For butylamine and benzylamine, considerably lower 
levels of activity were detected when using pyruvate 25 as a cosubstrate, although it is 
unclear why. The highest level of activity was observed for octylamine 49, together with 
pyruvate, indicating that CpkG prefers medium-chain alkylamines. This is consistent with 
its proposed role in coelimycin biosynthesis. 
 
 
Figure 2.3: Amino donor and acceptor specificities of CpkG as determined by the CuSO4/MeOH staining 
method.130 The specificities for the different substrate combinations are shown relative to the specificity of 
CpkG for octylamine and pyruvate as amino donor and acceptor. Data are represented as means ± 1 standard 
deviation from triplicate experiments. 
 
Utilising the preferred substrates, octylamine and pyruvate, the formation of octanal 57 
was examined by LC-MS. Because aldehydes typically have a poor ionisation efficiency, 
both the product of the reaction and an authentic standard of octanal were derivatised with 
D-cysteine prior to analysis (scheme 2.4).131 The retention time and molecular weight of 
the derivatised reaction product were consistent with those of the authentic standard 
(figure 2.4), thereby proving that octanal was formed during the reaction. 





Scheme 2.4: Assay employed for the detection and derivatisation of octanal 57 with D-cysteine (400 μM),131 
following reaction of pyruvate 25 (200 μM) and octylamine 49 (200 μM) with CpkG (90 μM).  
 
 
Figure 2.4: Extracted ion chromatograms at m/z = 232.1366 ± 0.005 (corresponding to the [M+H]
+
 ion of 
the D-cysteine derivative of octanal) from LC-MS analyses of the CpkG-catalysed reaction of octylamine 
with pyruvate. From top to bottom: enzymatic reaction; control from which the enzyme was omitted; and 
authentic standard. 
 
2.1.3.1.1 Determination of amino acid stereochemistry 
 
To determine the stereochemical outcome of the CpkG-catalysed reaction of octylamine 
with pyruvate, the alanine 51 produced was derivatised with enantiomerically-pure 
Marfey’s reagent (scheme 2.5).132  
 
Scheme 2.5: Assay employed to establish the stereochemistry of alanine 51 produced,132 following reaction 
of octylamine 49 (10 mM) and pyruvate 25 (10 mM) with CpkG (20 μM). 
 
The Marfey’s-derivatised product was then compared to authentic standards of 
derivatised L- and D-alanine by LC-MS. As these compounds are diastereomers, they 
display different retention times under optimised elution conditions. Analysis of the 




chromatograms revealed that only L-alanine is formed during the transamination reaction 
(figure 2.5). Because the reaction is reversible, this suggests that CpkG has preference for 
L-amino acid substrates, and may function as an (S)-selective ω-TA. 
 
 
Figure 2.5: Extracted ion chromatograms at m/z = 342.1044 ± 0.005 (corresponding to the [M+H]+ ion of 
Marfey’s-derivatised alanine) from LC-MS analyses of the CpkG-catalysed reaction of octylamine with 
pyruvate. From top to bottom: Marfey’s derivatisation of the product of the reaction; Marfey’s 
derivatisation of the control reaction from which enzyme was omitted; Marfey’s derivatisation of an 
L-alanine standard; Marfey’s derivatisation of a D-alanine standard. 
  
2.1.3.2 α-Keto acid and amine detection 
 
Having established that octylamine and pyruvate are good substrates for CpkG in the 
reverse of the proposed biosynthetic reaction, reductive amination of octanal using 
alanine as an amino donor was subsequently examined.  
 
Pyruvate formation was monitored using a coupled assay with lactate dehydrogenase 
(LDH), that exploits the absorption of NADH, but not NAD+, at 340 nm (scheme 2.6).133 
 
 
Scheme 2.6: Assay employed to detect octylamine 49 and pyruvate 25 production, following reaction of 
octanal 57 (200 μM) and alanine 51 (200 μM) with CpkG (90 μM). Octylamine was observed by LC-MS 
comparison to an authentic standard, while pyruvate was detected by monitoring the decrease in absorbance 
at 340 nm after addition of LDH (1 μM) and NADH (200 μM).133 
 





A decrease in absorbance at 340 nm was observed, indicating that NADH was being 
oxidised during the conversion of pyruvate to lactic acid 58 (figure 2.6a). The octylamine 
formed during the same reaction was detected by LC-MS comparisons with an authentic 
standard (figure 2.6b).57  
 
 
Figure 2.6: (A) Detection of pyruvate formation from L-alanine using a coupled assay with LDH and 
NADH. The consumption of NADH was determined by monitoring the decrease in absorbance at 340 nm 
after CpkG addition (dark grey) and without CpkG addition (light grey). (B) Extracted ion chromatograms 
at m/z = 130.1590 ± 0.005 (corresponding to the [M+H]+ ion for octylamine) from LC-MS analyses of the 
CpkG-catalysed reaction of octanal with L-alanine. From top to bottom: enzymatic reaction; control 
reaction from which the enzyme was omitted; and authentic standard. 
 
2.1.3.3 Utilisation of synthetic substrate mimics 
 
Once the transaminase activity of CpkG had been confirmed, two substrate analogues (59 
and 60), containing the same 5’-hydroxyl functional group and carbon chain length as the 
proposed true intermediates of the coelimycin biosynthetic pathway (28 and 29), were 
synthesised (scheme 2.7).  
 
In the first step, commercially-available δ-dodecalactone 61 was reduced with DIBAL-H, 
following a procedure described by Zhou and coworkers.134 5-Hydroxydodecanal 59, 
existing predominantly as lactol 62, was afforded in moderate yield. Subsequently, 
benzylamine, Pd/C and H2 were added to effect a mild, one-pot conversion of the 
aldehyde to the corresponding primary amine 60 via reductive amination. Several 
milligrams of product were purified by HPLC for use in in vitro assays. 





Scheme 2.7: Left: Synthesis of 5-hydroxydodecanal 59 by reduction of δ-dodecalactone 61 (1.0 eq.) with 
DIBAL-H (1.0 eq.). Right: Synthesis of 1-aminododecan-5-ol 60 by reaction of 59 (1.0 eq.) with 
benzylamine (1.3 eq.), Pd/C (catalytic) and H2 (1 atm). 
 
Compounds 59 and 60 were then incubated with holo-His6-CpkG and either alanine 51 
or pyruvate 25, respectively (scheme 2.8). The products of the reaction were then 
analysed by LC-MS, after derivatisation, if appropriate, as described in sections 2.1.3.1. 
 
 
Scheme 2.8: General assay for the detection of 1-aminododecan-5-ol 60 (forward reaction) or 
5-hydroxydodecanal 59 (reverse reaction), from incubation of the appropriate substrates (200 μM) with 
CpkG (90 μM). For the reverse reaction, 59 was derivatised with D-cysteine (400 μM) prior to LC-MS 
analysis. 
 
Amine 60 and aldehyde 59 were readily detected in the forward and reverse reactions, 
respectively (figure 2.7). This implicates CpkG in catalysing the analogous conversion of 
28 to 29 in coelimycin biosynthesis.  
 
 
Figure 2.7: (A) Extracted ion chromatograms at m/z = 202.2165 ± 0.005 (corresponding to the [M+H]+ ion 
for 1-aminododecan-5-ol) from LC-MS analyses of the CpkG-catalysed reaction of 5-hydroxydodecanal 
with L-alanine. From top to bottom: enzymatic reaction; control reaction from which the enzyme was 
omitted; and authentic standard. (B) Extracted ion chromatograms at m/z = 304.1941 ± 0.005 
(corresponding to the [M+H]+ ion for D-cysteine-derivatised 5-hydroxydodecanal) from LC-MS analyses 
of the CpkG-catalysed reaction of 1-aminododecan-5-ol with pyruvate. From top to bottom: enzymatic 
reaction; control reaction from which the enzyme was omitted; and authentic standard. 




2.2 Crystal structures of CpkG 
 
2.2.1 Crystallisation screens 
 
In collaboration with Dr. Lona Alkhalaf, University of Warwick 
To gain further insight into the transamination mechanism, substrate tolerance and 
stereoselectivity of CpkG, the recombinant holo-protein was purified by nickel affinity 
chromatography for crystallisation trials. Initially, trials were performed in the absence 
of substrate, using three commercially available screens (JCSG-plus, Structure and PACT 
premier) and a Honeybee robot. 
 
A crystal was obtained from a PACT premier screen (figure 
2.8) that diffracted to 2.85 Å. A full data set was acquired, 
enabling the structure of CpkG to be solved by molecular 
replacement and refinement (Dr. Lona Alkhalaf, see 
appendices 2 and 3). CrmG, an ω-TA sharing 50 % sequence 
identity, was used as the template.135 
 
Unfortunately, the electron density around the cofactor and active site residues was not 
well defined; possibly because PLP was present in both covalently-bound and unbound 
forms. Therefore, crystallisation trials were repeated under optimised conditions (0.2 M 
sodium malonate dibasic monohydrate, 0.15 M bis-tris propane, 20 % w/v PEG, pH 6.5) 
and in the presence of L-alanine 51, in order to fully convert PLP to its PMP equivalent. 
A crystal structure (CpkG_ala) was determined at 2.60 Å resolution.  
 
2.2.2 Overall structure of CpkG 
 
The crystal structure of CpkG_ala confirms that the protein is indeed homodimeric, as it 
is composed of two identical monomer units (figure 2.9a). Each monomer contains three 
domains; a large domain, a small domain, and an additional domain (figure 2.9b). 
 
The large domain contains a central seven-stranded mixed β-sheet, while the small 
domain contains two three-stranded antiparallel β-sheets near to both the N- and 
C-termini. These features are characteristic of a fold-type I conformation, adopted by 
Figure 2.8: A crystal obtained 
from a PACT premier screen 




(S)-selective ω-TAs.136,137,138 Thus, the structure is consistent with the observation that 




Figure 2.9: (A) A cartoon display of the CpkG homodimer. Monomer units are highlighted in violet and 
teal, while PMP ligands are depicted as spheres. (B) A cartoon display of the domain architecture of a CpkG 
monomer. The large domain, small domain and additional domain are highlighted in blue, green and 
magenta, respectively, while the PMP ligand is depicted as sticks in CPK colouring. (C) The predicted 
substrate binding tunnel positioned behind the primary amino group of PMP, displayed in surface view. 
 
Both domains also comprise several α-helices and unstructured loops. At the interface of 
the two domains, a molecule of PMP is bound. The substrate L-alanine or product 
pyruvate appear absent from the structure, presumably due to diffusion following the first 
half of the transamination reaction. However, it is possible to discern the putative 
substrate binding tunnel (figure 2.9c). 
 
The additional domain consists of a two-stranded antiparallel β-sheet and a helical bundle 
formed from two α-helices (figure 2.9b, magenta). To date, the only other PDB entry 
reported to contain a structurally similar domain is that of CrmG.135 Zhu and coworkers 
attempted to establish the function of the domain through structure-guided mutagenesis. 
Deletion of a small helix in the additional domain yielded a mutant with near identical 
activity compared to wild-type CrmG. Other deletions afforded insoluble variants, 
suggesting that the domain is important for maintaining the correct protein 
conformation.135  




An alternative hypothesis could be that the domain plays a role in protein-protein 
interactions. In coelimycin P1 biosynthesis, the ACP-bound thioester 22 is reductively 
cleaved by the TR domain to yield aldehyde 23, which is further reduced to alcohol 24 
(see section 1.3.1.4). However, interaction of the TR domain with CpkG could promote 
direct conversion of 23 to the corresponding amine before further reduction can occur 
(scheme 2.9).  
 
 
Scheme 2.9: Possible biosynthetic pathways leading to the formation of the amine intermediate. Grey: 
original proposed pathway; black: alternative pathway in which CpkC-TR and CpkG interact with one 
another, resulting in the direct conversion of the aldehyde to the amine. Note: the postulated isomerisation 
catalysed by CpkE has been omitted for clarity. 
 
Indeed, a similar phenomenon has previously been reported for the NRPS-derived 
myxochelins. Reduction of the peptidyl carrier protein (PCP)-tethered thioester yields an 
aldehyde intermediate, which is then further reduced to afford myxochelin A, or 
transaminated to produce myxochelin B.139 Moreover, as free aldehydes can be harmful 
to microbial cells,140 having protein-associated aldehyde could be an important 
detoxification mechanism in Streptomyces. This theory prompted investigations into 
binding interactions between CpkC-TR and CpkG (see section 2.3).  
 
2.2.3 Binding of PMP 
 
A closer look at the active site reveals that PMP is held in place by several polar 
interactions (figure 2.10a). A conserved aspartate (Asp317) and glutamine (Gln320) form 
hydrogen bonds with the pyridine nitrogen and 3’-hydroxyl group of PMP, respectively, 
while residues Gly129, Ala130 and Thr376 interact with the phosphate moiety. Two 
additional hydrogen bonds are present between the primary amino group of PMP, and the 
side-chain carboxylate and amino groups of Glu289 and Lys346, respectively. This lysine 
residue is predicted to covalently bind PLP through internal and external aldimine 
linkages during transamination. 





Figure 2.10: (A) Polar interactions of PMP with surrounding residues. (B) Face-to-edge π−π stacking 
interaction of PMP with Phe209. The carbon chains of PMP and residues are depicted in grey and teal, 
respectively, while other atoms are shown in CPK colouring. 
 
The aromatic ring of PMP partakes in a non-polar, face-to-edge π−π stacking interaction 
with Phe209 (figure 2.10b). This residue likely stabilises the formation of external 
aldimine and quinonoid intermediates during transamination.135,141  
 
2.2.4 Binding of PLP   
 
In an attempt to determine the mechanism of substrate binding, crystallisation trials were 
repeated in the presence of both L-alanine 51 and 5-hydroxydodecanal 59. A crystal 
structure (CpkG_ala_lactol) was subsequently solved to 2.60 Å resolution (Dr. Lona 
Alkhalaf, University of Warwick).  
 
The binding of L-alanine, 5-hydroxydodecanal or their corresponding products could not 
be observed, which may again be attributable to product diffusion. However, the PMP 
cofactor was instead replaced with a PLP-internal aldimine, through the predicted 
ε-amino linkage with Lys346 (figure 2.11a), suggesting that at least one complete 
transamination had occurred during crystallisation. 
 
The overall conformation and active-site fold are very similar in both the PMP- and PLP-
bound states. An additional hydrogen bonding interaction between Thr376 and the imine 
group of bound PLP appears to stabilise the cofactor (figure 2.11a). An overlay of the two 
structures reveals that several residues around the substrate binding pocket have 




undergone small conformational changes, namely Tyr64, Glu289, Arg488 (figure 2.11b). 
A similarly-positioned tyrosine residue (Tyr85) in human ornithine aminotransferase 
(OAT) has been demonstrated to have considerable flexibility and to be a key determinant 
in substrate recognition.142,143 
 
 
Figure 2.11: (A) Polar interactions of PLP with surrounding residues. (B) An overlay of CpkG_ala (teal) 
with CpkG_ala_lactol (violet). Residues that have undergone significant conformational alternations are 
depicted. Nitrogen, oxygen and phosphorous atoms are shown in CPK colours. 
 
Moreover, the corresponding glutamate and arginine residues in OAT have been proposed 
to operate together as a functional switch, permitting or restricting the binding of 
substrates at different points in the catalytic cycle.144 This ‘gateway’ system has since 
been observed in several other ω-TAs (e.g. acetylornithine aminotransferase from 
Thermus thermophilus HB8145 and γ-aminobutyrate aminotransferase from E. coli146) and 
allows the enzyme to confer specificity towards longer-chain amines lacking an 
α-carboxyl group, while maintaining the ability to bind the α-keto acid acceptor.138 
Interestingly, these residues have only been reported in α-ketoglutarate-dependent 
ω-TAs, which contain a second conserved arginine (Arg180 in OAT) to bind the 
γ-carboxylate group.138 This residue is absent in CpkG, which preferentially utilises 
pyruvate (see section 2.1.3.1). However, the presence of the Glu289-Arg488 ion pair 
suggests that it may operate in a similar manner.  
 
Future work could explore the soaking of ligands into pre-existing crystals, in order to 
prevent product diffusion, determine the mode of binding and predict the substrate scope 
of CpkG. 




2.3 Investigations into CpkG and CpkC-TR binding 
 
Following examination of the crystal structure of CpkG, it was proposed that CpkG and 
CpkC-TR may interact to promote the direct conversion of aldehyde 23 to the 
corresponding amine in coelimycin biosynthesis (see section 2.2.2). This hypothesis was 
investigated using two different techniques: native-PAGE analysis and pull-down assays.  
 
2.3.1 Native-PAGE analysis 
 
To investigate potential non-covalent binding interactions between CpkC-TR and CpkG, 
the N-terminal hexahistidine fusion proteins were overproduced in E. coli from the 
appropriate pET151 constructs (engineered by Ruby Awodi, University of Warwick). 
They were then purified to homogeneity by nickel affinity chromatography and gel 
filtration (figure 2.12a). 
 
The two proteins were subsequently incubated together, and speculative binding events 
were probed by monitoring protein migration under non-denaturing conditions. Thus, 
PAGE gels were prepared in the absence of SDS, and proteins were electrophoresed at 
4 ºC using a low applied voltage.  
 
If the two proteins interact, a higher 
band should be apparent in the gel, 
due to the larger hydrodynamic radius 
of the complex.147 However, the only 
observable bands corresponded to a 
mixture of CpkC-TR aggregates and 
the monomer and dimer of CpkG 
(figure 2.12b). This either suggests 
that the proteins do not interact, or 
that binding is transient or too weak 
for detection. Therefore, a second 
technique was utilised to distinguish 
between these possibilities. 
 
Figure 2.12: (A) SDS-PAGE analysis of His6-CpkC-
TR (L2) and His6-CpkG (L3), relative to a protein 
molecular weight marker (L1). The molecular weights 
of His6-CpkC-TR and His6-CpkG are 46.0 and 
60.6 kDa, respectively. (B) Native-PAGE analysis of 
His6-CpkC-TR (L1), His6-CpkG (L2) and a 1:1 
mixture of His6-CpkC-TR and His6-CpkG (L3).  
 




2.3.2 Pull-down assays 
 
Pull-down assays rely on the use of a ‘bait’ protein, which is tagged and immobilised on 
a specific ligand. Putative interactions with untagged ‘prey’ proteins can be inferred if 
they are captured and ‘pulled-down’ when the bait protein is eluted.148  
 
In these assays, His6-CpkC-TR and Ni-NTA resin were used as the bait and ligand, 
respectively. The His6-tag of CpkG was removed using TEV protease, a cysteine protease 
with a stringent sequence specificity, to obtain speculative prey protein (figure 2.13a). 
The two proteins were then incubated together and passed through the resin. CpkG could 
only be observed in the wash fraction and did not co-elute with His6-CpkC-TR (figure 
2.13c), suggesting that the two proteins do not form significant interactions. Similar 




Figure 2.13: Left: SDS-PAGE analysis of (A) CpkG and (B) CpkC-TR, following cleavage of 
hexahistidine tags with TEV protease. L1: Protein molecular weight marker; L2: His6-tagged protein 
standard; L3: Protein collected from wash fraction (20 mM imidazole); L4: Protein collected from elution 
fraction (300 mM imidazole). Right: SDS-PAGE analysis of fractions collected from pull-down assays, 
following incubation of (C) His6-CpkC-TR with CpkG, and (D) His6-CpkG with CpkC-TR. L1: Protein 




Overall, both the native-PAGE and pull-down assays indicate that CpkC-TR and CpkG 
do not form a heterodimeric complex. This could possibly be explained by analysis of a 
multiple sequence alignment of CpkG with other putative ω-TAs likely involved in 
polyketide alkaloid biosynthesis (see section 2.4); part of the additional domain appears 




to be missing (figure 2.14). Consequently, the domain may be non-functional, merely 
existing as an evolutionary relic, or may serve another purpose. 
 
Therefore, it is possible that Streptomyces coelicolor utilise an alternative aldehyde 
detoxification mechanism. Indeed, CpkC-TR is capable of fully reducing ACP-tethered 
thioester 22 to alcohol 24, via two NADH-mediated two-electron transfers.  
 
 
Figure 2.14: A partial display of a multiple sequence alignment of CpkG and homologues encoded within 
putative polyketide alkaloid biosynthetic gene clusters, produced using T-Coffee and BoxShade software. 
Darker regions indicate higher levels of homology between proteins. The additional domain of CpkG 
(residues 142-189) appears to contain fewer amino acids, which may have been necessary for interactions 
with CpkC-TR. 




2.4 Further polyketide alkaloid specialised metabolites 
 
2.4.1 Identification of polyketide alkaloid biosynthetic gene clusters 
 
In addition to coelimycin P1 18, there are numerous other polyketide alkaloids, whose 
gene clusters and biosyntheses remain to be characterised. Examples include latumcidin 
35, nigrifactin 36 and pyrindicin 37 (see section 1.6). Following investigations with 
CpkC-TR and CpkG, it was proposed that thioester reduction and transamination may 
constitute a universal mechanism in diverting polyketide intermediates towards alkaloid 
metabolism (scheme 2.10).57 
 
 
Scheme 2.10: Proposed universal biosynthesis of actinobacterial polyketide alkaloids 
 
To investigate this hypothesis, the GenBank database was examined for gene clusters 
containing genes encoding a CpkC-TR and CpkG homologue within 35 kb of each other 
(Dr. Emmanuel de los Santos, University of Warwick). Functional annotation of the 
sequences obtained using antiSMASH149 resulted in the identification of 22 
actinobacterial gene clusters that are hypothesised to direct the biosynthesis of polyketide 
alkaloids (figure 2.15).  
 
2.4.2 Prediction of polyketide intermediates 
 
To gain insight into the metabolic products of these gene clusters, the module and domain 
organisation of the encoded PKSs were analysed in an attempt to predict the structures of 
the polyketide intermediates. Two online databases, SBSPKS and the NCBI conserved 
domain search, were used for in silico analysis.44,150 Domain activities and specificities 
were then predicted manually by examination of key sequence motifs.  
 
The activity of the acyl carrier protein (ACP) and ketosynthase (KS) domains within each 
PKS was determined by the presence of a conserved serine residue or a CHH catalytic 
triad, respectively.151,38 Loading KSs were identified by a cysteine-glutamine mutation, 
which suggests that they function as decarboxylases and that carboxylated acyl-CoA 
species are recruited as substrates.47  





Figure 2.15: Overview of gene clusters harbouring PKS genes and homologues of cpkC-TR and cpkG57 




The substrate specificity of the acyltransferase (AT) domains was determined by 
sequence comparisons with AT domains of known specificity. In particular, the presence 
of a YASH or HAFH motif, and either a glutamine or branched non-polar residue within 
the conserved GHSxG motif, indicated the uptake of methylmalonyl- or malonyl-CoA, 
respectively.152,153 In the case of Saccharothrix espanaensis DSM 44229, an AT domain 
was missing from the loading module, and the AT domain present within the fourth 
module contained unusual RASH and GHSTG motifs, so predictions are tentative.  
 
The activity and stereospecificity of the ketoreductase (KR) domains was determined by 
sequence comparisons with KR domains of known stereospecificity. All of the KRs 
analysed contained a conserved LDD (or LDN) motif, indicating that they were B-type 
KRs, and thereby suggesting that an (R)-configured β-hydroxyl group would be 
formed.154 For branched intermediates (e.g. α-methyl-β-ketothioesters), the presence or 
absence of a proline residue in the catalytic region indicated that the α-substituent would 
have (S)- or (R)-stereochemistry, respectively.155 In several cases, the KR domain was 
determined to be inactive due to the absence of a catalytic tyrosine or conserved 
asparagine residue.156,155  
 
The activity of the dehydratase (DH) domains was evaluated by analysing conserved 
active site residues and motifs. Specifically, considerable alterations to the four signature 
motifs (HxxxGxxxxP, GYxYGPxF, LPFxW and Dxxx(Q/H)) suggested that the DH 
domain would be rendered inactive.157 For all active DH domains, the substrate double-
bonds were predicted to have trans-geometry, since all β-hydroxyl groups had previously 
been assigned to have (R)-stereochemistry.38  
 
The stereospecificity of the enoyl reductase (ER) domains was predicted by sequence 
comparisons to ER domains of known stereospecificity. A conserved tyrosine (at position 
52 in E. coli quinone oxidoreductase) indicated that the α-substituent would have (S)-
stereochemistry, while a conserved alanine (or occasionally valine or phenylalanine) 
denoted (R)-stereochemistry.158,51 
 
Utilising this information, and assuming a co-linear relationship between the number of 
modules and the number of precursors used for chain assembly, the structures of the 
polyketide intermediates were predicted (table 2.1).  




Table 2.1: Actinobacterial strain (left), predicted aldehyde intermediate (middle) and predicted 
corresponding metabolite (right) 
Actinosynnema mirum DSM 43827 
 
Novel 





Streptomyces sp. NRRL B-24891 




Streptomyces sp. ScaeMP-e10 
Streptomyces viridochromogenes (2) 





Streptomyces sp. NRRL F-5193 
Saccharothrix syringae NRRL B-16468 
 
36/ 
42 Saccharothrix sp. NRRL B-16348 
Verrucosispora maris AB-18-032 
Streptomyces sp. MSC090213JE08 





Streptomyces venezuelae ATCC 15439 
 
37 
Streptomyces viridochromogenes (1) 
 
37 
Saccharothrix espanaensis DSM 44229 
 
Novel 
Streptomyces sp. 769 
 
Novel 
Streptomyces griseus XylebKG-1 
 
Novel 
Streptomyces albus DSM 41398 
 
Novel 















Notably, in each of these assembly lines, the penultimate module either lacks a 
ketoreductase or dehydratase domain, or harbours a non-functional equivalent. This 
would result in fully-assembled polyketides with a 5’-keto or hydroxyl group, suggesting 
that they are predisposed for intramolecular imine formation following transamination.  
 
 
2.4.3 Prediction of polyketide alkaloid metabolites 
 
Interestingly, thirteen of the predicted aldehyde intermediates were found to have the 
same carbon skeletons as several known polyketide alkaloids. Of these, two (from 
Nocardia niigatensis NBRC 100131 and Streptomyces lividans TK24) are believed to be 
converted to coelimycin P1 18 or a derivative thereof, based on sequence similarity to the 
cpk cluster.  
 
Two other gene clusters produce a polyketide chain that corresponds to the carbon 
skeleton of cyclizidine 39 or JBIR-102 40, while a further five clusters assemble an 
intermediate corresponding to the scaffold of streptazone E 42 or nigrifactin 36. 
Encouragingly, two of these clusters, from Streptomyces sp. NCIB11649 and 
Streptomyces sp. MSC090213JE08, have since been shown to direct the production of 
cyclizidine and streptazone E, respectively,159,160 corroborating the robustness of the 
search algorithm and the reliability of the sequence-based predictions. The polyketide 
chains assembled by two of the other clusters correspond to the carbon skeleton of 
pyrindicin 37, and two further clusters are proposed to direct the biosynthesis of 
latumcidin 35, streptazolin 38, or a closely related metabolite. This is based on the 
structure of the carbon chains assembled by the PKS and the presence of genes encoding 
homologues of the cyclases recently reported to be involved in streptazone E 
biosynthesis.160 Routes to the formation of known polyketide alkaloids 35-39 and 42 from 
the corresponding predicted aldehyde intermediates have been tentatively proposed (see 
appendix 4). 
 
The polyketide chains produced by the PKSs encoded by the remaining nine clusters do 
not correspond to the carbon skeletons of any known metabolites. Thus, these clusters are 
likely to direct the biosynthesis of novel polyketide alkaloids. 
 




It is interesting to note that besides the CpkC-TR and CpkG homologues, the other 
putative tailoring enzymes encoded within the recently characterised cyclizidine and 
streptazone E biosynthetic gene clusters show little sequence similarity to those 
associated with the cpk cluster. This observation is consistent with the hypothesis that 
reductive chain release and transamination are a conserved set of enzymatic reactions in 
polyketide alkaloid biosynthesis, whereas downstream-acting tailoring enzymes are more 
divergent. 
 
2.4.4 Attempted detection of putative polyketide alkaloid from 
Streptomyces cyaneofuscatus NRRL B-2570 
 
In attempt to detect and characterise one of the predicted novel polyketide alkaloid 
metabolites, Streptomyces cyaneofuscatus NRRL B-2570 was acquired from the ARS 
culture collection. Analysis of the PKS module and domain organisation revealed that it 
is likely to assemble thioester 63, which is then expected to undergo reductive cleavage 
followed by transamination, catalysed by IF17_RS0112395-TR and IF17_RS0112380, 
respectively (scheme 2.11). Six other putative post-PKS tailoring enzymes are 
homologous to oxidoreductases, monooxygenases and cytochrome P450 enzymes (see 
appendix 5), suggesting that several oxidative steps are likely to follow. 
 
 
Scheme 2.11: Proposed biosynthesis of polyketide alkaloid intermediates in Streptomyces cyaneofuscatus 
NRRL B-2570 





S. cyaneofuscatus NRRL B-2570 was first cultured on growth media (SFM agar) 
followed by production media (ISP2, R3 and R5 agar). Metabolites were then extracted 
and analysed by LC-MS (figure 2.16). However, many peaks were apparent and it was 
difficult to identify the putative polyketide alkaloid(s). Therefore, alternative 
metabolomics approaches were pursued.  
 
 
Figure 2.16: Base peak chromatograms from LC-MS analyses of S. cyaneofuscatus metabolites extracted 
from ISP2 (top), R3 (middle) and R5 (bottom) agar  
 
2.4.4.1 Overexpression of a putative SARP 
 
It was noted that the putative polyketide alkaloid cluster within S. cyaneofuscatus 
contained a gene (IF17_RS0112435) encoding a Streptomyces Antibiotic Regulatory 
Protein (SARP); a transcriptional activator with a high specificity for specialised 
metabolite production in actinomycetes.108 SARPs comprise of a characteristic OmpR-
type winged helix-turn-helix DNA binding domain and a bacterial transcriptional 
activator domain (BTAD), close to the N-terminus.161  
 
There are many examples in which SARP overexpression leads to activation or 
overproduction of the corresponding specialised metabolite.162,163,164,165 Therefore, 
IF17_RS0112435 was overexpressed in attempt to trigger the (over)production of the 
putative polyketide alkaloid metabolite(s). 
 
 




2.4.4.1.1 Cloning of IF17_RS0112435 into pOSV556t 
 
Primers were designed to allow amplification of 
IF17_RS0112435 by PCR and subsequent cloning into 
pOSV556t; an integrative plasmid under the control of 
the constitutive ermE* promoter (figure 2.17). The 
plasmid contains antibiotic resistant markers for selection 
in E. coli (ampicillin, ampr) and Streptomyces 
(hygromycin, hygr), in addition to an origin of transfer, 
oriT, which permits interspecies conjugation. A gene 
encoding an integrase, int_pSAM2, allows the plasmid to 
integrate into the Streptomyces chromosome through 
site-specific recombination between the attP plasmid site 
and attB chromosomal site.166  
 
The forward primer contained a HindIII restriction site 
and an artificial conserved ribosomal binding site, while 
the reverse primer contained an XhoI restriction site. 
IF17_RS0112435 was amplified by PCR (figure 2.18a), 
and the DNA band of the expected size was excised from 
the gel and purified.  
 
 
Figure 2.18: (A) Gel from agarose electrophoresis following PCR amplification of IF17_RS0112435; (B) 
plasmid map with restriction sites used for analysis displayed; (C) gel from agarose electrophoresis 
following restriction digest with HindIII and XhoI; and (D) gel from agarose electrophoresis following 
restriction digest with NotI. 
 
Figure 2.17: Plasmid map of 
pOSV556t. An integrase gene 
(int_pSAM2), origins of 
replication (ColE1) and transfer 
(oriT), ampicillin and hygromycin 
resistance genes (ampr and hygr) 
and restriction sites (XhoI and 
HindIII) used for cloning are 
highlighted. 




The PCR product and plasmid were then digested similarly with HindIII and XhoI, 
purified and ligated together. The ligation mixture was subsequently used to transform 
E. coli TOP10 cells. Colonies containing the recombinant plasmid were selected for with 
ampicillin, and several were cultured overnight for plasmid DNA purification. Correct 
insertion of IF17_RS0112435 was examined by restriction digestion (HindIII, XhoI and 
NotI, figure 2.18b-d). Positive clones were confirmed by sequencing. 
 
2.4.4.1.2 Conjugation of pOSV556t::IF17_RS0112435 into S. cyaneofuscatus 
 
The construct (pOSV556t::IF17_RS0112435) was used to transform methylation-
deficient E. coli ET12567/pUZ8002 cells. Transformants were then mixed with 
S. cyaneofuscatus NRRL B-2570 spores to promote conjugation, and cultured on SFM 
agar supplemented with MgCl2. The following day the plates were overlaid with nalidixic 
acid and hygromycin, to selectively kill E. coli ET12567/pUZ8002 and wild-type 
S. cyaneofuscatus (not harbouring the plasmid), respectively. The plates were then 
incubated for 1 week and transconjugants were selected and cultured on SFM agar 
supplemented with hygromycin, to obtain spore stock solutions of the recombinant strain, 
denoted S. cyaneofuscatus::SARP. 
 
2.4.4.2 Inactivation of the PKS 
 
In addition to SARP overexpression, a gene encoding part of the PKS (IF17_RS0112385) 
was disrupted, to aid in the deduction of the metabolite(s) associated with the putative 
polyketide alkaloid cluster. 
 
2.4.4.2.1 Cloning of IF17_RS0112385 into pKC1132 
 
Primers were designed to target a region encoding the ACP of module 1 and the KS of 
module 2 in the PKS. Primers contained a HindIII and XbaI restriction site to facilitate 
cloning into pKC1132; a 3.5 kb conjugative suicide vector bearing an apramycin 
resistance gene (amr) and oriT from RK2 (figure 2.19).167 
 
 




Following amplification of the sequence (figure 
2.20a), the PCR product was purified and digested 
alongside the plasmid. The digested PCR product 
and plasmid were then ligated and the mixture was 
used to transform E. coli TOP10 cells. Colonies 
containing the recombinant plasmid were selected 
for with apramycin, and several were cultured 
overnight for plasmid DNA purification. Correct 
insertion of IF17_RS0112385 was examined by 
restriction digestion (HindIII, XbaI and SmaI, 




Figure 2.20: (A) Gel from agarose electrophoresis following PCR amplification of IF17_RS0112385; (B) 
plasmid map with restriction sites used for analysis displayed; (C) gel from agarose electrophoresis 
following restriction digest with HindIII and XbaI; and (D) gel from agarose electrophoresis following 
restriction digest with SmaI. 
 
2.4.4.2.2 Conjugation of pKC1132::IF17_RS0112385 into S. cyaneofuscatus  
 
 
Transformations of ET12567/pUZ8002 cells with the plasmid clone 
(pKC1132::IF17_RS0112385) and subsequent conjugations were performed as described 
in section 2.4.4.1.2. However, plates were overlaid with apramycin rather than 
hygromycin, to select for exconjugants. As pKC1132 is not capable of replicating 
independently in Streptomyces, apramycin-resistant exconjugants could only be produced 
via a single crossover event, resulting in disruption of the PKS gene. 
  
Figure 2.19: Plasmid map of 
pKC1132. The lacZα gene, an 
apramycin resistance gene (amR), 
origins of replication (reppUC) and 
transfer (oriT) and restriction sites 
used for cloning (HindIII and XbaI) 
are highlighted. 




Two conjugations were performed; one to disrupt the PKS gene in the wild-type strain, 
and one to disrupt the PKS gene in S. cyaneofuscatus::SARP, to generate the strains 
S. cyaneofuscatusPKS::am and S. cyaneofuscatus::SARP-PKS::am, respectively. 
 
2.4.4.3  Comparative metabolic profiling 
 
To investigate whether SARP overexpression or PKS disruption would induce or abolish 
metabolite production, respectively, S. cyaneofuscatus wild-type and recombinant strains 
(S. cyaneofuscatus::SARP, S. cyaneofuscatusPKS::am and S. cyaneofuscatus::SARP-
PKS::am) were cultured on ISP2, R3 and R5 agar. Metabolites were then extracted and 
analysed by LC-MS. 
 
 
Figure 2.21: Base peak chromatograms from LC-MS analyses of S. cyaneofuscatus metabolites extracted 
from R3 agar. Black trace: wild-type S. cyaneofuscatus; red trace: S. cyaneofuscatusPKS::am; green trace: 
S. cyaneofuscatus::SARP; blue trace: S. cyaneofuscatus::SARP-PKS::am. 
 
In all cases, SARP overexpression appeared to induce the production of three metabolites 
eluting at 15.2, 16.1 and 16.6 minutes. This was most pronounced using R3 media (figure 
2.21). Analysis of the peaks revealed that the metabolites had m/z values of 240.1202, 
312.1416 and 411.2103 and calculated molecular formulae of C10H19NNaO4, 
C13H22NNaO6 and C18H32N2NaO7, respectively. These formulae seemed promising; all 
contained one or two nitrogen atoms, predicted to derive from a transamination reaction 
and possibly an amino acid addition, as in coelimycin P1 biosynthesis. Furthermore, all 
contained multiple oxygen atoms, which could result from post-PKS tailoring oxidation 
reactions. For example, the genes IF17_RS0112400, IF17_RS0112425 and 




IF17_RS0112430 are hypothesised to encode a putative FAD-dependent 
monooxygenase, an amine oxidase and a cytochrome P450 enzyme, respectively. 
 
Interestingly, while the corresponding peaks for the PKS disruption mutants were of a 
much lower intensity, they were still evident. This was assumed to be attributable to 
homologous recombination, which could result in reformation of the wild-type strain, as 
mutants were grown in the absence of apramycin. 
 
2.4.4.4 Overproduction, purification and characterisation of putative polyketide 
alkaloid metabolite(s) 
 
In attempt to overproduce and purify the putative polyketide alkaloid(s), 
S. cyaneofuscatus::SARP spores were cultured on R3 agar. Metabolites were then 
extracted, dried and separated by HPLC (in collaboration with Dr. Yousef Dashti, 
University of Warwick). Fractions with m/z values of 240.1202 and 411.2103 were 
purified sufficiently to obtain NMR data. The compound with an m/z value of 312.1416 
was not obtained in adequate yield.  
 
 
Figure 2.22: (A) Characterised (64 and 65) and predicted (67) structures of S. cyaneofuscatus::SARP 
metabolite fragments; and (B) structure of valinomycin 66 with isolated and predicted fragments 
highlighted. 




Unfortunately, the structures of the two metabolites were unambiguously determined to 
be (depsi)peptides 64 and 65 (figure 2.22a). Both compounds appear to be fragments of 
valinomycin 66 (figure 2.22b), an antibiotic produced by at least eleven Streptomyces 
strains.168 Indeed, upon searching the genome of S. cyaneofuscatus NRRL B-2570, a 
cluster was determined to be nearly identical to the valinomycin biosynthetic gene cluster 
in S. tsusimaensis ATCC 15141 (figure 2.23).169 The compound with an observed m/z 
value of 312.1416 is thus likely to be another valinomycin fragment, 67 (figure 2.22a). 
 
 
Figure 2.23: Comparison of predicted (top) and known (bottom) valinomycin biosynthetic gene clusters in 
Streptomyces cyaneofuscatus NRRL B-2570 and Streptomyces tsusimaensis ATCC 15141
169
, respectively 
(Dr. Emmanuel de los Santos, University of Warwick). Homologous genes are coloured similarly, and are 
proposed to encode a type II thioesterase (green), NRPS modules 1 and 2 (blue), NRPS modules 3 and 4 
(purple) and a transposase (pink). 
 
 
Hydrolysis of valinomycin likely occurred during the mildly acidic work-up; extractions 
with ethyl acetate alone did not yield the three metabolites. Indeed, cultivation of 
S. cyaneofuscatus::SARP in AM1 and SMM media, followed by neutral extractions, 
revealed an additional peak in the LC-MS trace that was absent from the wild-type strain 
(figure 2.24a). This metabolite had the same molecular formula as valinomycin (figure 
2.24b).  
 
It seems interesting that valinomycin production was augmented by overexpressing the 
SARP from a different gene cluster. However, other examples of SARP-mediated cross-
regulation between pathways have been reported, prompting such regulators to be termed 
‘cluster-situated’ rather than ‘pathway-specific’. For example, Huang and coworkers 
showed that induction of redZ, a gene encoding a SARP within the undecylprodigiosin 
(Red) cluster, resulted in activation of the Red, calcium-dependent antibiotic (CDA) and 
actinorhodin (Act) pathways in S. coelicolor A3(2). Deletion of redZ abolished 
expression of red genes, but also delayed expression of cda and act genes.170 





Figure 2.24: (A) Base peak chromatograms from LC-MS analyses of S. cyaneofuscatus metabolites 
extracted from AM1 liquid media. Black trace: wild-type S. cyaneofuscatus; green trace: 
S. cyaneofuscatus::SARP. (B) Observed [M+Na]+ for metabolite eluting at 26.5 min, likely corresponding 
to valinomycin (calculated [M+Na]+ = 1133.6204).  
 
Thus far, further attempts to detect the putative polyketide alkaloid metabolite using 
various media and extraction procedures have been unsuccessful. This could be due to 
poor expression of the gene cluster under laboratory conditions; certain activating signals 
may be necessary to effect transcription or translation. Therefore, other approaches could 
be trialled, such as co-cultivation, deletion of putative repressor genes or promoter 
exchange.171 Current endeavours within the Challis group are exploring transformation-
associated-recombination (TAR) cloning, in attempt to capture the gene cluster for 
expression in a heterologous host.  
 
2.4.5 Whole genome sequencing of Streptomyces abikoensis, a 
latumcidin producer 
 
In collaboration with Dr. Emmanuel de los Santos, University of Warwick 
While bioinformatic searches were underway, Streptomyces abikoensis DSM 40831, a 
known producer of the polyketide alkaloid latumcidin 35, was acquired from the DSMZ 
culture collection. It was thought that sequencing the genome could provide a 
complementary approach to aid in establishing the biosynthetic origin of such 
metabolites. 
 
Therefore, S. abikoensis was cultured and its genomic DNA extracted and purified. The 
DNA was then sequenced by The Genome Analysis Centre (TGAC) using Pacific 
Biosciences (PacBio) technologies. 1-15 kb reads were then assembled into a single 




contig to yield a draft genome consisting of 7.5 Mbp, with a GC content of 72.2 %. 
Annotation and mining of the genome revealed the presence of 74 putative specialised 
metabolite gene clusters, predicted to direct the biosynthesis of a range of PKs, NRPs, 
RiPPs (ribosomally synthesised and post-translationally modified peptides), terpenes, 
fatty acids and siderophores (Dr. Emmanuel de los Santos, see appendices 6 and 7). 
 
As expected, a gene cluster encoding a CpkC-TR and CpkG homologue, in addition to a 
type I modular PKS, was identified (figure 2.25). Analysis of the PKS module and domain 
organisation (see section 2.4.2) led to the prediction of aldehyde intermediate 68, which 
corresponds to the carbon skeleton of latumcidin (figure 2.26). Production of latumcidin 
by the strain was thereafter reconfirmed by high-resolution LC-MS analysis (Dr. Yousef 
Dashti and Dr. Daniel Zabala, University of Warwick, see appendix 8). Thus, it seems 
likely that this gene cluster directs the biosynthesis of latumcidin, although this would 
need to be corroborated through targeted gene deletions and metabolic profiling.  
 
 
Figure 2.25: The organisation of a gene cluster within Streptomyces abikoensis DSM 40831, predicted to 
direct the biosynthesis of latumcidin 35. The proposed functions of the proteins encoded by the genes are 
as follows. Purple: precursor supply; red: PKS component (with TR domain highlighted in yellow); blue: 
post-PKS tailoring; green: regulatory; grey: hypothetical. 
 
 
Figure 2.26: Structures of the predicted polyketide aldehyde 68 and latumcidin 35, with carbon atoms 
numbered accordingly 
 
Many of the biosynthetic genes within the cluster encode homologues of streptazone E 
enzymes (see appendix 7). For instance, abik_03611 and abik_03620 encode homologues 
of the putative flavin-dependent monooxygenase and flavin-reductase, respectively, 
while abik_03619 and abik_03621 encode homologues of the two putative cyclases. This 
led to the hypothesis that the bicyclic scaffold is formed through a similar mechanism to 




that proposed by Ohno and coworkers.160 The remaining three biosynthetic post-PKS 
tailoring genes (abik_03606, abik_03607 and abik_03615) are predicted to encode short-
chain dehydrogenases. Utilising this information, a biosynthetic route to latumcidin 




Scheme 2.12: A proposed biosynthesis of latumcidin 35, based on the predicted functions of genes within 
cluster 43 of Streptomyces abikoensis DSM 40831 and the pathways proposed for streptazone E160 42 and 
coelimycin P130 18 biosynthesis  




Initially, the type I modular PKS likely assembles a pentaketide chain, which is then 
reductively cleaved by Abik_03616-TR. The trans-2,3-double bond of the resulting 
aldehyde 68 is then likely reduced, possibly by putative dehydrogenases Abik_03606, 
Abik_03607 or Abik_03615. Interestingly, the gene cluster does not encode a homologue 
of CpkE, the putative isomerase in coelimycin biosynthesis, suggesting that the double 
bond is not isomerised. Intermediate 69 then likely undergoes transamination, catalysed 
by Abik_03624, followed by oxidation, catalysed by one of the aforementioned 
dehydrogenases. Spontaneous intramolecular cyclisation and a further dehydrogenation 
would yield intermediate 73. An epoxidation, catalysed by flavin redox partners 
Abik_03620 and Abik_03611, and cyclisation, catalysed by cyclases Abik_03619 and 
Abik_03621, could then ensue. Dehydration, followed by a final epoxidation, would then 
afford latumcidin 35. Because only one putative monooxygenase and flavin reductase are 
encoded within the cluster, it is possible that Abik_03620 and Abik_03611 also catalyse 
the second epoxidation. This is plausible, as the epoxidation is occurring across the same 
double bond.  
 
Many of the regulatory genes within the putative latumcidin cluster are homologous to 
those of the coelimycin cluster (see appendix 7), suggesting a similar mode of 
transcriptional control. For example, abik_03609 and abik_03623 encode homologues of 
the SARPs CpkN and CpkO, while abik_03613 and abik_03626 encode homologues of 
the TetR-like repressors ScbR and ScbR2, respectively. In addition, abik_03614 encodes 
a butenoloid synthase, while abik_03627 encodes a two-component system histidine-
kinase, homologous to CpkM. The function of the putative regulatory gene abik_03622 
is unclear. 
 
Overall, bioinformatics predictions strongly support that this gene cluster directs the 
biosynthesis of latumcidin; future work could confirm this through in vivo gene-
knockouts. Furthermore, the hidden biosynthetic potential encoded within the remaining 




In summary, CpkG was demonstrated to have transaminase activity and a broad substrate 
tolerance, readily catalysing the interconversion of a range of primary amines with 




aldehydes. Assays with synthetic substrate mimics of proposed intermediates in the cpk 
biosynthetic pathway demonstrated that CpkG is responsible for nitrogen incorporation 
into coelimycin. Crystal structures of CpkG allowed for the identification of the PLP 
binding site, key active site residues, a rare additional domain, and hinted at the 
transamination mechanism. The characteristic fold-type I conformation, coupled with 
Marfey’s analysis, established CpkG as an (S)-selective ω-TA. Future work could 
investigate the biocatalytic capability of CpkG to generate chiral amines from ketones; a 
key research priority identified by the pharmaceutical industry.172  
 
Bioinformatic searches revealed 22 actinobacterial biosynthetic gene clusters encoding 
homologues of CpkC-TR and CpkG, that are predicted to direct the biosynthesis of both 
known and novel polyketide alkaloids. Attempts to detect one such metabolite from 
S. cyaneofuscatus NRRL B-2570 were unsuccessful, instead resulting in the inadvertent 
overproduction of valinomycin. Other strategies, such as TAR cloning, may prove more 
effective. Moreover, the characterisation of TR and ω-TA enzymes within these systems 
could lead to promising alternative methods for the efficient and biocatalytic synthesis of 
polyketide alkaloids in the near future.  
 
Sequencing the genome of the known latumcidin producer, S. abikoensis DSM 40831, 
enabled the discovery of a gene cluster containing cpkC-TR and cpkG homologues, as 
predicted. Together with the recent characterisation of the streptazone E and cyclizidine 
clusters, these findings strongly support the hypothesis that thioester reduction and 
transamination are a universal sequence of reactions in polyketide alkaloid biosynthesis.  
Future work could involve the generation of gene-knockouts or the purification of 
recombinant enzymes to aid in the elucidation of latumcidin biosynthesis. In addition, 
genome mining could accommodate the prediction and identification of further 





   




3 RESULTS AND DISCUSSION II: Characterisation of 
post-PKS tailoring enzymes in coelimycin biosynthesis 
 
  








CpkI, which shows sequence similarity to known short-chain dehydrogenases (SDHs), 
could catalyse the re-oxidation of alcohol 24 to aldehyde 23 in coelimycin biosynthesis. 
CpkE, belonging to the α,β-hydrolase fold superfamily of enzymes, has been tentatively 
suggested to catalyse a subsequent isomerisation of the trans-configured 2,3-double bond 
to a cis-configured 3,4-double bond, to afford intermediate 28 (scheme 3.1).30 To 
investigate these possibilities, it was necessary to clone and overexpress the biosynthetic 
genes and purify the corresponding proteins.  
 
 
Scheme 3.1: Proposed reactions catalysed by CpkI and CpkE in coelimycin biosynthesis30 
 
3.1.2 Cloning, overproduction and purification of proteins 
 
Primers were designed to allow for directional cloning of cpkI and cpkE into the 
pET151/D-TOPO expression vector (figure 3.1). A four-base overhang (5’-CACC) was 
introduced in the forward primer to enable the PCR product to anneal to the overhang 
(5’-GGTG) on the complementary strand of the vector in the correct orientation. Both the 
forward and reverse primers contained 16-25 nucleotides of the coding sequences of cpkI 
or cpkE, including the start and stop codons, as appropriate. 
 





Figure 3.1: Map of the pET151/D-TOPO vector used for the assembly of protein expression constructs.173 
Key features (clockwise): T7 promoter; lac operator (lacO); ribosome binding site (RBS); start codon 
(ATG); N-terminal His6-tag; V5 epitope; TEV recognition site; TOPO® cloning site; SacI restriction site; 
T7 transcription termination region; ampicillin resistance gene (β-lactamase); pBR322 origin of replication 




Figure 3.2: Gels from agarose electrophoresis following PCR amplifications of (A) cpkI; and (B) cpkE, at 




Using these primers, the genes were amplified by PCR (figure 3.2) and ligated with 
pET151/D-TOPO. The ligation mixtures were then used to transform E. coli One Shot® 
TOP10 cells. Colonies harbouring the plasmid were selected for with ampicillin and 
several were cultured overnight for plasmid DNA isolation. Correct insertion of the genes 
was then determined by restriction digestion using selected endonucleases (figure 3.3a). 
8/12 cpkI and 7/12 cpkE clones appeared to be positive (figure 3.3b) and several were 
sequenced, to ensure that mutations had not been introduced during PCR.  
 





Figure 3.3: (A) Plasmid maps with restriction sites used for analysis; and (B) gels from agarose 
electrophoresis following restriction digests, of pET151::cpkI (top) and pET151::cpkE (bottom). The 
expected sizes of the DNA fragments are labelled. 
 
Following confirmation of the sequences of the 
inserts, the constructs were transferred to E. coli One 
Shot® BL21 StarTM (DE3); a strain suitable for high-
level recombinant protein expression. Subsequently, 
cpkI and cpkE were overexpressed and the 
corresponding N-terminal His6-fusion proteins 
purified by nickel affinity chromatography, as 
described in section 2.1.2.  
 
SDS-PAGE analysis indicated that the proteins were 
pure and of the expected molecular weights (figure 
3.4). The exact molecular weights of the proteins 
were later verified by HRMS using maximum 
entropy deconvolution algorithms (figure 3.5; 
calculated molecular weights of His6-CpkI and His6-
CpkE are 31214 and 34813 Da, and respectively).  
 
 
Figure 3.4: SDS-PAGE analysis 
of purified His6-CpkI (L2) and 
His6-CpkE (L3) alongside a 
protein molecular weight marker 
(L1) 





Figure 3.5: Measured (left) and deconvoluted (right) mass spectra of His6-CpkI (top) and His6-CpkE 
(bottom). The calculated molecular weights of the proteins are 31214 and 34813 Da, respectively. 
 
3.1.3 Preliminary in vitro assays 
 
To investigate the hypothesised oxidoreductase activity of CpkI, a substrate analogue 
(dodecane-1,5-diol, 76), containing the same 1,5-diol functionality and carbon chain 
length as the proposed true intermediate of the coelimycin biosynthetic pathway (24), was 
synthesised. This involved reducing commercially-available δ-dodecalactone 61 with two 
equivalents of LiAlH4 (scheme 3.2). 
 
 
Scheme 3.2: Synthesis of dodecane-1,5-diol 76 by reduction of δ-dodecalactone 61 (1.0 eq.) with LiAlH4 
(1.5 eq.) 
 
Subsequently, dodecane-1,5-diol 76 was incubated with His6-CpkI and either NAD
+ or 
NADP+ as a cofactor. Any 5-hydroxydodecanal 59 produced during the reaction was then 
derivatised with D-cysteine (scheme 3.3) and analysed by LC-MS alongside a similarly 
derivatised authentic standard. Unfortunately, a peak corresponding to the molecular 
weight of (4S)-2-(4-hydroxyhexyl)thiazolidine-4-carboxylic acid 77 could not be 
detected (figure 3.6a). 




Scheme 3.3: Assay employed to probe the possible oxidation of dodecane-1,5-diol 76 (200 μM) by CpkI 
(90 μM) and NAD(P)+ (200 μM), followed by derivatisation with D-cysteine (400 μM) 
 
Figure 3.6: (A) Extracted ion chromatograms at m/z = 304.1941 ± 0.05 (corresponding to the [M+H]
+
 ion 
for (4S)-2-(4-hydroxyhexyl)thiazolidine-4-carboxylic acid). From top to bottom: reaction of His6-CpkI with 
dodecane-1,5-diol and NAD+; reaction of His6-CpkI with dodecane-1,5-diol and NADP+; and D-cysteine 
derivatised authentic standard. (B) Extracted ion chromatograms at m/z = 230.1751 ± 0.05 (corresponding 
to the [M+H]
+
 ion for tris-derivatised octenal). From top to bottom: reaction of trans-octen-2-al with 
His6-CpkE and tris; control reaction from which the enzyme has been omitted; and authentic standard of 
tris-derivatised cis-octen-3-al. Experiments were performed in duplicate. 
 
To investigate the hypothesised isomerase activity of CpkE, the recombinant protein was 
incubated with trans-octen-2-al 78; a substrate mimic of the proposed true intermediate 
of the coelimycin biosynthetic pathway (23), containing the same α,β-unsaturated 
aldehyde functionality. Tris(hydroxymethyl)amino methane (tris) was added to act as a 
simultaneous buffer and derivatising agent (scheme 3.4).  
 
 
Scheme 3.4: Assay employed to probe the possible isomerisation of trans-octen-2-al 78 (200 μm) by CpkE 
(100 μM), and derivatisation with tris (20 mM) 
 
The mixture was then analysed by LC-MS alongside an authentic standard of derivatised 
cis-octen-3-al 79, which was synthesised by oxidising cis-octen-3-ol 80 with DMP 
(scheme 3.5) and used immediately due to rapid cis to trans isomerisation. 





Scheme 3.5: Synthesis of cis-octen-3-al 79 by oxidation of cis-octen-3-ol 80 (1.0 eq.) with DMP (1.3 eq.) 
 
Examination of the retention times of the tris-derivatised isomers revealed that no trans 
to cis isomerisation had occurred during the reaction (figure 3.6b). 
 
Therefore, it seems likely that CpkI and CpkE do not catalyse these reactions in 
coelimycin biosynthesis; instead they may catalyse other steps or have different 
enzymatic activities. For example, CpkE, as a member of the α,β-hydrolase fold 
superfamily, could function as an esterase, lipase, haloalkane dehalogenase, peroxidase 
or epoxide hydrolase.174 Alternatively, it may be necessary to optimise reaction 
conditions or synthesise closer substrate mimics to effect catalysis (see section 3.2.4.4 for 
further investigations). 
 




CpkD, ScF and CpkH show sequence similarity to known flavin-dependent 
dehydrogenases and epoxidases, and have been proposed to catalyse the oxidative 
conversion of intermediate 29 to coelimycin A 19 (scheme 3.6).30  
 
 
Scheme 3.6: Proposed reactions catalysed by CpkD, CpkH and ScF in coelimycin biosynthesis30 




Previous attempts to decipher the roles of the oxidative enzymes and the order of pathway 
intermediates in vivo yielded inconclusive results (see section 1.4). Therefore, the genes 
were cloned and overexpressed, and the corresponding proteins purified, for in vitro 
investigations.   
 
3.2.2 Cloning, overproduction and purification of proteins 
 
cpkD, scF and cpkH were amplified by PCR and cloned into pET151 as described in 
section 3.1.2 (figure 3.7). However, because ScF and CpkH are known substrates of the 
TAT secretion system,95 the corresponding genes were amplified as truncated sequences, 
without the N-terminal TAT signal peptide (predicted using PRED-TAT175), to prevent 
secretion of the proteins during expression. 
 
 
Figure 3.7: (A) Gels from agarose electrophoresis following PCR amplifications at selected annealing 
temperatures; (B) plasmid maps with restriction sites used for analysis; and (C) gels from agarose 
electrophoresis following restriction digests of pET151 constructs harbouring cpkD (top), scF (middle) and 
cpkH (bottom). The expected sizes of the DNA fragments are labelled. 




Following verification of the inserts by 
sequencing, the proteins were overproduced in 
E. coli and purified by nickel affinity 
chromatography. All appeared to be pure and of 
the correct molecular weight by SDS-PAGE 
analysis (figure 3.8; calculated molecular weights 
of His6-CpkD, His6-ScF and His6-CpkD are 
51807, 60363 and 58827 Da, and respectively). 
Interestingly, the proteins were bright yellow in 
colour, indicative of flavin binding. 
 
 
3.2.3 Examination of flavin binding and NAD(P)H utilisation 
 
3.2.3.1 UV/Vis spectroscopic analysis to identify the flavin cofactor 
 
To determine if the flavin cofactor was present, and if so, the form of flavin bound (flavin 
mononucleotide (FMN) or flavin adenine dinucleotide (FAD)), absorbance spectra for 
each protein were recorded from 300-600 nm (figure 3.9). The wavelength at maximum 
absorbance, λmax, was then compared to literature values for FAD (450 nm) and FMN 
(446 nm).176,177 ScF and CpkH were both found to bind FAD, while for CpkD the result 
was ambiguous, suggesting that the enzyme could bind either or both cofactors. 
 
 
Figure 3.9: UV/Vis spectra of flavoproteins: (A) His6-CpkD; (B) His6-ScF; and (C) His6-CpkH 
Figure 3.8: SDS-PAGE analysis of 
purified His6-CpkD (L2), His6-ScF 
(L3) and His6-CpkH (L4) alongside a 
protein molecular weight marker (L1) 
 




3.2.3.2 Mass spectrometric analysis to determine the mode of binding 
 
To determine whether the flavin cofactor was bound covalently or non-covalently, the 
intact proteins were analysed by HRMS (figure 3.10). 
 
 
Figure 3.10: Measured (top) and deconvoluted (bottom) mass spectra of (A) His6-CpkD; (B) His6-ScF; and 
(C) His6-CpkH. The calculated protein molecular weights are 51807 Da, 60363 Da (+ FAD = 61148 Da) 
and 58827 Da (+ FAD = 59611 Da), respectively.  
 
For CpkD, there was a single peak corresponding to the 
molecular weight of the apo-protein, suggesting non-
covalent binding of flavin. For ScF and CpkH, additional 
peaks were apparent at approximately +784 Da, 
indicating covalent binding of FAD. This observation is 
consistent with the measured UV/Vis absorption spectra 
(figure 3.9) and with ScF and CpkH being extracellular 
enzymes. Presumably, stronger binding of flavin would 
be favourable, as once excreted, the proteins would have 
limited access to free flavin.178 Furthermore, covalent 
flavin attachment could aid with stabilising the protein 
tertiary structure during transport across the lipid 
bilayer.179 
Figure 3.11: Extracted ion 
chromatograms at m/z = 784.1499 
± 0.05 (top trace, corresponding to 
the [M-H]− ion of FAD) and m/z = 
455.0973 ± 0.05 (bottom trace, 
corresponding to the [M-H]− ion of 
FMN) 
 




To deduce the nature of the cofactor bound non-covalently to CpkD, the enzyme was 
boiled and the supernatant analysed by LC-MS. Peaks corresponding to FMN (calculated 
m/z = 455.0963 Da, observed = 455.0970 Da) and FAD (calculated m/z = 784.1499 Da, 
observed = 784.1495 Da) were apparent (figure 3.11), suggesting that either both 
cofactors are present, or that solely FAD is bound, but fragments within the mass 
spectrometer. 
 
3.2.3.3 Prediction of sites of covalent FAD attachment 
 
In an attempt to predict the amino acid residue(s) covalently bound to FAD, the sequences 
of ScF and CpkH were compared to those of characterised flavoproteins using the NCBI 
BLAST database. ScF and CpkH were found to share a respective 56 % and 49 % 
sequence identity with TamL, an FAD-dependent dehydrogenase involved in 
tirandamycin biosynthesis.180 The crystal structure of TamL revealed that two residues, 
Cys122 and His62, are covalently attached to FAD via the C-6 atom of the isoalloxazine 
ring and the 8α-methyl group (figure 3.12).  
 
 
Figure 3.12: Amino acid residues involved in the covalent binding of FAD to TamL. Note: Only the 
isoalloxazine moiety of FAD is shown.  
 
A multiple sequence alignment showed that these residues are conserved in ScF and 
CpkH (figure 3.13), suggesting a similar bicovalent mode of binding. Attempts to 
experimentally validate this by tryptic digestion and MS/MS analysis were unsuccessful, 
presumably due to photodegradation of FAD adducts. 
 
 
Figure 3.13: A partial view of a multiple sequence alignment of TamL, ScF and CpkH, produced using 
T-Coffee and BoxShade software. Darker regions indicate higher levels of homology. Residues implicated 
in covalent FAD binding are highlighted with a purple box.  




3.2.3.4 UV/Vis spectroscopic analysis of flavin reduction by NAD(P)H  
 
To examine whether CpkD, ScF and CpkH could bind and utilise NAD(P)H to reduce 
their flavin cofactors, the enzymes were incubated with either NADH or NADPH and the 
absorbance monitored at 340 nm. In each case, a decrease in absorbance could be 
observed upon NADH addition (figure 3.14), implying that NADH was being oxidised 
during the concomitant reduction of flavin. Little or no change in absorbance could be 
observed upon NADPH addition. This suggests that all three enzymes selectively bind 
NADH, and are capable of catalysing redox chemistry without a partner protein. This is 
consistent with the absence of a flavin reductase-encoding gene within the cpk 
biosynthetic gene cluster. 
 
 
Figure 3.14: UV/Vis monitoring at A340 to detect the oxidation of NADH (dark grey) or NADPH (light 
grey), by (A) His6-CpkD; (B) His6-ScF; and (C) His6-CpkH 
 
3.2.4 Probing flavin-dependent dehydrogenase activity 
 
3.2.4.1 Incubation of 1-aminododecane-5-ol with CpkD, ScF and CpkH 
 
One of the three flavoproteins, CpkD, ScF or CpkH, has been proposed to catalyse the 
oxidation of the C-5 hydroxyl group of 31 during coelimycin biosynthesis. This is then 
predicted to be followed by spontaneous intramolecular imine formation (scheme 3.7).  
 
To investigate which of the enzymes exhibit dehydrogenase activity, 1-aminododecane-
5-ol 60 (figure 3.15), previously synthesised for assays with CpkG (see section 2.1.3.3), 
was incubated separately with His6-CpkD, His6-ScF and His6-CpkH (scheme 3.8). The 
reaction mixtures were then analysed by LC-MS. In the CpkH-catalysed reaction, a peak 
with the same molecular weight and predicted molecular formula as 6-heptyl-2,3,4,5-




tetrahydropyridine 81 was apparent (figure 3.16). The peak was not evident in the 






Scheme 3.8: Assay employed to probe flavin-dependent dehydrogenase activity, by incubation of 
1-aminododecane-5-ol (200 μM) with CpkD, ScF or CpkH (20 μM) 
 
 
Figure 3.16: (A) Extracted ion chromatograms at m/z = 182.1903 ± 0.05 (corresponding to the [M+H]+ ion 
for 6-heptyl-2,3,4,5-tetrahydropyridine). From top to bottom: reaction of 1-aminododecan-5-ol with CpkD, 
ScF, CpkH and without enzyme. (B) Measured m/z and predicted molecular formula for the compound 
eluting at 15.4 min. 
 
In order to confirm the product of the CpkH-catalysed reaction, an authentic standard of 
6-heptyl-2,3,4,5-tetrahydropyridine 81 was synthesised from 1-aminododecan-5-ol 60 in 
three steps (scheme 3.9). This involved a Boc-protection of the amine, followed by a 
Scheme 3.7: Proposed oxidation reaction catalysed by CpkD, ScF or CpkH  
  
Figure 3.15: Proposed 
substrate mimic of 31 




DMP-mediated oxidation of the hydroxyl group. Deprotection of the amine with TFA and 
a subsequent base work-up afforded the desired product in moderate yield.  
 
 
Scheme 3.9: Synthesis of 6-heptyl-2,3,4,5-tetrahydropyridine 81 from 1-aminododecan-5-ol 60; 18 % yield 
over 5 steps from δ-dodecalactone 61 
 
The assay with CpkH was then repeated. 
LC-MS analysis indicated that the product of 
the enzymatic reaction and the authentic 
standard displayed identical retention times 
(figure 3.17). Thus, CpkH is a flavin-
dependent dehydrogenase and likely catalyses 
the oxidation of 31 to 32 in coelimycin 
biosynthesis. This supports the data obtained 
from comparative metabolic profiling with a 
cpkH deletion mutant (see section 1.4).  
 
Notably, NAD+ cannot be used for the 
regeneration of FAD, due to the unfavourable 
redox potential (Eºcell = -0.1 V)
181; in vivo, the oxidation of FADH2 is performed by 
electron carriers such as cytochromes.77 Therefore, in these assays, molecular oxygen, 
phenazine methosulfate (PMS) and ferrocenium hexafluorophosphate were trialled as 
external oxidants, however low levels of conversion of 60 to 81 were consistently 
observed. Thus, reaction conditions may require optimisation, or alternatively, CpkH may 
only catalyse one turnover, possibly due to product inhibition.  
 
3.2.4.2 Synthesis of (R,E)- and (S,E)-1-aminododec-2-en-5-ol 
 
In order to investigate the enantio- and configurational selectivity of CpkH, the synthesis 
of two enantiomers of 60 bearing trans-double bonds ((R,E)- and (S,E)-1-aminododec-2-
Figure 3.17: Extracted ion chromatograms at 
m/z = 182.1903 ± 0.05 (corresponding to the 
[M+H]+ ion for 6-heptyl-2,3,4,5-tetrahydro-
pyridine). From top to bottom: reaction of 
1-aminododecan-5-ol with CpkH; control 
reaction from which the enzyme was omitted; 
and authentic standard.  
 




en-5-ol 84) was devised. According to KR stereochemical predictions and the proposed 
coelimycin biosynthetic pathway, only the (R)-enantiomer is expected to be oxidised. In 
the absence of additional tailoring enzymes, intramolecular cyclisation should not occur, 
due to restrictions imposed by the trans-double bond, meaning that the presence of the 
ketone intermediate could be conclusively confirmed (scheme 3.10). Furthermore, the 








Scheme 3.11: Synthetic routes to (R)-84 and (S)-84. a) CDI, monomethyl malonate potassium salt, MgCl2, 
THF, r.t., o/n; b) [Ru(OAc)2((R)-BINAP)] or [Ru(OAc)2((S)-BINAP)], MeOH, HCl, H2 (49 atm), 50 °C, 
o/n; c) tert-butyl-dimethylsilyl chloride, imidazole, DMF, 0 °C → r.t., o/n; d) DIBAL-H, DCM, -78 °C, 
1 h; e) ethyl(triphenylphosphoranylidene)acetate, THF, r.t., o/n; f) DIBAL-H, DCM, -78 °C, 3 h; g) (R)-
enantiomer: triphenylphosphine, N-chlorosuccinamide, THF, r.t., 3.5 h; (S)-enantiomer: triethylamine, 
tosyl chloride, DCM, 0 °C → r.t., o/n; h) potassium phthalimide, DMF, r.t., 72 h; i) (1S)-(+)-10-
camphorsulfonic acid, MeOH, DCM, r.t., 1.5 h; j) 40 % aq. MeNH2, EtOH, r.t, 2 h. 




A synthetic route was developed, enabling the assembly of both enantiomers in ten steps 
(scheme 3.11). In the first reaction, octanoic acid 86 was derivatised with 
1’-carbonyldiimidazole (CDI), and the resulting activated imidazolide mixed with 
monomethyl malonate potassium salt and magnesium chloride to form methyl-3-
oxodecanoate 87 in quantitative yield. The β-keto ester was then asymmetrically reduced 
with Noyori’s (R)- or (S)-BINAP-Ru dichloride catalyst182 under a high pressure of H2 
(scheme 3.12), to afford (R)- or (S)-methyl-3-hydroxydecanoate 88, respectively. Due to 
the bias provided by the diastereomeric transition states (scheme 3.13), the hydride 
transfers proceeded in high enantiomeric purity (see section 3.2.4.3).183  
 
 
Scheme 3.12: Catalytic cycle for the asymmetric hydrogenation of β-keto esters by [Ru(Cl)2BINAP)], 
generated in situ from [Ru(OAc)2BINAP)] and methanolic HCl. In the first step, the active RuII 
monohydride complex is formed from reaction of the dichloride precatalyst with H2. The β-keto ester 
substrate then chelates to the complex, displacing two solvent ligands. The keto oxygen is then protonated, 
increasing the electrophilicity at the carbonyl carbon and thereby facilitating intramolecular hydride 
transfer. The chiral β-hydroxy ester product is then displaced by incoming solvent ligands. The ruthenium 
complex then reacts with H2 to regenerate the monohydride, thus completing the catalytic cycle. L = 
solvent; PᴖP = BINAP.183  
 
The two enantiomers were then protected with trimethyl silyl (TMS) chloride, and the 
resulting β-silyl ether esters 89 reduced with one equivalent of diisobutylaluminium 
hydride (DIBAL-H) to afford the corresponding aldehydes 90. 
Ethyl(triphenylphosphoranylidene)acetate was subsequently added to install the required 
double bond via a Wittig reaction.184,185 Because a stabilised ylide was used, 
thermodynamic conditions prevailed, resulting in the predominant formation of the more 




stable trans-oxaphosphetane (scheme 3.14).186 This led to the isolation of E : Z isomers 
in >19 : 1 ratio. 
 
 
Scheme 3.13: Enantio-determining transition states during reaction of a β-keto ester with [RuCl2(R)-
BINAP] and H2, adapted from Noyori et al.183 The phenyl rings projecting forward and backward are 
depicted as shaded and colourless hexagons, respectively. BINAP rings have been omitted for clarity. In 
TSR, the R group occupies an open quadrant within the chiral template. In TSS, there is a significant 
nonbonding repulsion between the R group and the equatorial phenyl ring, indicated by the double-headed 




Scheme 3.14: Reaction of aldehyde 90 with ethyl(triphenylphosphoranylidene)acetate to form (E)-91 as 
the major product. Unfavourable 1,2-steric interactions between the R group and the ester moiety are 
minimised in the trans-oxaphosphetane transition state.186 
 
Esters 91 were then reduced with excess DIBAL-H to afford the corresponding alcohols 
92. Subsequently, (S)-92 was reacted with ρ-toluenesulfonyl chloride and triethylamine 




in an attempt to form the tosylate, however a chlorinated side product, (S)-93 (24 %), was 
isolated instead. This likely resulted from further reaction of the tosylate intermediate 
with a chloride ion, due to the enhanced electrophilicity provided by the vinyl group 
(scheme 3.15). Indeed, similar observations have been reported for benzyl alcohols.187 
 
 
Scheme 3.15: Reaction of vinyl alcohol (S)-92 with TsCl and Et3N to form a tosylate intermediate. The 
leaving group is subsequently displaced by a chloride ion to afford (S)-93. 
 
Since chlorides are also effective leaving groups, the side product was reacted on with 
potassium phthalimide to install a primary amino moiety via the Gabriel synthesis,188 
affording (S)-94 in 87 % yield. As this reaction worked well, and phthalimide 
displacements of alkyl tosylates are often reported in poor to moderate 
yields,189,190,191,192,193 rather than attempting to optimise sulfonylation conditions for the 
other enantiomer, the direct synthesis of chloride (R)-93 was attempted. 
 
Initially, (R)-92 was reacted with thionyl chloride. However, due to the highly acidic 
conditions, a mixture of compounds formed, including the cis-isomer and a possible 
Michael-addition product. Therefore, in a second attempt, (R)-92 was reacted with 
triphenylphosphine and N-chlorosuccinamide. Complete, clean conversion of alcohol 92 
to chloride 93 was observed in 3 hours. 
 
The chloride moiety of (R)-93 was then displaced by potassium phthalimide as described 
for the (S)-enantiomer, to afford (R)-94 in 97 % yield. Tetrabutylammonium fluoride 
(TBAF) was subsequently added to remove the silyl protecting group, however the 
reaction proceeded extremely slowly (> 4 days). Therefore, the TBS-intermediates were 
instead reacted with (1S)-(+)-10-camphorsulfonic acid (CSA), resulting in complete 
deprotection to afford (R)- and (S)-95 in 1.5 hours. 
 
In the final step, the phthalimido protecting groups were efficiently removed using 
aqueous methylamine. This reagent was chosen over the more commonly-used hydrazine, 
which has been shown to reduce unactivated carbon-carbon double bonds in the presence 
of oxygen.194  




Overall, the hypothetical CpkH substrates, (R,E)- and (S,E)-1-aminododec-2-en-5-ol 84, 
were synthesised in 52 % and 13 % yield, respectively, over ten steps. 
 
3.2.4.3 Determination of absolute stereochemistry and enantiomeric purity of 
(R,E)- and (S,E)-1-aminododec-2-en-5-ol 
 
In order to deduce the enantiomeric purity and confirm the absolute stereochemistry of 
the two putative substrates, the phthalimido intermediates 95 were derivatised with 
(R)- and (S)-Mosher’s acid195 to yield four diastereomers: (R,R)-, (R,S)-, (S,R)- and 
(S,S)-96 (scheme 3.16).  The 1H NMR shifts of the diastereomers were then compared. 
 
 
Scheme 3.16: Synthesis of Mosher’s esters of (R)- and (S)-95. Reaction conditions: (R)- or (S)-95 (1.0 eq.), 
(R)- or (S)-Mosher’s acid (MTPA: α-methoxy-α-trifluoromethylphenylacetic acid, 1.1 eq.), EDC (1.1 eq.), 
DMAP (0.1 eq.), DCM, r.t. 
 




As expected, the pairs of enantiomers ((R,R) and (S,S); (R,S) and (S,R)) displayed 
identical 1H-NMR spectra, while the pairs of diastereomers ((R,R) and (R,S); (S,R) and 
(S,S)) exhibited slightly different chemical shifts. These differences are mainly 
attributable to the magnetic shielding effect exerted by the phenyl ring; proximal protons 
(residing above or below the plane of the phenyl ring) experience a higher degree of 
shielding and thus have a more upfield chemical shift, while distal protons are less 
affected (figure 3.18).196,197 
 
 
Figure 3.18: Two different representations of (A) the (R,R)-diastereomer; (B) the (R,S)-diastereomer; (C) 
the (S,R)-diastereomer; and (D) the (S,S)-diastereomer of Mosher’s-derivatised 95, adapted from Hoye and 
coworkers.197 The shielding effect exerted by the phenyl group is indicated with a purple arrow. 
 
Therefore, protons 1-7 in the (R,S)- and (S,R)-diastereomers would be expected to be 
more shielded relative to those of the (R,R)- and (S,S)-diastereomers (figure 3.19). This 
effect can be readily observed and is particularly pronounced for protons 3 (ΔδSR = -0.07 
ppm), 4 (ΔδSR = -0.11 ppm) and 5 (ΔδSR = -0.10 ppm) (figure 3.20), thus confirming the 
predicted absolute stereochemistry of both compounds.  
 





Figure 3.19: Structure of 96 with protons labelled 
 
 
Figure 3.20: A comparison of 1H NMR spectra from 4.2–5.8 ppm of (A) (R,R)-96; (B) (R,S)-96; (C) (S,R)-
96; and (D) (S,S)-96. Protons 3, 4, 5 and 7 in spectra (B) and (C) are shifted upfield compared to those of 
(A) and (D). 
 
By measuring the intensities of analogous resonances, the enantiomeric ratio (er) and 
enantiomeric excess (ee) of both (R)- and (S)-95 were determined to be 96 : 4 and 92 %, 
respectively. 
 
3.2.4.4 Incubation of (R,E)- and (S,E)-1-aminododec-2-en-5-ol with CpkH, CpkE 
and CpkI 
 
Following the synthesis of (R,E)- and (S,E)-1-aminododec-2-en-5-ol 84 and the 
confirmation of their absolute stereochemistry, the putative substrates were incubated 
separately with His6-CpkH as described in section 3.2.4.1 (scheme 3.10). The 
supernatants were then analysed by LC-MS. 




Peaks corresponding to the molecular weight of the oxidised compound, (E)-1-
aminododec-2-en-5-one 85, could not be detected in the extracted ion chromatograms 
from either reaction mixture. Peaks corresponding to (R,E)- and (S,E)-84 had not 
decreased in intensity relative to control experiments, suggesting that the starting 
materials had not been consumed during the assay. 
 
It therefore seems likely that these compounds need to be processed by other PKS-
tailoring enzymes prior to oxidation by CpkH. For example, a CpkE-catalysed 
isomerisation, as tentatively suggested in the originally-proposed biosynthetic pathway, 
or a CpkI-catalysed reduction of the double bond, could yield suitable cis- or saturated 
substrate analogues, respectively (scheme 3.17).  
 
 
Scheme 3.17: Assays employed to investigate the hypothetical conversion of (R,E)- or (S,E)-1-amino-
dodec-2-en-5-ol 84 (200 μM) to 6-heptyl-2,3-dihydropyridine 97 or 6-heptyl-2,3,4,5-tetrahydropyridine 81, 
catalysed by CpkH (20 μM) and either CpkE (20 μM) or CpkI (20 μM), respectively.  
 
To investigate these hypotheses, (R,E)- and (S,E)-84 were incubated with His6-CpkH, in 
conjunction with either His6-CpkE or His6-CpkI. For His6-CpkI, both NADH and 
NADPH were trialled as cofactors. Unfortunately, peaks corresponding to 6-heptyl-2,3-
dihydropyridine 97 or 6-heptyl-2,3,4,5-tetrahydropyridine 81 could not be detected in 
LC-MS chromatograms. 
 
It is possible that these compounds are not ideal substrate mimics for CpkE or CpkI, or 
that the enzymes catalyse alternative reactions or exhibit different activities. For example, 
given that the coelimycin biosynthetic pathway is proposed to proceed through several 
epoxide intermediates, it seems plausible that CpkE could function as an epoxide 
hydrolase. This could be a detoxification mechanism, to prevent reaction of the epoxides 
with DNA or other cellular components, or even part of the intended biosynthetic 




pathway, which is not observed due to the apparent trapping of coelimycin A 19 by amino 
acid components within the media. Indeed, a closer inspection of the sequence of CpkE 
reveals the presence of an aspartic acid residue in place of the usually-conserved catalytic 
nucleophilic serine residue within the GxSxG motif (GHDWG). This is a characteristic 
feature among dehalogenases and epoxide hydrolases.198  
 
Moreover, it is conceivable that CpkI does catalyse the reduction of the trans-double 
bond, but during polyketide chain assembly. This could be investigated by loading 
suitable substrates onto the ACP domain within CpkC, prior to incubation with CpkI and 
NAD(P)H. Alternatively, the final DH domain within the PKS could be inactive, despite 
sequence predictions. This would result in the presence of a 3’-hydroxyl residue rather 
than the proposed trans-double bond, meaning that ring formation could still occur. 
Future studies could focus on the synthesis of cis-, 3’-hydroxyl- and epoxide-containing 
substrate analogues for in vitro assays with CpkH, CpkC-DH and CpkE. Furthermore, 
ΔcpkE and ΔcpkI deletion mutants could be generated, to aid in determining the function 
of the corresponding enzymes in vivo.  
 
3.2.4.5 Synthesis of (R)- and (S)-1-aminododecane-5-ol  
 
In order to gain insight into the stereospecificity of CpkH, enantiomers of the known 
saturated substrate, 1-aminododecan-5-ol 60, were synthesised. This involved a Pd/C-
catalysed reduction of the carbon-carbon double bond of intermediates (R,E)- and (S,E)- 
2-(5-hydroxydodec-2-en-1-yl)isoindoline-1,3-dione 95 with H2, followed by a 
methylamine-mediated deprotection of the primary amine group (scheme 3.18). The first 
step proceeded in moderate yield, due to the unforeseen instability of the phthalimido 
group under hydrogenation conditions, while the final step afforded (R)- and (S)-60 in 
>90 % yield. 
 
 
Scheme 3.18: Left: Reduction of (R,E)- and (S,E)-95 (1.0 eq.) with Pd/C (catalytic) and H2 (1 atm), to form 
(R)- and (S)-98. Right: Deprotection of (R)- and (S)-98 (1.0 eq.) with MeNH2 (excess), to form (R)- and 
(S)-60. 




3.2.4.6 Incubation of (R)- and (S)-1-aminododecane-5-ol with CpkH 
 
Following the synthesis of (R)- and (S)-60, the enantiomeric substrates were incubated 
with His6-CpkH in independent assays (scheme 3.19). The supernatants were then 




Scheme 3.19: Assay employed to investigate the oxidation of (R)- or (S)-60 (200 μM), catalysed by CpkH 
(20 μM) 
 
From the extracted ion chromatograms, it is clear that CpkH has a strong preference for 
the (R)-enantiomer of 60 (figure 3.21). This is consistent with KR sequence predictions, 
and thus supports the proposed stereochemistry of the 5’-hydroxyl-containing 
intermediates within the coelimycin biosynthetic pathway.  
 
 
Figure 3.21: Extracted ion chromatograms at m/z = 182.1903 ± 0.05 (corresponding to the [M+H]+ ion for 
6-heptyl-2,3,4,5-tetrahydropyridine). From top to bottom: reaction of (R)-1-aminododecan-5-ol with His6-
CpkH (ion count = 45640 a.u.); reaction of (S)-1-aminododecan-5-ol with His6-CpkH (ion count = 1864 
a.u.); control reaction from which the enzyme was omitted; and authentic standard. Independent 
experiments were performed in triplicate. 




In order to quantify the preference of CpkH for (R)-60, the intensities of the product peaks 
were recorded. The ratio of the ion counts (45640 : 1864 = 96 : 4) corresponded to the 
enantiomeric purity of the synthetic substrates, suggesting that the product peak in the 
assay with (S)-60 is attributable to the presence of (R)-enantiomeric impurities. Therefore, 
this implicates CpkH as being a stereospecific, rather than stereoselective, FAD-
dependent dehydrogenase. 
 
3.2.5 Probing flavin-dependent monooxygenase activity 
 
3.2.5.1 Synthesis of ethyl (2E,4E,6E)-octa-2,4,6-trienoate 
 
Following the characterisation of CpkH as a flavin-dependent dehydrogenase, it was 
hypothesised that CpkD and/or ScF are likely to act as flavin-dependent monooxygenases 






To probe their prospective monooxygenase activities, the synthesis of a simple substrate 
mimic of 29 containing a triene functionality (99, figure 3.22) was planned (scheme 3.21). 
In a first attempt, trans,trans-2,4-hexadienal 100 was reacted with 
(carbethoxymethylene)triphenylphosphorane under Wittig184,185 conditions. However, 
the high temperature employed (120 ºC) caused polymerisation to occur. Therefore, 
instead, 100 was mixed with triethyl-4-phosphonoacetate and sodium hydride at low 
temperature in a Horner-Wadsworth-Emmons199 reaction. Ethyl (2E,4E,6E)-octa-2,4,6-
trienoate 99 was afforded in good yield, in a 9 : 1 ratio of 2E : 2Z isomers. 
Scheme 3.20: Proposed epoxidation reactions catalysed by CpkD and/or ScF  
  
Figure 3.22: Proposed 
substrate mimic of 29 






Scheme 3.21: Attempts to synthesise ethyl (2E,4E,6E)-octa-2,4,6-trienoate 99 from trans,trans-2,4-
hexadienal 100 
 
3.2.5.2 Incubation of ethyl (2E,4E,6E)-octa-2,4,6-trienoate with CpkD and ScF 
 
Following the synthesis of triene ester 99, the putative substrate was incubated with 
His6-CpkD and His6-ScF independently. His6-CpkD, which binds flavin non-covalently, 
was supplemented with additional FMN or FAD. NADH and N-acetylcysteamine (NAC) 
were also added to both reaction mixtures, to reduce the flavin cofactors to their required 
forms (FMNH2 or FADH2, see section 3.2.3.4) and to trap any formed epoxides, 
respectively (scheme 3.22). 
 
Scheme 3.22: Putative epoxidation of 99 (200 μM) by CpkD/ScF (20 μM), FMN/FAD (40 μM) and NADH 
(40 μM), followed by trapping with NAC (400 μM) 
 
The supernatants were then analysed by LC-MS. Clusters of peaks were apparent in the 
CpkD-catalysed reaction, with molecular ions corresponding to a NAC ring-opened 
mono-epoxide ([M+Na]+ = 324.1240) and bis-epoxide ([M+Na]+ = 340.1189) (figure 
3.23). The same peaks were not evident in the analogous ScF assay. Furthermore, in 
reactions where CpkD had been supplemented with FAD or FMN, the peaks were 
approximately 6-fold and 40-fold more intense, respectively. This suggests that CpkD has 




a preference for FMN, but can utilise both cofactors, and is thus consistent with the 
UV/Vis and HRMS data previously obtained (see sections 3.2.3.1 and 3.2.3.2). Peaks 
corresponding to tris-epoxide derivatives could not be detected, in agreement with the 
structures of the proposed intermediates in coelimycin biosynthesis.  
 
 
Figure 3.23: Extracted ion chromatograms at (A) m/z = 324.1240 ± 0.05 (corresponding to the [M+Na]+ 
ion for the NAC-derivatised mono-epoxide) and (B) 340.1189 ± 0.05 (corresponding to the [M+Na]+ ion 
for the NAC-derivatised bis-epoxide), Brown trace: reaction with His6-ScF; blue trace: reaction with His6-
CpkD; purple trace: reaction with His6-CpkD, supplemented with additional FAD; green trace: reaction 
with His6-CpkD, supplemented with additional FMN. Independent experiments were performed in 
triplicate. 
 
It was hypothesised that the clusters of peaks may correspond to a range of regioisomers 
and diastereomers of NAC-derivatised mono- and bis-epoxides (figure 3.24). However, 
to first prove that the compounds were products of CpkD catalysis, several control 
reactions were performed: without substrate; without NAC; without CpkD; with boiled 
CpkD; and without NADH (figure 3.25). 
 
 
Figure 3.24: Possible structures of a NAC ring-opened mono-epoxide (A) and bis-epoxide (B). Other 
structures may include regioisomers (e.g. epoxidation at carbons 6-7 and NAC addition at carbon 7), 
Michael-addition products (e.g. epoxidation at carbons 4-5 and NAC addition at carbon 9) and related 
diastereomers. 





Figure 3.25: Extracted ion chromatograms at (A) m/z = 324.1240 ± 0.05 (corresponding to the [M+Na]+ 
ion for the NAC-derivatised mono-epoxide) and (B) 340.1189 ± 0.05 (corresponding to the [M+Na]+ ion 
for the NAC-derivatised bis-epoxide) arising from the incubation of His6-CpkD with triene ester 99, FMN, 
NADH and NAC. From top to bottom: reaction without substrate; reaction without NAC; reaction without 
His6-CpkD; reaction with boiled His6-CpkD; and reaction without NADH. Independent experiments were 
performed in triplicate. 
 
As expected, product peaks could not be detected in the assays without substrate or NAC. 
However, a small peak (~1/1000 intensity) was apparent in the reaction without CpkD, 
but to which FMN had been added. It is possible that FMN can perform the epoxidation 
chemistry alone, but less efficiently. For instance, CpkD may serve to bind FMN and the 
substrate within close proximity, while favourably altering their pKa. Consistent with 
this, Schneider and coworkers recently reported that flavin derivatives can act as stand-
alone catalysts, which are less effective than their flavoprotein counterparts.200 
 
Surprisingly, a relatively intense cluster of peaks 
could be detected in the reaction with boiled 
His6-CpkD. To investigate this phenomenon, 
circular dichromism (CD) spectra of the enzyme 
were obtained, following incubation at 4 °C or 
100 °C for 1 hour. Comparison of the spectra 
revealed that His6-CpkD remains partially folded 
upon boiling, and thus is an exceptionally stable 
protein. This therefore accounts for the apparent 
catalytic activity observed (figure 3.26).  
 
Figure 3.26: CD spectra of non-
denatured (grey) and boiled (orange) 
His6-CpkD 




Scheme 3.23: Mechanism of FMN reduction by NADH (A) and NAC (B) 
 
The same peaks were also evident in the reaction 
without NADH. This was unexpected, as reduced 
flavin is necessary for monooxygenase activity. 
However, thiols are also known to reduce flavin, 
via the formation of a thiol-C(4a) flavin 
adduct.201,202 Therefore, NAC may be the 
responsible reducing agent (scheme 3.23). 
Indeed, a molecular ion corresponding to the 
oxidised NAC dimer (diNAC, m/z = 259.0545) 
could be detected in assays in which NAC had 
been added (figure 3.27). The presence of diNAC 
within the assay from which FMN was omitted 
can be attributed to the auto-oxidation of NAC; 
the NAC stock was determined to contain 10 % 
diNAC by NMR.  
Figure 3.27: Extracted ion chromatograms 
at m/z = 259.0545 ± 0.005 (corresponding 
to the [M+Na]+ ion for diNAC). Green 
trace: incubation of His6-CpkD with triene 
ester 99, FMN, NADH and NAC; purple 
trace: control reaction from which FMN 
was omitted; and brown trace: control 
reaction from which NAC was omitted. 




3.2.5.3 Tandem mass spectrometry and 18O2 incorporation experiments 
In collaboration with Dr. Lijiang Song, University of Warwick 
 
To gain insight into the structures of the compounds, the molecular ions at m/z = 324 and 
340 were subject to tandem mass spectrometry (Dr. Lijiang Song, University of 
Warwick). The data seemed promising, with fragment ions corresponding to plausible 
molecular formulae (see appendix 9). However, it proved challenging to propose 
mechanistically-viable structures. 
 
To further probe the origin of the compounds, the assay was repeated under an 18O2 
atmosphere (scheme 3.24). Because monooxygenases transfer one atom of molecular 
oxygen per catalytic reaction, any resulting mono- or bis-epoxide products should contain 
one or two atoms of 18O, respectively. This would result in an increase in intensity of 
peaks at +2 or +4 Da by HRMS.  
 
 
Scheme 3.24: Putative epoxidation of 99 (200 μM) by CpkD (20 μM) and FMN (40 μM), followed by 
derivatisation with NAC (400 μM), to yield NAC-adducts of a mono- and bis-epoxide (possible structures 
are shown). Under an 18O2-atmosphere, one or two atoms of 18O would be expected to be incorporated into 
the mono and bis-epoxide derivatives, respectively, resulting in an increase in intensity of peaks of 326 and 
344 Da. 
 
Therefore, 18O2 was bubbled through triene ester 99, His6-CpkD, FMN and NAC, prior 
to, and during incubation. Analysis of the extracted ion chromatograms for the mono-
epoxide derivative revealed a substantial increase in intensity of a peak at +2 Da (m/z = 
326), relative to the control reaction performed in air (figure 3.28). Similarly, the 
extracted ion chromatograms for the bis-epoxide derivative indicated an increase in 
intensity of peaks at +2 and +4 Da (m/z = 342 and 344) (figure 3.29). The peaks at m/z = 
324 and 340, corresponding to the 16O isotopes, had decreased in intensity, accordingly.  
 
It should be noted that there is not 100 % 18O incorporation, likely due to 16O isotopic 
impurities within the canister (~3 %) and difficulties associated with complete exclusion 
of air from the reaction mixtures.  





Figure 3.28: Extracted ion chromatograms from LC-MS analysis of reactions of CpkD, FMN, triene ester 
99 and NAC, in air (A) and under 18O2 (B). The extracted ion chromatograms at m/z = 324.1240 ± 0.05 
(green) and m/z = 326.1240 ± 0.05 (purple) correspond to the 16O and 18O isotopes of the mono-epoxide, 
respectively. Independent assays were performed in duplicate. 
 
 
Figure 3.29: Extracted ion chromatograms from LC-MS analysis of reactions of CpkD, FMN, triene ester 
99 and NAC, in air (A) and under 18O2 (B). The extracted ion chromatograms at m/z = 340.1189 ± 0.05 
(green), m/z = 342.1189 ± 0.05 (purple) and m/z = 344.1189 ± 0.05 (brown) correspond to the 16O, 18O1 and 
18O2 isotopes of the bis-epoxide, respectively. Independent assays were performed in duplicate. 




To quantify the incorporation of 18O2 into the NAC-derivatised mono-epoxide, the 
intensities of the peaks at m/z = 324 (A) and 326 (A+2) for the reaction and control 
mixtures were recorded (table 3.1). The intensity of the A+2 peak in the control 
experiment was then subtracted from the analogous peak in the 18O2 reaction, to account 
for contributions from naturally occurring isotopes (e.g. 13C2, 
34S) (table 3.2, figure 
3.30a). The ratio of unlabelled product : singly-labelled product was determined to be 
1 : 1.91. 
 
Similarly, to quantify the incorporation of 18O2 into the NAC-derivatised bis-epoxide, the 
intensities of the peaks at m/z = 340 (B), 342 (B+2) and 344 (B+4) for the reaction and 
control mixtures were recorded (table 3.1). The values were then corrected, as described 
previously. However, for the doubly-labelled product, isotopic contributions from both 
the unlabelled and singly-labelled product were considered. Because the latter could not 
be calculated, the contribution was assumed to be equal to that of the unlabelled product 
to the singly-labelled product (100 : 5.16 = 28.4 : 1.47) (table 3.2, figure 3.30b). The ratio 
of unlabelled : singly-labelled : doubly-labelled product was determined to be 1 : 0.28 : 
0.05. It is unclear why the incorporation of 18O is lower in the bis-epoxide, compared to 
the mono-epoxide. 
 
Table 3.1: Observed and relative intensities of peaks corresponding to isotopes of mono-epoxide (m/z = 324 
and 326) and bis-epoxide (m/z = 340, 342 and 344) derivatives, from reactions in air and under 18O2 
 m/z Control (in air) Reaction (under 18O2) 
Observed 
intensity / a.u. 
Relative 
intensity / % 
Observed 
intensity / a.u. 
Relative 




324 (A) 29600 100 13400 100 




340 (B) 9270 100 8970 100 
342 (B+2) 478 5.16 3010 33.6 
344 (B+4) 67.0 0.720 646 7.20 
  
Overall, these data support the incorporation of 18O into the enzymatic products, and thus 
imply that CpkD functions as a monooxygenase. It therefore seems likely that CpkD 




catalyses both epoxidations during coelimycin biosynthesis, leaving the role of ScF open 
to speculation. Future work could focus on the optimisation of the isotope incorporation 
experiments and the synthesis of the proposed true triene intermediate, 29, for use as a 
substrate. Furthermore, the enzymatic products could be purified by HPLC and 
characterised by NMR, or a variety of authentic standards could be synthesised for 
LC-MS comparisons.  
 
Table 3.2: The corrected relative intensities of peaks corresponding to mono- and bis-epoxide derivatives, 
following subtraction of isotopic contributions (e.g. 13C2, 34S, 13C4, 34S2, 13C234S) from unlabelled and 
singly-labelled products 
 m/z Relative 
intensity / 
% 
Isotopic contributions Corrected 
relative 
intensity / % 
From unlabelled 
product / % 
From singly- 




324 (A) 100 - - 100 




340 (B) 100 - - 100 
342 (B+2) 33.6 5.16 - 28.4 
344 (B+4) 7.20 0.720 1.47 5.01 
 
 
Figure 3.30: Histograms depicting the relative contributions of isotopes to the A+2, B+2 and B+4 peaks, 
following reaction of triene ester 99 with His6-CpkD, FMN and NAC under an 18O2-enriched atmosphere. 
For simplicity, contributions of naturally occurring isotopes are annotated as 13C2 and 13C4 responses. 
Calculations and data display are adapted from Johnson and coworkers.203 




Analysis of the sequence of CpkD and in silico predictions using Cofactory204 indicate 
that the enzyme contains a fingerprint ‘DG’ motif and a single Rossmann fold.205 
Together with the fact that CpkD is encoded by a single gene, and is capable of binding 
NADH, this suggests that CpkD belongs to the group A subcategory of 
monooxygenases.83 These enzymes are normally involved in the hydroxylation of 
aromatic substrates, although a few examples of epoxidases have also been 
reported.206,207,208 Interestingly, CpkD appears to be the first example of a group A 
monooxygenase capable of binding FMN, in addition to FAD. Crystallisation studies 
could aid in the elucidation of the mode of binding of FMN, NADH and the triene 




The coelimycin post-PKS tailoring genes (cpkI, cpkE, cpkD, scF and cpkH) were cloned 
into pET151 and the corresponding recombinant proteins overproduced in E. coli and 
purified. All proteins were determined to be pure and of the correct molecular weight by 
SDS-PAGE and HRMS analysis. 
 
His6-CpkI and His6-CpkE were incubated with synthetic dodecane-1,5-diol 76 and trans-
octen-2-al 78, to investigate their potential oxidoreductase and isomerase activities, 
respectively. Products could not be detected, suggesting that the assays require 
optimisation, or that the enzymes catalyse other reactions. A multiple sequence alignment 
of CpkE with other members of the α,β-hydrolase fold superfamily suggested that it may 
function as an epoxide hydrolase. 
 
His6-CpkD, His6-ScF and His6-CpkH were all characterised as flavoproteins by UV and 
HRMS analysis. Specifically, His6-CpkD was observed to bind both FAD and FMN non-
covalently, while His6-ScF and His6-CpkH were found to bind FAD covalently. 
His6-CpkH was subsequently shown to oxidise racemic 1-aminododecan-5-ol 60 to 
6-heptyl-2,3,4,5-tetrahydropyridine 81, and was thus characterised as an FAD-dependent 
dehydrogenase. To probe the stereo- and configurational selectivity of CpkH, four further 
substrates ((R)-60, (S)-60, (R,E)-84 and (S,E)-84) were synthesised in excellent yields 
over 10-12 steps. The enzyme specifically oxidised (R)-60 rather than (S)-60, in 
agreement with KR predictions and the proposed coelimycin biosynthetic pathway. 




Analogous substrates containing the trans-double bond were not tolerated in assays with 
CpkH alone, nor coupled assays with CpkE or CpkI. This led to the proposal that the 
released polyketide product may contain a saturated carbon-carbon bond or a 3’-hydroxyl 
functional group. 
 
Preliminary evidence from assays with synthetic triene ester 99, in addition to 
fragmentation studies and 18O2 incorporation experiments, implicate CpkD as an FMN-
dependent monooxygenase. Future work could involve purifying the enzymatic products 
or synthesising a range of stereo- and regioisomeric standards for LC-MS comparisons. 
Furthermore, crystallisation studies could assist in understanding of the mode of cofactor 
and substrate binding, and the mechanism of epoxidation. The role of ScF in coelimycin 
biosynthesis remains to be investigated. 
  




4 CONCLUSIONS AND PERSPECTIVES 




4.1 Biochemical and structural characterisation of CpkG 
 
CpkG was characterised as an ω-transaminase with a broad substrate tolerance. The His6-
tagged enzyme readily catalysed the conversion of several linear, branched, cyclic and 
aromatic amines to the corresponding aldehydes, utilising two different amino acceptors. 
The highest level of activity was observed for octylamine; the compound closest in 
structure to the proposed substrate of CpkG in the coelimycin biosynthetic pathway. 
Further complementary assays allowed for the detection of other products of the 
transamination reaction. The conversion of synthetic substrate mimic 59 to 60, and vice 
versa, demonstrated that CpkG is responsible for nitrogen incorporation into coelimycin.  
 
Crystal structures revealed that His6-CpkG is homodimeric, with a rare tri-domain 
architecture. Comparison of the structures and analysis of the active site allowed for the 
identification of key residues and provided insight into the transamination mechanism. 
Soaking of various amines and carbonyl compounds (e.g. 1-aminododecan-5-ol 60 and 
5-hydroxydodecanal 59) into pre-existing crystals could determine the mode of substrate 
binding within CpkG, while molecular modelling could then unveil the substrate scope. 
The overall fold-type I conformation, in conjunction with Marfey’s analysis, indicated 
that CpkG is an (S)-selective ω-transaminase. The unusual additional domain prompted 
binding assays with CpkC-TR, however an interaction could not be observed. A multiple 
sequence alignment of CpkG with other ω-transaminases involved in polyketide alkaloid 
biosynthesis indicated that the additional domain in CpkG could be non-functional.  
 
Future work could examine the potential of CpkG as a biocatalyst for the generation of 
chiral amines from ketones. Interestingly, an engineered (R)-selective ω-transaminase has 
been recently employed in the large-scale production of the anti-diabetic sitagliptin.209 
 
4.2 Identification of further polyketide alkaloid biosynthetic 
gene clusters 
 
Investigations with CpkC-TR and CpkG led to the hypothesis that thioester reduction and 
transamination may be a conserved sequence of reactions in polyketide alkaloid 
biosynthesis. Comprehensive computational searches uncovered 22 cryptic biosynthetic 




gene clusters from actinobacterial genomes that encode homologues of CpkC-TR and 
CpkG, in addition to a type I modular PKS. Based on PKS sequence predictions, thirteen 
gene clusters were proposed to direct the biosynthesis of known polyketide alkaloids, 
while the remaining nine are likely associated with novel metabolites. Attempts to detect 
one such metabolite from Streptomyces cyaneofuscatus NRRL B-2570 were 
unsuccessful; SARP overexpression instead resulted in the overproduction of the 
unrelated antibiotic valinomycin. Other strategies could explore the deletion of repressor 
genes, promoter exchange or TAR cloning.  
 
Sequencing the genome of the known latumcidin producer, Streptomyces abikoensis 
DSM 40831, led to the identification of a gene cluster containing cpkC-TR and cpkG 
homologues, as predicted. Furthermore, two of the gene clusters detected from the 
bioinformatics search have since been linked to streptazone E and cyclizidine production. 
These findings strongly support the hypothesis that thioester reduction and transamination 
are universal steps in polyketide alkaloid biosynthesis. Future work could involve 
generating gene-knockouts to link latumcidin production to the putative gene cluster in 
S. abikoensis, as well as exploring the vast biosynthetic potential encoded within the 
additional 73 clusters. Moreover, the genetic modification of polyketide biosynthetic gene 
clusters to include a cpkG homologue, and a TE-TR domain swap, could allow for the 
diversion of polyketide pathways towards the production of a range of novel and 
structurally-diverse polyketide alkaloids.  
 
4.3 In vitro investigations with CpkE and CpkI 
 
The coelimycin biosynthetic genes cpkI and cpkE were cloned into pET151, and the 
corresponding N-terminal His6 fusion proteins overproduced in E. coli and purified. The 
proteins were determined to be pure and of the correct molecular weight by SDS-PAGE 
and HRMS analysis. 
 
The potential oxidoreductase and isomerase activities of His6-CpkI and His6-CpkE were 
investigated by incubating the enzymes with synthetic dodecane-1,5-diol 76, trans-octen-
2-al 78, and both enantiomers of (E)-1-aminododec-2-en-5-ol 84, as appropriate. Products 




could not be observed, suggesting that the enzymes are very substrate-specific, or catalyse 
alternative biosynthetic steps. 
 
Examination of the sequence of CpkE revealed the presence of an aspartic acid residue in 
place of the conserved catalytic serine residue, indicating that it may function as an 
epoxide hydrolase. Additionally, CpkI might act as an external enoyl reductase, to reduce 
the carbon-carbon double bond of thioester 22 during polyketide chain assembly. Future 
work could therefore involve the synthesis of epoxide-containing substrates for 
incubation with CpkE, and CoA-thioesters harbouring trans-2,3-double bonds, for 
loading onto the CpkC-ACP domain prior to incubation with CpkI. Alternatively, ΔcpkE 
and ΔcpkI deletion mutants could be generated, to probe the roles of the corresponding 
enzymes in vivo.  
 
4.4 In vitro investigations with CpkD, ScF and CpkH 
 
The oxidative genes cpkD, scF and cpkH were cloned, overexpressed and the 
corresponding fusion proteins purified to homogeneity. All were characterised as 
flavoproteins by UV and HRMS analysis; His6-CpkD was found to bind both FAD and 
FMN non-covalently, while His6-ScF and His6-CpkH were observed to bind FAD 
covalently. A multiple sequence alignment of His6-ScF and His6-CpkH with TamL 
revealed that the mode of binding may be bicovalent, via conserved cysteine and histidine 
residues. This could be probed through crystallisation studies. 
 
His6-CpkH was demonstrated to oxidise synthetic racemic 1-aminododecan-5-ol 60 to 
6-heptyl-2,3,4,5-tetrahydropyridine 81, and thereby characterised as an FAD-dependent 
dehydrogenase, in line with data obtained from in vivo analysis of a cpkH deletion mutant. 
To investigate the stereo- and configurational selectivity of CpkH, four further 
prospective substrates ((R)-60, (S)-60, (R,E)-84 and (S,E)-84) were synthesised over 
10-12 steps in excellent yield. The enzyme was observed to exclusively oxidise (R)-60, 
rather than (S)-60, consistent with KR stereochemical predictions, but could not tolerate 
compounds with a trans-double bond. Future work could explore the synthesis of 
analogues containing a 3’-hydroxyl functional group or cis-double bond, to gain further 
insight into the nature of the pathway intermediates and the order of the biosynthetic steps. 





Initial investigations with His6-CpkD and triene ester 99 suggested that the enzyme 
catalyses the formation of several mono- and bis-epoxides, utilising FMN as a preferred 
cofactor. Fragmentation studies and 18O2 incorporation experiments supported the 
apparent monooxygenase activity observed. Further investigations could focus on the 
purification and characterisation of the enzymatic products, the synthesis of various 
standards for LC-MS comparisons, or the synthesis of more accurate substrate mimics.  
 
As CpkD appears to catalyse both epoxidation reactions in coelimycin biosynthesis, the 
role of ScF is somewhat unclear. However, because the protein is secreted, and its closest 
homologue is CpkH, it may catalyse a similar, late-stage dehydrogenation reaction. This 
would be difficult to investigate, as the reaction is likely not observable due to the 
interception of the pathway by amino acid adducts (N-acetylcysteine and glutamate). It 
remains possible that ScF catalyses the oxidation of the 9’-hydroxyl group of 33 (or a 
similar intermediate) to the corresponding ketone (scheme 4.1). This could be probed by 
synthesising a 9’-hydroxyl-containing substrate analogue.  
 
4.5 Updated biosynthetic pathway 
 
Following in vitro investigations with the post-PKS tailoring enzymes, the coelimycin 
biosynthetic pathway was updated (scheme 4.1). Initially, a hexaketide thioester 22 is 
assembled by modular PKS enzymes CpkA, CpkB and CpkC, from six molecules of 
malonyl-CoA 27. This thioester may contain a trans-2,3-double bond, a 3’-hydroxyl 
group or a saturated carbon-carbon bond, depending on the activity of the final DH 
domain and the actions of any external ERs (such as CpkI). The ACP-bound thioester is 
then reductively cleaved by CpkC-TR and NADH to yield aldehyde 23, which may be 
further reduced and re-oxidised (possibly catalysed by CpkI or an alternative enzyme). 
The aldehyde is then subject to reductive amination by CpkG, which utilises PLP and an 
amino acid (e.g. L-alanine) as co-substrates. Amine 29 then undergoes two epoxidations, 
catalysed by CpkD and necessary cofactors O2, FMN and NADH. Subsequently, CpkH 
catalyses an FAD-mediated oxidation of the hydroxyl group of 31, and a spontaneous 
intramolecular cyclisation yields coelimycin A 19.  At some stage prior to the formation 
of 19, a further transformation is necessary, depending on the nature of the dashed bond. 




Addition of N-acetylcysteine and loss of water affords intermediate 33, which undergoes 
a final oxidation (possibly catalysed by ScF) and tautomerisation to form coelimycin P1 
18 (scheme 4.1). 
 
 
Scheme 4.1: Updated proposed biosynthesis of coelimycin A 19 and coelimycin P1 18. [O] represents an 
unknown dehydrogenase.  
 
Further investigations are necessary to determine the structure of polyketide thioester 22, 
the order of the oxidative steps and the enzymatic roles of CpkI, CpkE and ScF. Complete 
elucidation of coelimycin biosynthesis could allow for the re-engineering of the pathway 
in the future, for the generation of novel and stable bioactive analogues.  
  











5.1 Instruments and equipment 
 
Autoclaving was performed at 121 °C and 1 bar for 10 min. Liquid and solid cultures 
were incubated in New Brunswick Scientific Innova shakers or Thermo Scientific 
Heraeus static incubators, respectively. Optical densities were measured using a Thermo 
Scientific BioMate 3 spectrophotometer. Centrifugations were performed using 
Eppendorf models 5415D, 5424, 5804R and 5810R, or a Sorvall RC 6 Plus equipped with 
an SS34 or SLA3000 rotor. Streptomyces strains were handled in a Bassaire laminar flow 
hood. PCR reactions were performed using an Eppendorf Mastercycler Gradient or 
Eppendorf Mastercycler Personal. DNA and protein concentrations were determined 
using a Thermo Scientific NanoDrop Lite spectrophotometer. Agarose gel electrophoresis 
was performed using a BioRad tank in conjunction with either a PowerPacTM Basic or a 
PowerPacTM 300. Visualisation was achieved with a UVP BioDoc-It® Imaging System 
2UV Transilluminator. Electroporations were conducted with a BioRad Gene Pulser® II 
(200 Ω, 25 μF, 1.8 kV) in combination with a BioRad Pulse Controller Plus. Cell lysis 
was performed using a Constant Systems Ltd TS-Series Cabinet cell disruptor (One-Shot 
mode, 20 KPSI). Proteins were analysed by SDS-PAGE gel electrophoresis using a 
BioRad Mini-PROTEAN® Tetra cell. UV-Vis measurements of solutions in 3 mm path 
length sub-micro quartz cuvettes (Starna scientific) were recorded using a Varian Cary 
50 Bio UV-Visible Spectrophotometer (single wavelength) or a Perkin Elmer® Lambda 
3S UV/Vis Spectrophotometer (multiple wavelengths). UV-Vis measurements of 
solutions in 96-well plates were recorded using a Tecan GENios microplate reader. 
 
Solvents were evaporated using a BUCHI Rotavapor R-200 or R-210 connected to a 
BUCHI Vacuum Pump V-700. Melting points were obtained by a Stuart Scientific 
SMP10 instrument. NMR spectra were measured using a Bruker DPX-300 (1H: 300 MHz, 
13C: 75 MHz) or DPX-400 (1H: 400 MHz, 13C: 100 MHz) instrument, both equipped with 
a proton carbon dual probe. High field NMR spectra were obtained following submission 
to the University of Warwick NMR service, using a Bruker AV-500 (1H: 500 MHz, 13C: 
125 MHz), AV III-600 (1H: 600 MHz, 13C: 150 MHz) or AV II-700 (1H: 700 MHz, 13C: 
175 MHz) instrument. 1H NMR data are reported as follows: chemical shift (δ, ppm), 
multiplicity (singlet (s); doublet (d); triplet (t); quartet (q); quintet (quint); doublet of 
doublets (dd); doublet of doublet of doublet of doublets (dddd); doublet of triplets (dt); 
triplet of doublets (td); broad (br.); multiplet (m)), integration, assignment and coupling 




constant (Hz). Assignments were assisted by use of COSY, HMQC and HMBC spectra. 
All low-resolution mass spectra were obtained on an Agilent 6130B Single Quad ESI 
spectrometer while high resolution mass spectra were recorded on a Bruker MaXis ESI 
spectrometer by the University of Warwick Mass Spectrometry service.  
 
Analytical reverse-phase high performance liquid chromatography (HPLC) was 
performed on an Agilent 1100 HPLC instrument connected with a variable wavelength 
detector and an Agilent ZORBAX Eclipse Plus C18 analytical column (4.6 × 150 mm, 
5 μm). Preparative reverse-phase HPLC was performed on an Agilent 1200 or 1260 
Infinity HPLC instrument connected with a diode array detector and an Agilent PrepHT 
XDB-C18 or BetaSil C18 preparative column (21.2 × 150 mm, 5 μm), respectively. 
Liquid chromatography-high resolution mass spectrometry (LC-HRMS) was performed 
using a Thermo Scientific Dionex Ultimate 3000 RS UHPLC coupled to a Bruker MaXis 
Impact ESI-TOF mass spectrometer using an Agilent ZORBAX Eclipse XDB-C18 
analytical column (2.1 × 5 mm, 1.8 μm) for small molecules, or an Advanced 
Chromatography Technologies ACE 3 C4-300 reverse phase column (100 × 2.1 mm) for 






Bacto yeast extract, Bacto agar, Bacto Tryptic Soy Broth and tryptone were all purchased 
from Becton Dickinson and Company (USA). GelRed Nucleic Acid Gel Stain and 
InstantBlue were purchased from Cambridge Bioscience (UK) and Expedeon (UK), 
respectively. All other chemical reagents were purchased from Sigma Aldrich (USA), 
Thermo Fisher Scientific (UK) or Alfa Aesar (USA) and used without further purification 
unless otherwise stated. Solvents were purchased from Thermo Fisher Scientific unless 
otherwise stated. Anhydrous solvents were obtained by distillation under argon using 
calcium hydride as a drying reagent, and stored over 4 Å molecular sieves. TLC was 
performed using aluminium plates pre-coated with silica gel 60 F254 (Merck, Germany) 
and flash chromatography was performed on silica gel (Aldrich, 40-63 µm, 60 Å). UV 
light or potassium permanganate staining were used for compound detection. All water 
used was deionised, unless stated otherwise.  




5.2.2 Kits and enzymes 
 
Kits used for DNA purification, plasmid DNA extraction, TOPO® cloning and ligations 
were all purchased from Thermo Fisher Scientific (UK). Restriction enzymes, 
corresponding buffers and Taq polymerase were also purchased from Thermo Fisher 
Scientific. Kits used for trypsin profile in-gel digests were purchased from Sigma Aldrich 
(USA). Phusion polymerase was obtained from New England Biolabs (USA). T4 DNA 
ligase and buffers were acquired from Roche (Germany). 
 
5.2.3 Growth and production media 
 
Luria-Bertani Medium (LB): LB Broth powder (Miller’s) was dissolved in water to a 
concentration of 25 g/L and sterilised by autoclaving. To prepare LB agar, 15 g/L Bacto 
agar was added prior to sterilisation. 
 
Tryptone Soya Broth (TSB): Bacto Tryptic Soy Broth (30 g/L) was dissolved in water 
and sterilised by autoclaving.9 
 
Soya Flour Mannitol Medium (SFM): Soya flour (20 g/L) and D-mannitol (20 g/L) 
were dissolved in tap water. Bacto agar (20 g/L) was added and the contents were 
sterilised by autoclaving.9 
 
International Streptomyces Project Medium 2 (ISP2): Difco yeast extract (4 g/L), 
Merck malt extract (10 g/L) and glucose (4 g/L) were dissolved in water and the pH of 
the solution adjusted to 7.3. Bacto agar (20 g/L) was added and the contents were 
sterilised by autoclaving.210  
 
International Streptomyces Project Medium 4 (ISP4): ISP4 powder was dissolved in 
water to a concentration of 37 g/L and sterilised by autoclaving. To prepare ISP4 agar, 
20 g/L Bacto agar was added prior to sterilisation. 
 
GYM Streptomyces Medium: Glucose (4 g/L), Difco yeast extract (4 g/L), Merck malt 
extract (10 g/L) and CaCO3 (2 g/L) were dissolved in water and the pH of the solution 




adjusted to 7.2. Bacto agar (12 g/L) was added and the contents were sterilised by 
autoclaving.211 
 
R3 Medium: Glucose (10 g/L), Difco yeast extract (5 g/L), Difco casamino acids 
(0.1 g/L), L-proline (3 g/L), MgCl2.6H2O (10 g/L), CaCl2.2H2O (4 g/L), K2SO4 (0.2 g/L), 
KH2PO4 (0.05 g/L), TES (5.6 g/L) and trace element solution* (2 mL/L) were dissolved 
in water. The pH of the solution was adjusted to 7.2 with 1 M NaOH and the contents 
were sterilised by autoclaving. To prepare R3 agar, 22 g/L Bacto agar was added prior to 
sterilisation.212 
 
R5 Medium: Sucrose (103 g/L), K2SO4 (0.25 g/L), MgCl2.6H2O (10.12 g/L), glucose 
(10 g/L), Difco casamino acids (0.1 g/L), trace element solution* (2 mL/L), Difco yeast 
extract (5 g/L) and TES (5.73 g/L) were dissolved in water and sterilised by autoclaving. 
To prepare R5 agar, 22 g/L Bacto agar was added prior to sterilisation. At the time of use, 
0.5 % KH2PO4 (10 mL/L), 5 M CaCl2.2H2O (4 mL/L), 20 % L-proline (15 mL/L) and 1 N 
NaOH (7 mL/L) were added in the order listed.9  
 
Alkaloid Medium 1 (AM1): Glucose (20 g/L), peptone (5 g/L), meat extract (5 g/L), 
yeast extract (3 g/L), CaCO3 (3 g/L) and NaCl (5 g/L) were dissolved in water. The pH 
of the solution was adjusted to 7.0 and the contents were sterilised by autoclaving.213 
 
Supplemented Minimal Medium (SMM): Difco casamino acids (2 g/L) and TES (5.73 
g/L) were dissolved in water and the pH of the solution adjusted to 7.2 with 5 M NaOH. 
The contents were then sterilised by autoclaving. At the time of use, 50 mM 
NaH2PO4/K2HPO4 (10 mL/L), 1 M MgSO4 (5 mL/L), glucose (50 % w/v, 18 mL/L) and 
trace element solution* (1 mL/L) were added in the order listed.9  
 
*Trace element solution: ZnCl2 (40 mg/L), FeCl3.6H2O (200 mg/L), CuCl2.2H2O 
(10 mg/L), MnCl2.4H2O (10 mg/L), Na2B4O7.10H2O (10 mg/L) and (NH4)6Mo7O24.4H2O 










STE buffer: 100 mM NaCl, 10 mM Tris-HCl (pH 8.0), 1 mM EDTA 
 
TBE buffer (10 ×): 108 g Tris-HCl (pH 8.0-8.3), 55.0 g boric acid, 11.7 g EDTA, water 
to 1 L 
 
Ni2+-affinity washing buffer: 100 mM NaCl, 20 mM Tris-HCl (pH 8.0), 20 mM imidazole 
 
Ni2+-affinity elution buffers: 100 mM NaCl, 20 mM Tris-HCl (pH 8.0), 50-300 mM 
imidazole 
 
Concentration buffer: 100 mM NaCl, 20 mM Tris-HCl (pH 8.0) 
 
Concentration buffer (CpkG): 100 mM NaCl, 50 mM HEPES (pH 7.6), 20 µM PLP 
 
Crystallisation buffer (CpkG): 20 mM NaCl, 50 mM HEPES (pH 7.8) 
 
Storage/gel filtration buffer: 100 mM NaCl, 20 mM Tris-HCl (pH 8.0), 10 % glycerol 
 
Phosphate buffer (100 mM, pH 7.0): 1 M K2HPO4
 (61.5 mL), 1 M KH2PO4
 (38.5 mL), 
water to 1 L 
 
SDS-PAGE sample buffer (2 ×)*: 500 mM Tris-HCl (2.5 mL, pH 6.8), 100 % glycerol 
(2.0 mL), β-mercaptoethanol (400 µL), bromophenol blue (20.0 mg), SDS (400 mg), 
water to 10 mL 
 
SDS-PAGE running buffer (10 ×)*: 250 mM Tris-HCl (pH 8.8), 2 M glycine, 1 % SDS 
 
*For preparation of native-PAGE sample and running buffers, β-mercaptoethanol and 
SDS were omitted 
 
 






Table 5.1: Antibiotics used within this project 





Ampicillin 100 100 H2O Melford (UK) 
Hygromycin 50 25 H2O Roche (Germany) 
Kanamycin 50 50 H2O Melford (UK) 
Chloramphenicol 25 25 MeOH Duchefa Biochemie (Holland) 
Nalidixic acid 25 20 0.3 M NaOH Duchefa Biochemie (Holland) 
Apramycin 50 25 H2O PanReac AppliChem (Germany) 
 
5.2.6 Bacterial strains 
 
Table 5.2: Bacterial strains used within this project 
Bacterial strain Use Supplier 
Escherichia coli   
One Shot® TOP10 chemically 
competent cells 
Transformations, cloning and plasmid 
DNA isolation 
Thermo Fisher Scientific 
(UK) 
One Shot® BL21 Star™ (DE3) 
chemically competent cells 
High level recombinant protein 
expression 
Thermo Fisher Scientific 
(UK) 
ET12567/pUZ8002 Conjugations Lab stock 
Streptomyces   
coelicolor M145 PCR amplification of cpk genes Lab stock 
cyaneofuscatus NRRL B-2570 Attempted detection of novel 
polyketide alkaloid 
ARS culture (NRRL) 
collection (USA) 
cyaneofuscatus::SARP Attempted detection of novel 
polyketide alkaloid 
Genetically engineered 
in this study 
cyaneofuscatusPKS::am Attempted detection of novel 
polyketide alkaloid 
Genetically engineered 
in this study 
cyaneofuscatus::SARP-PKS::am Attempted detection of novel 
polyketide alkaloid 
Genetically engineered 
in this study 
abikoensis DSM 40831 Genome sequencing for identification 
of latumcidin gene cluster 
DSMZ culture collection 
(Germany) 






Table 5.3: Vectors used within this project 
Vector Use Resistance Supplier 
pET151 Overexpression of proteins with an 
N-terminal His-tag 
Ampicillin Thermo Fisher Scientific 
(UK) 
pOSV556t  Integrative plasmid for genetic 




Pernodet Group (University 
of Paris-Sud, France) 
pKC1132 Suicide plasmid for insertional 
inactivation of IF17_RS0112385 via a 
single crossover 
Apramycin Lab stock 
 
5.2.8 PCR Primers 
 
PCR primers were designed as recommended by the TOPO® cloning manual for pET151 
constructs, or to include restriction sites and/or ribosomal binding sites for pOSV556t and 
pKC1132 constructs. All primers were purchased from Sigma-Aldrich. 
 
Table 5.4: PCR primers used within this project 
Primer ID Sequence (5’ → 3’) Use 
cpkE_fw CACCATGACGGCGACCCGGATC Amplification of cpkE 
from S. coelicolor M145 
and ligation with pET151 cpkE_rv TCAGTGGGTCTGCCGGTACGCG 
cpkI_fw CACCATGACTGAGAGATTGAGGAGTTT
CC 
Amplification of cpkI from 
S. coelicolor M145 and 
ligation with pET151 
cpkI_rv TCAGAGGCCGAGGCCG 
cpkD_fw CACCATGAGAAGAAAGCGCGAAGGCCG Amplification of cpkD 
from S. coelicolor M145 
and ligation with pET151 cpkD_rv TCACCGCTGGGCTCCGGCGATC 
cpkH_fw CACCGCACAGCCCTCACCCGCC Amplification of cpkH 
from S. coelicolor M145 
and ligation with pET151 cpkH_rv TCAGGCCGGCTCGATACC 
scF_fw CACCGCAGGCCCCGAGGACCTC Amplification of scF from 
S. coelicolor M145 and 
ligation with pET151 scF_rv CTACGGCTTGCGGATGCC 






Amplification of SARP 
(IF17_RS0112435) from 






CCGCGATGGCCGACCGGCT Sequencing of middle 







TACAAGCATAAAGCTGGCATGC Sequencing of outer 





IF17_RS0112385_fw CACAAGCTTGGAGGACCTGTGGAACCT Amplification of PKS 
region (IF17_RS0112385) 











5.3 Biological procedures 
 
5.3.1 Growth, preparation and storage of microbial cells 
 
5.3.1.1 General culture conditions 
 
E. coli and Streptomyces strains were grown at 37 °C and 30 °C, respectively, in selected 
media (see section 5.2.3) containing an appropriate antibiotic (see sections 5.2.5 and 
5.2.7), if necessary. Liquid cultures were incubated with shaking at 180 rpm. 
 
5.3.1.2 Preparation and storage of Streptomyces spore stock solutions 
 
Single colonies of S. coelicolor, S. cyaneofuscatus or S. abikoensis were selected and 
spread onto GYM, SFM, ISP2 or ISP4 agar plates. The cultures were then incubated at 
30 ºC for one week. Sterile water (3 mL) was added to each plate and the surface scraped 
using sterile plastic spreaders to suspend the spores. The spore suspension was then 
filtered through sterile non-absorbent glass wool and the filtrate centrifuged (6000 rpm, 
20 ºC, 5 min) to pellet the spores. The majority of the supernatant was then decanted and 
to the remainder was added an approximate equal volume of 50 % glycerol. The spore 
stock solution was then stored at -78 °C. 




For preparation of a spore stock of ARS-acquired S. cyaneofuscatus or DSMZ-acquired 
S. abikoensis, the freeze-dried cells were first resuspended in TSB media (500 µL) and 
aliquots (100 µL) were spread onto agar plates. The plates were then incubated at 30 ºC 
for one week before selection of single colonies.  
 
5.3.1.3 Preparation and storage of chemically competent E. coli cells  
 
LB medium (5 mL) was inoculated with an E. coli BL21Star or TOP10 glycerol stock 
solution (100 µL) and incubated with shaking at 37 °C overnight. Fresh LB medium 
(500 mL) was then inoculated with overnight culture (5 mL), and the cells incubated with 
shaking at 37 °C until OD600 = 0.4. The cells were subsequently incubated on ice for 
20 min and harvested by centrifugation (3000 rpm, 4 °C, 10 min). The media was 
decanted, and the cells resuspended in cold 0.1 M CaCl2 (50 mL) then left on ice for 
30 min. The cells were then centrifuged as before, the media decanted, and the cells 
resuspended in cold CaCl2 (5 mL) containing 15 % glycerol. The cells were divided into 
aliquots (100 µL), left on ice for 1 h, flash frozen in liquid N2 and stored at -78 °C. 
 
5.3.1.4 Preparation and storage of electrocompetent E. coli cells  
 
LB medium (5 mL) containing the appropriate antibiotic(s) (see sections 5.2.5 and 5.2.7) 
was inoculated with an E. coli ET12567/pUZ8002 glycerol stock solution (100 µL) and 
incubated with shaking at 37 ºC overnight. Fresh LB medium (5 mL) containing the 
appropriate antibiotic(s) was inoculated with overnight culture (100 µL) and incubated 
with shaking at 37 ºC until the OD600 = 0.6. E. coli cells were then harvested by 
centrifugation (4000 rpm, 4 ºC, 8 min), the medium decanted and the cell pellet 
resuspended in sterile 10 % glycerol. The cells were centrifuged as before and washed 
again with 10 % glycerol. Cells were then resuspended in 10 % glycerol (200 µL) and 
aliquots (100 µL) were flash frozen in liquid N2 and stored at -78 ºC. 
 
5.3.2 DNA isolation and purification 
 
5.3.2.1 Isolation of genomic DNA from Streptomyces 
 
TSB media (25 mL) was inoculated with the appropriate spore stock solution (50 µL) and 
incubated with shaking at 30 °C for 2-3 days. The culture was centrifuged (4000 rpm, 




20 ºC, 10 min) and the supernatant discarded. The cells were washed twice with STE 
buffer (5 mL) then resuspended in STE buffer (2.5 mL). Lysozyme (2.5 mL, 10 mg/mL 
STE buffer) was added and the cells were incubated at room temperature for 30 min with 
gentle rocking. 10 % SDS (250 µL) was then added and the mixture was incubated for a 
further 5 min with gentle rocking. The mixture was then incubated at 70 °C for 5 min and 
subsequently left on ice for 5 min. 5 M potassium acetate (630 µL) was added and the 
mixture was incubated on ice for 5 min. Phenol-chloroform (2.5 mL) was added and the 
mixture was mixed gently by inverting for 5 min at room temperature. The contents were 
then centrifuged (7000 rpm, 20 °C, 10 min) and the supernatant decanted into a fresh 
tube. The supernatant was then washed again with phenol-chloroform (2.5 mL). 
3 M sodium acetate (500 µL) and isopropanol (3 mL) were added, the mixture centrifuged 
(7000 rpm, 4 °C, 10 min) and the supernatant discarded. The DNA pellet was washed 
with 70 % EtOH, left to dry overnight and dissolved in RNase water (250 µL). The 
concentration of the genomic DNA was measured using a NanoDrop spectrophotometer. 
 
5.3.2.2 Isolation of plasmid DNA from E. coli  
 
LB media (5 mL) supplemented with ampicillin was inoculated with a single colony or 
stock solution (1 µL) of E. coli One Shot® TOP10 cells harbouring pET151 derivatives, 
and incubated with shaking at 37 °C overnight. The culture was then centrifuged 
(2000 rpm, 20 ºC, 10 min) and the supernatant discarded. Plasmid DNA was extracted 
using a GeneJET Plasmid Miniprep kit according to the manufacturer’s instructions, and 
the DNA concentration measured using a NanoDrop spectrophotometer. 
 
5.3.3 DNA manipulation 
 
5.3.3.1 Polymerase chain reaction (PCR) 
 
Following the design of primers, reactions were performed using the following reagent 










Table 5.5: Volumes of reagents used for 20 µL PCR reactions 
Reagents and quantities for use with Taq 
polymerase 
Reagents and quantities for use with Phusion 
polymerase 
Reagent Volume / µL Reagent Volume / µL 
Template DNA* 0.8 Template DNA* 2.0 
Buffer 2 2.0 5 × Phusion HF/GC buffer 4.0 
dNTP mix (10 mM) 0.4 dNTP mix (10 mM) 0.4 
Forward primer (10 µM) 0.6 Forward primer (10 µM) 1.0 
Reverse primer (10 µM) 0.6 Reverse primer (10 µM) 1.0 
Taq polymerase 0.2 Phusion polymerase 0.2 
DMSO 2.0 DMSO 0.6 
Sterile H2O 13.4 Sterile H2O 10.8 
*Initially diluted to 10-50 ng/µL (genomic DNA) or 0.2-2000 pg/µL (plasmid DNA) 
 
In some cases, a higher concentration of DMSO or MgCl2 (present within the buffer) was 
added. Reactions were then performed using the following PCR cycle conditions: 
 
1. Initial denaturation: 98 °C, 30 s 
2. Denaturation: 98 °C, 10 s 
3. Annealing: Tm – 5 °C*, 30 s     × 30 
4. Extension: 72 °C, 1 min** 
5. Final extension: 72 °C, 10 min 
6. Resting: 4 °C, ∞ 
 
*Annealing temperatures were approximately 5 °C below the melting temperatures of the 
primers (estimated using Integrated DNA Technologies Oligo Analyzer) or optimised 
from gradient PCR trials. 
 
**Extension times were increased for larger regions of DNA (1 min/kb using Taq 
polymerase or 30 s/kb using Phusion polymerase). 
 




5.3.3.2 Agarose gel electrophoresis and gel extraction 
 
Agarose (1 g) was added to 1 × TBE buffer (100 mL) and dissolved by heating. The 
solution was then cooled to room temperature and GelRed (2.5 µL) was added. The 
contents were poured into a mould and a comb put in place. Once set, the gel was 
transferred to a tank filled with 1 × TBE buffer and samples containing 1 × DNA loading 
dye were loaded alongside an appropriate DNA size marker. The DNA fragments were 
then electrophoresed at 80-110 V for 0.5-2 h depending on the separation required. 
 
Following electrophoresis, DNA fragments were visualised using a UV-transilluminator. 
If required, PCR products were excised from the gel using a GeneJET Gel Extraction kit 
according to the manufacturer’s instructions, and the DNA concentration measured using 
a NanoDrop spectrophotometer. 
 
5.3.3.3 Restriction digests 
 
5.3.3.3.1 Restriction digests for analysis of recombinant vectors 
 
To double-stranded DNA (3 µL) was added the appropriate restriction enzyme(s) 
(1-3 µL), buffer (2 µL) and water (up to 20 µL). The buffer was selected by supplier 
recommendation (single digests) or by using the Thermo Scientific DoubleDigest 
Calculator (double digests). Reaction mixtures were incubated at 37 °C for 15 min (for 
fast digest enzymes) to 2 h. Fragments were then analysed by agarose gel electrophoresis. 
 
5.3.3.3.2 Restriction digests for subsequent ligation with pOSV556t and pKC1132 
 
To the PCR product (48 µL) were added the appropriate restriction enzymes (1.5-3 µL), 
buffer (6 µL) and water, if necessary (up to 60 µL), and the mixture incubated at 37 °C 
for 75 min. The digested DNA was then purified using the GeneJET PCR Purification kit 
according to the manufacturer’s instructions. 
 
Meanwhile, to the plasmid (40 µL) were added the appropriate restriction enzymes 
(1.5-3 µL), buffer (5 µL) and water, if necessary (up to 50 µL), and the mixture incubated 
at 37 °C for 70 min. At this time, shrimp alkaline phosphatase (rSAP) (1-2 µL) was added 




to dephosphorylate linearised plasmid DNA and the mixture was incubated at 37 °C for 
a further 20 min. The mixture was then electrophoresed (see section 5.3.3.2) and the linear 





5.3.3.4.1 Ligations with pET151 
 
Following purification of the PCR product, ligations were performed using the TOPO 
cloning kit according to the manufacturer’s instructions, although higher insert:vector 
ratios (7:1) were typically used. 
 
5.3.3.4.2 Ligations with pOSV556t and pKC1132 
 
Following purification of the PCR product and either pOSV556t or pKC1132, ligations 
were performed using the Rapid DNA Ligation kit according to the manufacturer’s 
instructions. Insert:vector ratios were calculated using the in silico Ligation Calculator. 
 
5.3.4 DNA transfer 
 
5.3.4.1 Transformation of chemically competent E. coli cells 
 
To chemically competent cells (50 µL) was added either plasmid DNA (2 µL) or ligation 
mixture (3 µL), as required, under flame. Cells were incubated on ice for 30 min, 
transferred to a 42 ºC water bath for 30 s then returned to ice for 1 min to recover. Sterile 
LB medium (250 µL) was added and the transformation mixture shaken horizontally at 
37 ºC for 1 h. Different volumes of the transformation mixture were then spread onto two 
pre-warmed LB agar plates supplemented with ampicillin, and the plates were incubated 
at 37 ºC overnight. 
 
5.3.4.2 Transformation of electrocompetent E. coli cells 
 
To electrocompetent ET12567/pUZ8002 cells (100 µL) was added either recombinant 
pOSV556t or pKC1132 (1.5 µL), under flame. The contents were then transferred into an 




ice-cold 0.2 cm electroporation cuvette and shocked at 1.8 kV for approximately 4.9 ms. 
Sterile LB (800 µL) was added and the transformation mixture was shaken horizontally 
at 37 ºC for 1 h.  Different volumes of the transformation mixture were then spread onto 
two pre-warmed LB agar plates supplemented with chloramphenicol, kanamycin and 
either ampicillin (pOSV556t) or apramycin (pKC1132), and the plates were incubated at 
37 ºC overnight.  
 
5.3.4.3 DNA transfer from E. coli to Streptomyces via conjugation 
 
Following the transformation of electrocompetent ET12567/pUZ8002 cells with 
pOSV556t or pKC1132 derivatives (see section 5.3.4.2), LB medium (5 mL) 
supplemented with chloramphenicol, kanamycin and either ampicillin (pOSV556t) or 
apramycin (pKC1132) was inoculated with a single colony and incubated with shaking at 
37 ºC overnight. Fresh LB medium (5 mL) supplemented with the antibiotics described 
above was then inoculated with overnight culture (100 µL) and incubated with shaking at 
37 ºC for 4-5 h. The cells were then harvested by centrifugation (4000 rpm, 4 ºC, 8 min), 
washed twice with LB medium (5 mL) to remove trace antibiotics and then resuspended 
in LB medium (500 µL). 
 
Meanwhile, to fresh LB medium (450 µL) was added the appropriate Streptomyces spore 
stock solution (50 µL). The spores were incubated at 55 ºC for 15 min then cooled on ice 
for 2 min. Subsequently, the spores (500 µL) were mixed with the E. coli cells (500 µL) 
and centrifuged (6000 rpm, 2 min). Differing aliquots were then spread onto two pre-
warmed SFM plates containing 10 mM MgCl2, and incubated at 30 ºC for 20 h. The plates 
were then overlaid with sterile water (1 mL) containing nalidixic acid (20 µL) to 
selectively kill E. coli cells, and hygromycin or apramycin (25 µL) to select for 
exconjugants containing pOSV556t or pKC1132 derivatives, respectively. The plates 










5.3.5 Protein overexpression, purification and analysis 
 
5.3.5.1 IPTG-induced gene expression 
 
To sterile LB medium (10 mL) supplemented with ampicillin was added a single BL21 
Star(DE3) transformant and the culture incubated with shaking at 37 ºC overnight. The 
following day, sterile LB medium (1 L) supplemented with ampicillin was inoculated 
with overnight culture (10 mL/L) and incubated with shaking at 37 ºC until OD600 = 0.6. 
At this time, sterile isopropyl-β-thiogalactopyranoside (IPTG) was added to a final 
concentration of 0.5 mM to induce expression of the cloned gene and the culture was 
incubated with shaking at 15 ºC overnight. 
  
5.3.5.2 Recombinant fusion protein purification 
 
Cells were harvested by centrifugation (5000 rpm, 4 ºC, 15 min), the supernatant decanted 
and the pellet resuspended in washing buffer (20 mL/L culture) containing PMSF 
(10 µM). Cells were lysed with a cell disrupter and the cellular debris removed by 
centrifugation (11000 rpm, 4 ºC, 30 min). The cell-free extract was then passed through 
a 0.45 µm syringe filter (GE Healthcare) and loaded onto a 1 mL HiTrapTM HP affinity 
column (GE Healthcare), which was washed with washing buffer (15 mL). The protein 
was then eluted in a stepwise approach with elution buffer containing 50 mM (5 mL), 
100 mM (5 mL), 200 mM (3 mL) and 300 mM (3 mL) imidazole. Fractions containing the 
fusion protein (as determined by SDS-PAGE analysis, see section 5.3.5.3) were pooled 
and concentrated (6000 rpm, 4 ºC) using Amicon® Ultra-15 centrifugal filters with a 
10 or 30 kDa molecular weight cut-off membrane (Merck Millipore) then exchanged 
twice into concentration buffer*. Glycerol was added to a final concentration of 25 % and 
the protein was aliquoted, flash frozen in liquid N2 and stored at -78 ºC. 
 
*For purification of CpkG, all buffers were supplemented with PLP (20 µM). For concentration and storage 
of CpkG, a HEPES-based buffer was used (see section 5.2.4). 
 
5.3.5.3 SDS-PAGE gel electrophoresis 
 
SDS-PAGE gels were prepared as shown in table 5.6. 
 




Table 5.6: Volumes of reagents used for the preparation of 8 %, 10 % and 12 % gels 
Resolving gel Stacking gel 
Reagent Volume (mL) Reagent Volume 
(mL) 
 8 %  10 %  12 %    
H2O 4.6 3.8 3.3 H2O 1.40 
30 % acrylamide mix 2.7 3.4 4.0 30 % acrylamide mix 0.33 
1.5 M Tris-HCl (pH 8.8) 2.5 2.5 2.5 1.0 M Tris-HCl (pH 6.8) 0.25 
10 % SDS 0.1 0.1 0.1 10 % SDS 0.02 
10 % ammonium persulfate 0.1 0.1 0.1 10 % ammonium persulfate 0.02 
TEMED 0.006 0.005 0.004 TEMED 0.002 
 
Protein samples containing 1× SDS-PAGE loading dye (10 µL) were then loaded onto 
the gel alongside a protein molecular weight marker (5 µL) and electrophoresed at 200 V 
for 35-45 min. Gels were subsequently stained with InstantBlue and gently rocked for 
15 min to effect visualisation.  
 
5.3.5.4 Determining protein concentration 
 
Protein absorbance at 280 nm was measured using a NanoDrop spectrophotometer. 
Molecular weights were obtained from NCBI and extinction coefficients from the 
ExPASy ProtParam tool. Concentrations were then calculated using the equation: 





5.3.5.5 Determining protein molecular weight 
 
Proteins were diluted to 10 µM in water and analysed by high-resolution LC-MS 
according to the elution profile in table 5.7. The mass spectrometer was operated in 








Table 5.7: Elution conditions used for LC-MS analyses of purified recombinant proteins 
Time / min H2O / %  
(0.1 % FA) 
MeOH / %  
(0.1 % FA) 
Flow rate / mL 
0.0 90 10 0.1 
8.0 90 10 0.1 
47.5 0 100 0.1 
52.5 0 100 0.1 
57.5 90 10 0.1 
 
5.3.5.6 CD spectroscopic analysis of proteins 
 
Proteins were diluted to 0.1 mg/mL in 5 mM phosphate buffer (pH 7.0) and the absorbance 
measured from 180-250 nm using a Jasco J-815 CD Spectrometer. Blank samples 
containing only buffer were used as calibrants. Instrument settings were as follows: 
sensitivity: standard; data pitch: 0.2 nm; bandwidth: 1.0 nm; data integration time: 1 s; 
scanning speed: 100 nm/min; accumulation: 4.  
 
5.3.5.7 Tryptic digestion of proteins 
 
The protein of interest (30 µg) was electrophoresed and the desired band excised from 
the gel. The protein was then digested using the Trypsin Profile IGD Kit, according to the 
manufacturer’s instruction. The peptide fragments were subsequently analysed by 
LC-MS according to the elution profile in table 5.7. 
  
5.3.5.8 Analysis of putative protein-protein interactions 
 
5.3.5.8.1 Native-PAGE analysis 
 
His6-CpkC-TR (1 mg/mL) and His6-CpkG (1 mg/mL) were incubated for 1 h at 4 °C in 
gel filtration buffer, in a total volume of 30 µL. The sample was diluted in native-PAGE 
loading buffer (7.5 µL) and electrophoresed (90 V, 4 °C, 2 h) alongside His6-CpkC-TR 
and His6-CpkG standards.  
 




5.3.5.8.2 Pull-down assays 
 
His6-CpkC-TR (2 mg/mL, 800 µL) was incubated with TEV protease (lab stock, 40 µL) 
for 3 h at 37 °C. The mixture was subsequently loaded onto a 1 mL HiTrapTM HP affinity 
column (GE Healthcare) and washing buffer (10 mL) and elution buffer (300 mM 
imidazole, 5 mL) were sequentially applied. Following confirmation of cleaved CpkC-TR 
in the wash fraction by SDS-PAGE analysis, the protein was concentrated (6000 rpm, 
4 ºC) to 1 mg/mL and incubated with CpkG (1 mg/mL) for 1 h at 4 °C. The mixture was 
passed through a second 1 mL HiTrapTM HP affinity column and washing buffer and 
elution buffer were applied as previously described. CpkC-TR and His6-CpkG were 
detected in the wash and elution fractions, respectively. 
 
5.3.6 Attempted detection of putative polyketide alkaloid metabolites 
 
5.3.6.1 Extraction of metabolites from agar 
 
ISP2, R3 and R5 agar were inoculated with Streptomyces cyaneofuscatus spore stock 
solutions (10 µL). The cultures were then incubated at 30 ºC for 7 days. The agar was 
then cut with a glass vial and to ~5 cm2 portions were added EtOAc (3 mL) and 0.1 M 
HCl (1 mL). The contents were shaken for ~2 min to allow phase separation and 500 µL 
of the organic layer was transferred to a vial and left to evaporate.  
 
5.3.6.2 Extraction of metabolites from liquid media 
 
TSB media (10 mL) was inoculated with Streptomyces cyaneofuscatus spore stock 
solutions (10 µL). The cultures were then incubated at 30 ºC with shaking for 2 days. 
ISP2, R5, SMM and AM1 production media (50 mL) were then inoculated with preculture 
(25 µL), and incubated at 30 ºC with shaking for 7 days. The cells were centrifuged 
(5000 rpm, 20 ºC, 15 min) and to the supernatant (500 µL) was added EtOAc (500 µL). 
The layers were then mixed and centrifuged (3000 rpm, 20 ºC, 3 min) to allow phase 








5.3.6.3 Sample preparation for LC-MS 
 
The metabolite residues were dissolved in MeOH (0.5 mL), then transferred to a PVDF 
micro spin filter (Grace Davison Discovery Sciences) and centrifuged (12000 rpm, 
2 min). The samples were analysed by high-resolution LC-MS according to the elution 
profile in table 5.8 and the absorbance was monitored at 210 nm.  
 
Table 5.8: Elution conditions used for LC-MS detection of putative polyketide alkaloid metabolites in vivo, 
and to assess enzymatic activity in vitro 
Time / min H2O / %     
 (0.1 % FA) 
Acetonitrile / %  
(0.1 % FA) 
Flow rate / mL/min 
0.0 95 5 0.2 
5.3 95 5 0.2 
18.3 0 100 0.2 
22.3 0 100 0.2 
25.3 95 5 0.2 
34.0 95 5 0.2 
 
5.3.7 Overproduction and purification of valinomycin fragments  
 
42 R3 agar plates were inoculated with S. cyaneofuscatus::SARP spore stock solutions 
(10 µL) and incubated at 30 ºC for 6 days. The agar was then cut with a scalpel and 
washed with 0.1 M HCl (300 mL). Metabolites were then extracted with EtOAc 
(3 × 300 mL), dried over MgSO4 and concentrated under vacuum. The crude extract was 
redissolved in MeOH (3 mL), pre-adsorbed to dental cotton then packed into a cartridge 
(manufactured by University of Warwick), and purified by preparative HPLC according 











Table 5.9: Elution conditions used for HPLC purification detection 64 and 65 
Time / min H2O / %     Acetonitrile / %  Flow rate / mL/min 
0.0 95 5 9.0 
5.0 95 5 9.0 
50.0 0 100 9.0 
55.0 0 100 9.0 
56.0 95 5 9.0 
60.0 95 5 9.0 
 
5.3.7.1 Characterisation data 
 




δH ((CD3)2CO, 500 MHz): 0.78 (d, 3H, H-12, J = 7.0 Hz), 0.86 (d, 3H, H-5/6, J = 7.0 Hz), 
0.88 (d, 3H, H-5/6, J = 7.0 Hz), 0.91 (d, 3H, H-13, J = 7.0 Hz), 1.95-2.03 (m, 1H, H-11), 
2.05-2.14 (m, 1H, H-4), 3.74 (t, 1H, H-9, J = 4.5 Hz), 4.21 (dd, 1H, H-3, J = 9.0 Hz, 
5.0 Hz), 5.56, (d, 1H, H-10, J = 5.5 Hz), 7.48 (d, 1H, H-7, J = 8.5 Hz), 12.65 (br. s, 1H, 
H-1); δC ((CD3)2CO, 125 MHz): 16.1 (C-12), 17.7 (C-5), 19.1 (C-6), 19.2 (C-13), 30.3 
(C-4), 31.3 (C-11), 56.3 (C-3), 75.1 (C-9), 172.9 (C-1), 173.1 (C-8); HRMS: Calculated 
for [M+Na]+ 240.1206, found 240.1202. 
 








δH ((CD3)2CO, 500 MHz): 0.82-0.93 (6 × dd, 12H, H-5, H-6, H-11, H-12, H-16, H-17), 
1.23 (d, 3H, H-22, J = 6.5 Hz), 2.02-2.18 (m, 3H, H-4, H-10, H-15), 4.04 (q, 1H, H-20, 
J = 6.5 Hz), 4.12 (dd, 1H, H-3, J = 8.0 Hz, 6.0 Hz), 4.29 (dd, 1H, H-14, J = 8.5 Hz, 
6.0 Hz), 4.81 (d, 1H, H-9, J = 5.0 Hz), 5.63 (br. s, 1H, H-21), 7.62 (d, 1H, H-18, J = 8.5 
Hz), 8.08 (d, 1H, H-7, J = 8.5 Hz); ((CD3)2CO, 125 MHz): 17.1, 17.8, 18.1, 18.7, 18.9, 
19.1, 19.2 (C-5, C-6, C-11, C-12, C-16, C-17), 21.2 (C-22), 29.8 (C-4), 30.1 (C-10), 30.4 
(C-15), 56.8 (C-14), 57.2 (C-3), 67.2 (C-20), 77.9 (C-9), 168.6 (C-8), 170.7 (C-13), 172.7 
(C-2), 174.6 (C-19); Calculated for [M+Na]+ 411.2102, found 411.2103. 
 
5.4 Biochemical assays 
 
 
5.4.1 In vitro investigations with CpkG 
 
5.4.1.1 UV-Vis spectroscopic analysis of PLP binding to CpkG 
 
UV-Vis absorbance spectra were obtained for His6-CpkG (60 µM) and PLP (60 µM) 
independently. Prior to analysis, His6-CpkG was exchanged from HEPES buffer (50 mM 
HEPES (pH 7.6), 100 mM NaCl, 20 µM PLP) into Tris buffer (20 mM Tris-HCl, (pH 8.0), 
100 mM NaCl) to remove unbound PLP. Absorbance measurements were recorded from 
300-600 nm and performed in triplicate. 
 
5.4.1.2 Spectrophotometric analysis of the substrate specificity of CpkG  
 
The enzymatic activity and substrate specificity of CpkG were characterised by 
employing a spectrophotometric assay that relies on the detection of a blue α-amino acid-
copper (II) complex. 20 µM His6-CpkG was combined in separate reactions with 10 mM 
amino donor (benzylamine 45, cyclohexylamine 46, isobutylamine 47, butylamine 48 or 
octylamine 49) and 10 mM amino acceptor (pyruvate 25 or α-ketoglutarate 50) in 100 mM 
potassium phosphate buffer (pH 7.0) in a total volume of 160 µL. Reactions were carried 
out in 96-well plates and incubated overnight at room temperature. Following overnight 
incubation, 40 µL of a CuSO4/MeOH solution (prepared as described by Hwang and 
Kim130) was added to each reaction and the resulting mixtures were filtered by 
centrifugation (12000 rpm, 2 min) using PVDF micro spin filters (Grace Davison 
Discovery Sciences). Supernatants were subsequently analysed by measuring the 




absorbance at 595 nm and reactions were performed in triplicate. Reaction mixtures 
incubated without enzyme served as negative controls. Blank samples consisted of 
100 mM potassium phosphate buffer (pH 7.0) with and without 20 µM His6-CpkG. The 
results were expressed as relative specificities calculated by first subtracting the mean 
absorbance value of the blank samples from each measured absorbance value, to obtain 
background-corrected values. Subsequently, the mean absorbance values of the test 
samples were divided by the mean absorbance value of the control samples. Relative 
specificities were then determined by comparison to the specificity of CpkG for 
octylamine and pyruvate as amino donor and acceptor. 
 
5.4.1.3 Determination of the absolute stereochemistry of alanine 
 
The absolute stereochemistry of alanine 51, formed by the CpkG-catalysed 
transamination of pyruvate 25 with octylamine 49, was determined by derivatisation with 
Marfey’s reagent. His6-CpkG (20 µM) was combined with octylamine (10 mM), pyruvate 
(10 mM) and phosphate buffer (100 mM, pH 7.0) in a final volume of 80 µL. After 
incubation for 2 h at room temperature, proteins were removed by centrifugation 
(12000 rpm, 15 min) using a Vivaspin 500 centrifugal filter with a 5 kDa MWCO 
(Sartonius Stedim Biotech). Acetone (65 µL), NaHCO3 (1 M, 7.5 µL) and 1 % Marfey’s 
reagent in acetone (17 µL) were then added to 40 µL of the filtrate and the resulting 
mixture was incubated at 37 °C for 1.5 h. Authentic standards of the Marfey’s derivatives 
of L- and D-alanine were prepared similarly by adding acetone (65 µL),  1 M NaHCO3 
(7.5 µL) and 1 % Marfey’s reagent in acetone (17 µL) to solutions  of L- and D-alanine 
(10 mM) in phosphate buffer (100 mM, pH 7.0) in a final volume of 40 µL. These mixtures 
were incubated as described above. Reactions were quenched with 1 M HCl (7.5 µL) and 
the remaining acetone was removed by evaporation. Deionised water (200 µL) and 
acetonitrile (200 µL) were then added to each sample. Precipitates were removed by 
centrifugation (12000 rpm, 1 min) using spin filters. The samples were subsequently 
analysed by LC-MS according to the elution profile in table 5.8 and the absorbance was 








5.4.1.4 Detection of aldehyde 
 
Production of octanal 57 in the CpkG-catalysed reaction with pyruvate 25 and octylamine 
49 was detected by derivatisation with D-cysteine and subsequent high-resolution LC-MS 
analysis. His6-CpkG (90 µM) was combined with octylamine (200 µM), pyruvate 
(200 µM) and phosphate buffer (25 mM, pH 7.0) in a final volume of 125 µL. After 
incubation for 15 min at 37 °C, D-cysteine (400 µM) was added and the resulting mixture 
incubated for 10 min at 50 °C. MeOH (125 µL) was then added to precipitate the enzyme. 
Precipitates were removed by centrifugation (12000 rpm, 1 min) using PVDF micro spin 
filters (Grace Davison Discovery Sciences) and the supernatants were analysed by 
LC-MS according to the elution profile in table 5.8. An authentic octanal standard 
(200 µM) was derivatised and analysed similarly. Independent assays were performed in 
duplicate.  
 
Production of 5-hydroxydodecanal 59 was detected similarly, from the CpkG-catalysed 
reaction with pyruvate and 1-aminododecan-5-ol 60.  
 
5.4.1.5 Detection of pyruvate and amine 
 
Production of pyruvate 25 in the CpkG-catalysed reaction with alanine 51 and octanal 57 
was analysed using a lactate dehydrogenase (LDH)-coupled assay, while production of 
octylamine 49 was analysed by LC-MS. Reactions contained His6-CpkG (90 µM), octanal 
(200 µM), L- or D-alanine (200 µM), lactate dehydrogenase (from Lactobacillus 
leichmanii, 1 µM), NADH (200 µM) and phosphate buffer (25 mM, pH 7.0) in a total 
volume of 250 µL. The absorbance at 340 nm was monitored for 15 min at 25 °C, at 
which time MeOH (450 µL) was added to precipitate the enzymes. Precipitates were 
removed by centrifugation (12000 rpm, 1 min) using PVDF micro spin filters (Grace 
Davison Discovery Sciences) and the supernatants were analysed by LC-MS according 
to the elution profile in table 5.8. An authentic octylamine standard (200 µM) was 
analysed similarly. Independent assays were performed in duplicate.  
 
Production of 1-aminododecan-5-ol 60 was detected similarly, from the CpkG-catalysed 
reaction with alanine and 5-hydroxydodecanal 59. 
 




5.4.2 In vitro investigations with CpkE and CpkI 
 
5.4.2.1 Incubation of trans-octen-2-al with CpkE 
 
To investigate the putative isomerase activity of CpkE, His6-CpkE (100 µM) was 
combined with trans-octen-2-al 78 (200 µM) and storage buffer in a total volume of 
60 µL. After incubation for 3 h at room temperature, MeOH (120 µL) was added and 
precipitants were removed by centrifugation (12000 rpm, 15 min). The supernatant was 
analysed by LC-MS according to the elution profile in table 5.8. A control reaction and 
an authentic standard of cis-octen-3-al 79 (200 µM) in storage buffer were analysed 
similarly.  
 
5.4.2.2 Incubation of dodecane-1,5-diol with CpkI 
 
To investigate the putative oxidoreductase activity of CpkI, His6-CpkI (90 µM) was 
combined with dodecane-1,5-diol 76 (200 µM), NAD+ or NADP+ (200 µM), phosphate 
buffer (pH 7.0) and water in a final volume of 100 µL. After incubation for 1 h at room 
temperature, D-cysteine (400 µM) was added and the mixture incubated for 10 min at 
50 °C. MeOH (200 µL) was then added and precipitants were removed by centrifugation 
(12000 rpm, 15 min). The supernatant was analysed by LC-MS according to the elution 
profile in table 5.8. A control reaction and an authentic standard of 5-hydroxydodecanal 
59 (200 µM) were derivatised and analysed similarly. 
 
5.4.3 In vitro investigations with CpkD, ScF and CpkH 
 
5.4.3.1 UV-Vis spectroscopic analysis of flavin binding 
 
His6-CpkD, His6-ScF and His6-CpkH (without added flavin) were diluted to 50 µM with 
concentration buffer. Absorbance spectra were recorded from 300-600 nm and values 
obtained for a blank (concentration buffer) were subtracted. Measurements were 
performed in triplicate and absorbance maxima were compared to literature values for 
FAD (450 nm) and FMN (446 nm).176,177 
 
 




5.4.3.2 UV-Vis spectroscopic analysis of NAD(P)H oxidation by flavoprotein 
 
His6-CpkD, His6-ScF and His6-CpkH (10 nmol) were separately incubated with either 
NADH or NADPH (25 nmol) and concentration buffer in a total volume of 140 µL. The 
absorbance at 340 nm was monitored for 25 min at 25 ºC and measurements were 
performed in duplicate. 
 
5.4.3.3 CpkH-catalysed oxidation of 1-aminododecan-5-ol 
 
To investigate putative flavin-dependent dehydrogenase activity, racemic 
1-aminododecan-5-ol 60 (200 µM) was incubated with either His6-CpkD, His6-ScF or 
His6-CpkH (20 µM) in a total volume of 62.5 µL. After incubation for 3 h at 30 ºC, MeOH 
(125 µL) was added to precipitate the proteins and the mixtures were centrifuged 
(12000 rpm, 1 min) using PVDF micro spin filters (Grace Davison Discovery Sciences). 
The supernatants were analysed alongside a synthetic authentic standard, 6-heptyl-
2,3,4,5-tetrahydropyridine 81 (200 µM), by LC-MS according to the elution profile in 
table 5.8. Independent assays were performed in duplicate. To investigate the 
enantioselectivity of CpkH, (R)- and (S)-60 were incubated separately with His6-CpkH as 
described above. Independent assays were performed in duplicate. 
 
5.4.3.4 Incubation of (R,E)- or (S,E)-1-aminododec-2-en-5-ol with coelimycin 
biosynthetic enzymes 
 
To investigate the configurational selectivity of CpkH, (R,E)- or (S,E)-1-aminododec-2-
en-5-ol 84 (200 μM) were incubated with His6-CpkH (20 µM) in a total volume of 
62.5 µL. To investigate the potential epimerase or oxidoreductase activities of CpkE, 
CpkD, ScF and CpkI, the His6-fusion proteins (20 µM) were separately added to the above 
assays. After incubation for 3 h at 30 °C, MeOH (125 µL) was added to precipitate the 
proteins and the mixtures were centrifuged (12000 rpm, 15 min). The supernatants were 
analysed by LC-MS according to the elution profile in table 5.8. Independent assays were 








5.4.3.5 CpkD-catalysed epoxidation of ethyl (2E,4E,6E)-octa-2,4,6-trienoate 
 
To investigate putative flavin-dependent monooxygenase activity, ethyl(2E,4E,6E)-octa-
2,4,6-trienoate 99 (200 µM) was incubated with FAD or FMN (40 µM), NADH (40 µM), 
NAC (400 µM) and either His6-CpkD or His6-ScF (20 µM) in a total volume of 62.5 µL. 
After incubation for 3 h at room temperature, MeOH (125 µL) was added to precipitate 
proteins and the mixtures were centrifuged (12000 rpm, 15 min). The supernatants were 
then analysed by LC-MS according to the elution profile in table 5.8. MS/MS was 
performed to obtain fragmentation data for the ions at 324 and 340 m/z present within the 
His6-CpkD sample (Dr. Lijiang Song, University of Warwick). Independent assays were 
performed in triplicate. 
 
Performed in collaboration with Dr. Lijiang Song, University of Warwick 
For analysis of 18O2 incorporation, 
18O2 (2.64 atm, 97 %) was bubbled separately through 
a solution of substrate, NADH and NAC for 5 min, and a solution of His6-CpkD and FMN 
for 5 min. The two solutions were then combined and 18O2 was bubbled through for a 
further 5 min. The tube was then sealed and the mixture incubated and analysed as 
described above. Independent assays were performed in duplicate. 
 
5.5 Crystallisation of CpkG 
 
Performed in collaboration with Dr. Lona Alkhalaf, University of Warwick 
CpkG was overproduced in E. coli as an N-terminal hexahistidine fusion protein and 
purified to homogeneity by nickel affinity chromatography (see section 5.3.1). It was then 
concentrated to 10 mg / mL for sitting drop crystallisation trials, which were conducted 
with 100 nL aliquots, a Honeybee 963 robot and three 96-well commercially-available 
screens (JCSG-plus, Structure and PACT premier).  
 
For co-crystallisation with substrates, conditions were optimised (0.2 M sodium malonate 
dibasic monohydrate, 0.15 M bis-tris propane, 20 % w/v PEG, pH 6.5) and the hanging-
drop method was used. To obtain CpkG_ala crystals, the enzyme was mixed with 
L-alanine 51 at a final concentration of 2 mM. To obtain CpkG_ala_lactol crystals, 
saturating conditions of 5-hydroxydodecanal 59 were used. 
 




5.6 Chemical procedures 
 
5.6.1 Synthesis of putative CpkI substrate and CpkE standard 
 




To δ-dodecalactone 61 (100 µL, 475 µmol, 1.0 eq.) in dry THF (2.5 mL) at 0 °C under 
argon was slowly added LiAlH4 (1 M, 713 µL, 713 µmol, 1.5 eq.). The reaction was stirred 
for 40 min at room temperature, then cooled to 0 °C and quenched with 2 M HCl. The 
product was extracted with EtOAc (3 × 15 mL), then washed with H2O (20 mL), sat. aq. 
NaHCO3 (20 mL) and brine (20 mL). The organics were dried over anhydrous MgSO4 
and concentrated under reduced pressure to afford 76 as a white solid (64.1 mg, 67 %). 
 
m.p.: 42-45 °C; δH (CDCl3, 400 MHz): 0.86 (t, 3H, H-14, J = 6.5 Hz), 1.19-1.34 (m, 10H, 
H-9–13), 1.35-1.66 (m, 8H, H-3–5, H-8), 2.37 (br. s, 2H, H-1, H-6), 3.54-3.58 (m, 1H, 
H-7), 3.62 (t, 2H, H-2, J = 6.0 Hz); δC (CDCl3, 100 MHz): 14.2 (C-14), 21.9 (C-4), 22.8 
(C-13), 25.8 (C-9), 29.4 (C-11), 29.8 (C-10), 32.0 (C-12), 32.6 (C-3), 37.0 (C-5), 37.7 
(C-8), 62.6 (C-2), 71.9 (C-7); HRMS: Calculated for [M+Na]+ 225.1825, found 225.1827. 
Data are consistent with those reported by Wiesner, Soai and their respective 
coworkers.214,215 
 




To cis-octen-3-ol 80 (119 µL, 792 µmol, 1.0 eq.) in dry DCM (7 mL) at 0 °C under argon 
was added DMP (440 mg, 1.04 mmol, 1.3 eq.) and the reaction stirred for 1 h. The reaction 
mixture was then diluted with pentane (20 mL) and washed with H2O (6 × 10 mL). The 




organics were dried over anhydrous MgSO4 and concentrated under reduced pressure to 
afford 79 as a colourless oil (96.3 mg, 96 %), which was used immediately and without 
purification due to rapid isomerisation.  
 
δH (CDCl3, 400 MHz): 0.85 (t, 3H, H-8, J = 7.0 Hz), 1.23-1.35 (m, 4H, H-6, H-7), 
1.96-2.09 (m, 2H, H-5), 3.14 (d, 2H, H-2, J = 7.0 Hz), 5.45-5.52 (m, 1H, H-3), 5.62-5.69 
(m, 1H, H-4), 9.61 (br. t, 1H, H-1); HRMS: Derivatised with tris for detection; calculated 
for [[M+tris]+H]+ 230.1751, found 230.1741. 
 
5.6.2 Synthesis of racemic CpkG and CpkH substrates and standards 
 




To δ-dodecalactone 61 (210 µL, 1.00 mmol, 1.0 eq.) in dry DCM (2.5 mL) at -78 °C 
under argon was slowly added DIBAL-H (1 M, 1.00 mL, 1.00 mmol, 1.0 eq.). The reaction 
was stirred at room temperature for 1 h, at which time DCM (10 mL) and potassium 
sodium tartrate (10 mL) were added. The resulting suspension was stirred for 1 h, the 
organic phase separated and the aqueous phase extracted with DCM (2 × 20 mL). The 
combined organics were washed with brine (20 mL), dried over anhydrous MgSO4 and 
concentrated under reduced pressure. The crude material was purified on silica gel (1 : 3 
EtOAc : pet. ether) to afford 59 (132 mg, 66 %) as a colourless oil. 
 
Note: compound exists as mixture of hemiacetal diastereomers (99 %, A:B ≈ 0.62:0.38) 
and open-chain aldehyde (1 %); δH (CDCl3, 400 MHz): 0.87 (t, 3H, H-13, J = 6.5 Hz), 
1.12-1.71 (m, 14.38H, H-3/4b, H-5, H-7–12), 1.81-1.87 (m, 1.62H, H-3a, H-3/4b, H-4a), 
2.81-2.92 (m, 0.38H, H-1b), 3.36-3.55 (m, 1.24H, H-1a, H-6a), 3.91 (m, 0.38H, H-6b), 
4.68 (t, 0.62H, H-2a, J = 7.0 Hz), 5.29 (s, 0.38H, H-2b), 9.77 (s, 0.01H, H-1’ (open chain 
aldehyde)); δC (CDCl3, 100 MHz): 14.2 (C-13), 17.6 (C-4b), 22.3 (C-4a), 22.8 (C-12), 
25.5 (C-8a), 25.6 (C-8b), 29.4 (C-10a), 29.4, (C-10b), 29.8 (C-9a), 29.8 (C-9b), 30.0 




(C-5b), 30.5 (C-5a), 31.3 (C-3b), 32.0 (C-11), 33.0 (C-3a), 36.2 (C-7b), 36.3 (C-7a), 68.9 
(C-6b), 76.7 (C-6a), 92.0 (C-2b), 96.6 (C-2a); HRMS: Calculated for [M+Na]+ 223.1669, 
found 223.1667. Data are consistent with those reported by Li and coworkers.216 
 




To 5-hydroxydodecanal 59 (39.5 mg, 197 µmol, 1.0 eq.) in MeOH (1.5 mL) was added 
benzylamine (28.1 µL, 257 µmol, 1.3 eq.) and the solution stirred for 4 h at room 
temperature. 10 % Pd/C (84.0 mg) was added and the flask purged with H2 × 5 (1 atm) 
before being left to stir for a further 12 h. The reaction mixture was filtered through celite 
and concentrated under reduced pressure to afford 60 as a white solid in quantitative yield. 
5 mg was purified by analytical HPLC (table 5.10, elution time = 8.8 min) for use in 
enzymatic assays. 
 
m.p.: 82-85 °C; δH (CDCl3, 500 MHz): 0.88 (t, 3H, H-14, J = 7.0 Hz), 1.20-1.33 (m, 10H, 
H-9–13), 1.35-1.80 (m, 10H, H-1, H-3–5, H-8), 2.84-2.99 (m, 2H, H-2), 3.49-3.60 (m, 
1H, H-6); δC (CDCl3, 125 MHz): 14.3 (C-14), 22.4 (C-4), 22.8 (C-13), 26.1 (C-9), 27.6 
(C-3), 29.5 (C-11), 29.9 (C-10), 32.0 (C-12), 36.4 (C-5), 38.0 (C-8), 39.3 (C-2), 71.1 
(C-6); HRMS: Calculated for [M+H]+ 202.2165, found 202.2169. 
 
Table 5.10: Elution conditions used for HPLC purification of 1-aminododecan-5-ol 60 
Time / min H2O / %     
 (0.1 % FA) 
MeOH / %  
(0.1 % FA) 
Flow rate / mL/min 
0.0 40 60 5.0 
5.0 40 60 5.0 
25.0 0 100 5.0 
28.0 0 100 5.0 
30.0 40 60 5.0 
 








To 1-aminododecan-5-ol 60 (45.0 mg, 223 µmol, 1.0 eq.) in anhydrous DCM (1 mL) 
under argon was added di-tert-butyl dicarbonate (72.8 mg, 334 µmol, 1.5 eq.) and the 
solution stirred for 2 h at room temperature. H2O (10 mL) was added and the product 
extracted with DCM (3 × 10 mL). The combined organic layers were washed sequentially 
with sat. aq. NaHCO3 (15 mL) and brine (15 mL), dried over anhydrous MgSO4 and 
concentrated under reduced pressure to afford 82 as a pale yellow oil, which was used 
without purification in the next step.   
 
δH (CDCl3, 400 MHz): 0.81 (t, 3H, H-17, J = 6.5 Hz), 1.15-1.30 (m, 10H, H-12–16), 
1.31-1.41 (m, 8H, H-6–8, H-11), 1.45 (s, 9H, H-1), 3.06 (m, 2H, H-5), 3.50 (m, 1H, H-9), 
4.56 (br. s, 1H, H-4); δC (CDCl3, 100 MHz): 14.1 (C-17), 22.7 (C-16), 22.8 (C-7), 25.7 
(C-12), 27.5 (C-1), 29.4 (C-14), 29.7 (C-13), 30.2 (C-6), 31.9 (C-15), 37.0 (C-8), 37.6 
(C-11), 40.4 (C-5), 71.7 (C-9), 85.2 (C-2), 146.8 (C-3); HRMS: Calculated for [M+Na]+ 
324.2509, found 324.2510. 
 




To tert-butyl (5-hydroxydodecyl)carbamate 82 (63.7 mg, 211 µmol, 1.0 eq.) in anhydrous 
DCM (1 mL) under argon was added Dess-Martin periodinane (DMP) (108 mg, 
254 µmol, 1.2 eq.) and the mixture stirred for 2.5 h at room temperature. 20 % 
Na2S2O3.5H2O (3 mL) and sat. aq. NaHCO3 (3 mL) were added sequentially and the 
mixture stirred for a further 10 min. The product was extracted with EtOAc (3 × 10 mL) 
and the combined organics washed with brine (15 mL) and dried over anhydrous MgSO4. 




The solvent was removed under reduced pressure to afford 83 as a colourless oil, which 
was used without purification in the next step.  
 
δH (CDCl3, 400 MHz): 0.80 (t, 3H, H-16, J = 6.5 Hz), 1.13-1.28 (m, 6H, H-13–15), 
1.34-1.41 (m, 4H, H-6, H-12), 1.42-1.56 (m, 13H, H-1, H-7, H-11), 2.31 (t, 2H, H-10, 
J = 7.5 Hz), 2.35 (t, 2H, H-8, J = 7.0 Hz), 3.04 (q, 2H, H-5, J = 6.5 Hz), 4.54 (br. s, 1H, 
H-4); δC (CDCl3, 100 MHz): 14.1 (C-16), 20.8 (C-7), 22.7 (C-15), 24.0 (C-11), 27.5 
(C-1), 29.2 (C-13), 29.3 (C-12), 29.6 (C-6), 31.8 (C-14), 40.2 (C-5), 42.2 (C-8), 43.0 
(C-10), 85.2 (C-2), 146.8 (C-3), 210.9 (C-9); HRMS: Calculated for [M+Na]+ 322.2353, 
found 322.2355. 
 




To tert-butyl (5-oxododecyl)carbamate 83 (67.0 mg, 222 µmol, 1.0 eq.) in DCM (1 mL) 
at -10 °C was added TFA (0.30 mL) over 5 min. The solution was allowed to warm to 
room temperature and stirred for 5 h. The solution was basified with 2 M NaOH (pH > 12), 
diluted with H2O (5 mL) and extracted with DCM (3 × 10 mL). The combined organics 
were washed with sat. aq. NaHCO3 (15 mL), H2O (15 mL) and brine (15 mL), dried over 
anhydrous MgSO4 and concentrated under reduced pressure. The crude oil was purified 
by silica gel chromatography (1 : 19 MeOH : DCM) to afford 81 as an orange semi-solid 
(9.50 mg, 27 % over 4 steps).  
 
δH (CDCl3, 500 MHz): 0.87 (t, 3H, H-12, J = 7.0 Hz), 1.25-1.42 (m, 8H, H-8–11), 1.65 
(quint, 2H, H-7, J = 7.0 Hz), 1.81-1.84 (m, 4H, H-2, H-3), 2.52-2.58 (br. s, 2H, H-4), 2.71 
(t, 2H, H-6, J = 7.0 Hz), 3.67-3.73 (br. s, 2H, H-1); δC (CDCl3, 125 MHz): 14.2 (C-12), 
17.8 (C-2), 20.2 (C-3), 22.7 (C-11), 26.9 (C-7), 29.3 (C-9), 29.4 (C-4), 29.9 (C-8), 31.7 
(C-10), 38.4 (C-6), 45.4 (C-1), 167.9 (C-5); HRMS: Calculated for [M+H]+ 182.1903, 
found 182.1904. Data are consistent with those reported by Fukuda and coworkers.217 
 




5.6.3 Synthesis of enantiopure CpkH substrates 
 




To octanoic acid 86 (1.10 mL, 6.93 mmol, 1.0 eq.) in anhydrous THF (14 mL) under 
argon was added CDI (1.35 g, 8.32 mmol, 1.2 eq.) and the reaction stirred at room 
temperature for 2 h. Monomethyl malonate potassium salt (1.62 g, 10.4 mmol, 1.5 eq.) 
and anhydrous MgCl2 (792 mg, 8.32 mmol, 1.2 eq.) were subsequently added and the 
mixture stirred at room temperature overnight. The mixture was then quenched with 0.1 M 
HCl and the product extracted with EtOAc (3 × 75 mL). The combined organic layers 
were washed sequentially with 5 % NaHCO3 (100 mL), H2O (100 mL) and brine 
(100 mL) and dried over anhydrous MgSO4. The solvent was removed under reduced 
pressure to afford 87 as a yellow oil (1.41 g, 100 %). 
 
δH (CDCl3, 300 MHz): 0.81 (t, 3H, H-11, J = 6.5 Hz), 1.12-1.35 (m, 8H, H-7–10), 1.54 
(quint, 2H, H-6, J = 7.0 Hz), 2.49 (t, 2H, H-5, J = 7.5 Hz), 3.40 (s, 2H, H-3), 3.68 (s, 3H, 
H-1); δC (CDCl3, 75 MHz): 14.0 (C-11), 22.5 (C-10), 23.4 (C-6), 28.9 (C-8), 28.9 (C-7), 
31.6 (C-9), 43.0 (C-5), 48.9 (C-3), 52.2 (C-1), 167.6 (C-2), 202.8 (C-4); HRMS: 
Calculated for [M+Na]+ 223.1308, found 225.1305. Data are consistent with those 
reported by Sieben and coworkers.218 
 




To [Ru(OAc)2((R)-BINAP)] (200 mg, 238 µmol, 1.0 eq.) in dry MeOH (10 mL) was 
added 1 M HCl in MeOH (238 µL, 238 µmol, 1.0 eq.). The suspension was stirred at 
ambient temperature for 30 min, at which time methyl-3-oxodecanoate 87 (4.98 g, 
24.9 mmol, 105 eq.) was added. The flask was purged with H2 (49 atm) three times over 




5 min and stirred under H2 at 50 °C overnight. The reaction mixture was cooled, 
concentrated under reduced pressure and the resulting residue purified by silica gel 
chromatography (4 : 1 EtOAc : hexane) to afford (R)-88 as a colourless oil (4.03 g, 80 %).  
 
δH (CDCl3, 300 MHz): 0.85 (t, 3H, H-12, J = 6.5 Hz), 1.16-1.57 (m, 12H, H-6–11), 2.39 
(dd, 1H, H-3a, J = 16.5 Hz, 9.0 Hz), 2.50 (dd, 1H, H-3b, J = 16.5 Hz, 3.5 Hz), 2.71 (br. s, 
1H, H-5), 3.69 (s, 3H, H-1), 3.98 (m, 1H, H-4); δC (CDCl3, 75 MHz): 14.2 (C-12), 22.7 
(C-11), 25.6 (C-7), 29.3 (C-9), 29.5 (C-8), 31.9 (C-10), 36.6 (C-6), 41.2 (C-3), 51.8 (C-1), 
68.1 (C-4), 173.6 (C-2); HRMS: Calculated for [M+Na]+ 225.1460, found 225.1461. Data 
are consistent with those reported by Wu and coworkers.219 
 




Compound (S)-88 was synthesised following the procedure described for (R)-88, using 
[Ru[(OAc)2((S)-BINAP)] as the catalyst. Yield: 4.69 g, 93 %. NMR and LRMS data are 
consistent with those for (R)-88. 
 




To a solution of methyl-(R)-3-hydroxydecanoate 88 (3.86 g, 19.1 mmol, 1.0 eq.) in 
anhydrous DMF (30 mL) under argon were added imidazole (2.60 g, 38.2 mmol, 2.0 eq.) 
and tert-butyl-dimethylsilyl chloride (4.31 g, 28.6 mmol, 1.5 eq.) sequentially at 0 °C. 
The mixture was stirred at room temperature for 20 h then quenched with H2O (30 mL) 
and stirred for a further 30 min. The product was extracted with Et2O (3 × 30 mL) and 
the combined organic layers were washed with brine, dried over anhydrous MgSO4 and 




concentrated under reduced pressure. The residue was purified by silica gel 
chromatography (1 : 99 Et2O : pet. ether) to afford (R)-89 as a colourless oil (5.58 g, 
92 %).  
 
δH (CDCl3, 300 MHz): 0.02 (s, 3H, H-5/6), 0.05 (s, 3H, H-5/6), 0.84-0.91 (m, 12H, H-8, 
H-15), 1.19-1.35 (m, 10H, H-10–14), 1.42-1.53 (m, 2H, H-9), 2.41 (s, 1H, H-3a), 2.44 (d, 
1H, H-3b, J = 1.5 Hz), 3.65 (s, 3H, H-1), 4.11 (quint, 1H, H-4, J = 6.0 Hz); δC (CDCl3, 
75 MHz): -4.7 (C-5/6), -4.4 (C-5/6), 14.2 (C-15), 18.1 (C-7), 22.8 (C-14), 25.1 (C-10), 
25.9 (C-8), 29.4 (C-12), 29.8 (C-11), 31.9 (C-13), 37.8 (C-9), 42.7 (C-3), 51.6 (C-1), 69.7 
(C-4), 172.5 (C-2); HRMS: Calculated for [M+Na]+ 339.2326, found 339.2325. Data are 
consistent with those reported by Kocieński and coworkers.220 
 




Compound (S)-89 was synthesised from (S)-88, following the procedure described for 
(R)-89. Yield: 6.02 g, 88 %. NMR and LRMS data are consistent with those for (R)-89. 
 




To a solution of methyl (R)-3-((tert-butyldimethylsilyl)oxy)decanoate 89 (5.41 g, 
17.1 mmol, 1.0 eq.) in anhydrous DCM (100 mL) at -78 °C under argon was added 
DIBAL-H (18.8 mL, 1 M in hexanes, 18.8 mmol, 1.1 eq.), dropwise. After 1 h, DCM 
(100 mL) and sat. aq. sodium potassium tartrate (200 mL) were added. The resulting 
suspension was stirred for 1 h at room temperature, the organics separated and the 




aqueous layer extracted with DCM (2 × 100 mL). The combined organics were washed 
with brine (200 mL), dried over anhydrous MgSO4 and concentrated under reduced 
pressure. The crude material was purified by silica gel chromatography (1 : 19 Et2O : pet. 
ether) to afford (R)-90 as a colourless oil (4.48 g, 92 %). 
 
δH (CDCl3, 300 MHz): 0.06 (s, 3H, H-4/5), 0.08 (s, 3H, H-4/5), 0.84-0.91 (m, 12H, H-7, 
H-14), 1.21-1.37 (m, 10H, H-9–13), 1.42-1.53 (m, 2H, H-8), 2.51 (dd, 2H, H-2, 
J = 5.5 Hz, 2.5 Hz), 4.18 (quint, 1H, H-3, J = 5.5 Hz), 9.82 (t, 1H, H-1, J = 2.5 Hz); 
δC (CDCl3, 75 MHz): -4.5 (C-4/5), -4.3 (C-4/5), 14.2 (C-14), 18.2 (C-6), 22.8 (C-13), 25.3 
(C-9), 26.0 (C-7), 29.4 (C-11), 29.8 (C-10), 31.9 (C-12), 38.1 (C-8), 51.0 (C-2), 68.5 
(C-3), 202.3 (C-1); HRMS: Calculated for [M+Na]+ 309.2220, found 309.2224. Data are 
consistent with those reported by Kocieński and coworkers.220 
 




Compound (S)-90 was synthesised from (S)-89, following the procedure described for 
(R)-90. Yield: 4.76 g, 90 %. NMR and LRMS data are consistent with those for (R)-90. 
 




To a solution of (R)-3-((tert-butyldimethylsilyl)oxy)decanal 90 (4.42 g, 15.4 mmol, 
1.0 eq.) in anhydrous THF (85 mL) under argon was added ethyl(triphenyl 
phosphoranylidene)acetate (8.06 g, 23.1 mmol, 1.5 eq.) and the reaction stirred at room 
temperature overnight. After completion, the solvent was removed under reduced 




pressure and the crude material purified by silica gel chromatography (2 : 23 EtOAc : 
pet. ether) to afford (R)-91 as a colourless oil (5.09, 93 %).   
 
δH (CDCl3, 300 MHz): 0.04 (s, 6H, H-8–9), 0.84-0.92 (m, 12H, H-11, H-18), 1.21-1.36 
(m, 13H, H-1, H-13–17), 1.37-1.49 (m, 2H, H-12), 2.25-2.40 (m, 2H, H-6), 3.76 (quint, 
1H, H-7, J = 5.5 Hz), 4.19 (q, 2H, H-2, J = 7.0 Hz), 5.83 (d, 1H, H-4, J = 15.5 Hz), 6.96 
(dt, 1H, H-5, J = 15.5 Hz, 7.5 Hz); δC (CDCl3, 75 MHz): -4.4 (C-8, C-9), 14.2 (C-18), 
14.4 (C-1), 18.2 (C-10), 22.8 (C-17), 25.4 (C-13), 26.0 (C-11), 29.4 (C-15), 29.8 (C-14), 
32.0 (C-16), 37.4 (C-12), 40.3 (C-6), 60.3 (C-2), 71.5 (C-7), 123.3 (C-4), 146.3 (C-5), 
166.7 (C-3); HRMS: Calculated for [M+Na]+ 379.2641, found 379.2639. Data are 
consistent with those reported by Nemoto and coworkers.221 
 




Compound (S)-91 was synthesised from (S)-90, following the procedure described for 
(R)-91. Yield: 5.20 g, 91 %. NMR and LRMS data are consistent with those for (R)-91. 
 




To a solution of ethyl (R,E)-5-((tert-butyldimethylsilyl)oxy)dodec-2-enoate 91 (5.01 g, 
14.1 mmol, 1.0 eq.) in anhydrous DCM (98 mL) at -78 °C under argon was added 
DIBAL-H (35.1 mL, 1 M in hexane, 35.1 mmol, 2.5 eq.), dropwise. The reaction mixture 
was stirred for 3 h at -78 °C then quenched by the slow addition of MeOH. The mixture 
was diluted with DCM (100 mL) and stirred with sat. aq. sodium potassium tartrate 
(200 mL) for 2 h at room temperature. The organics were separated and the aqueous layer 
extracted with DCM (2 × 100 mL). The combined organics were washed with brine 




(200 mL), dried over anhydrous MgSO4 and concentrated under reduced pressure to 
afford (R)-92 as a colourless oil (4.38 g, 99 %). 
 
δH (CDCl3, 300 MHz): 0.03 (s, 6H, H-7–8), 0.83-0.93 (m, 12H, H-10, H-17), 1.18-1.34 
(m, 10H, H-12–16), 1.35-1.47 (m, 2H, H-11), 2.25-2.40 (m, 2H, H-5), 3.76 (quint, 1H, 
H-6, J = 5.5 Hz), 4.19 (d, 2H, H-2, J = 4.0 Hz), 5.83 (m, 2 × 1H, H-3–4); δC (CDCl3, 
75 MHz): -4.3 (C-7/8), -4.4 (C-7/8), 14.2 (C-17), 18.3 (C-9), 22.8 (C-16), 25.5 (C-12), 
26.0 (C-10), 29.4 (C-14), 29.9 (C-13), 32.0 (C-15), 37.0 (C-12), 40.3 (C-5), 63.9 (C-2), 
72.2 (C-6), 129.8 (C-3), 131.3 (C-4); HRMS: Calculated for [M+Na]+ 337.2533, found 
337.2529. Data are consistent with those reported by Kirsch and coworkers.222 
 




Compound (S)-92 was synthesised from (S)-91, following the procedure described for 
(R)-92. Yield: 4.35 g, 96 %. NMR and LRMS data are consistent with those for (R)-92. 
 




To a solution of (R,E)-tert-butyl(1-chlorododec-2-en-5-yl)oxy)dimethylsilane 92 
(100 mg, 318 µmol, 1.0 eq.) in anhydrous THF (2 mL) under argon were added 
triphenylphosphine (120 mg, 445 µmol, 1.4 eq.) and N-chlorosuccinamide (63.7 mg, 
477 µmol, 1.5 eq.), sequentially. The reaction was stirred at room temperature for 3.5 h, 
then diluted with ice-cold hexane (20 mL) and filtered. The filtrate was concentrated 
under reduced pressure and the crude material purified by silica gel chromatography 
(1 : 99 EtOAc : pet. ether) to afford (R)-93 as a colourless oil (96.2 mg, 91 %). 
 




δH (CDCl3, 300 MHz): 0.04 (s, 6H, H-6–7), 0.81-0.93 (m, 12H, H-9, H-16), 1.18-1.34 
(m, 10H, H-11–15), 1.35-1.47 (m, 2H, H-10), 2.13-2.28 (m, 2H, H-4), 3.68 (quint, 1H, 
H-5, J = 5.5 Hz), 4.19 (d, 2H, H-1, J = 7.0 Hz), 5.63 (dt, 1H, H-2, J = 14.5 Hz, 7.0 Hz), 
5.79 (dt, 1H, H-3, J = 14.5 Hz, 7.0 Hz); δC (CDCl3, 75 MHz): -4.4 (C-6/7), -4.3 (C-6/7), 
14.3 (C-16), 18.3 (C-8), 22.8 (C-15), 25.5 (C-14), 26.0 (C-9), 29.4 (C-13), 29.9 (C-12), 
32.0 (C-14), 37.1 (C-11), 40.1 (C-4), 45.5 (C-1), 72.0 (C-5), 128.1 (C-2), 132.8 (C-3); 
HRMS: Calculated for [M+Na]+ 355.2194, found 355.2192. 
 




To a solution of (S,E)-tert-butyl(1-chlorododec-2-en-5-yl)oxy)dimethylsilane 92 (4.34 g, 
13.8 mmol, 1.0 eq.) in anhydrous DCM (100 mL) at 0 °C under argon were slowly added 
triethylamine (2.88 mL, 20.7 mmol, 1.5 eq.) and a solution of ρ-toluenesulfonyl chloride 
(2.89 g, 15.2 mmol, 1.1 eq.) in DCM (10 mL). The reaction mixture was stirred at 0 °C 
for 3 h, then allowed to warm to room temperature and stirred overnight. The mixture 
was washed sequentially with 1 M HCl (100 mL), H2O (100 mL) and 5 % aq. Na2SO4 
(100 mL), and the organics dried over anhydrous MgSO4 and concentrated under reduced 
pressure. The crude material was purified by silica gel chromatography (1 : 99 EtOAc : 
pet. ether) to afford (S)-93 as a colourless oil (1.11 g, 24 %). 
 
δH (CDCl3, 300 MHz): 0.04 (s, 6H, H-6–7), 0.81-0.93 (m, 12H, H-9, H-16), 1.18-1.34 
(m, 10H, H-11–15), 1.35-1.47 (m, 2H, H-10), 2.13-2.28 (m, 2H, H-4a, H-4b), 3.68 (quint, 
1H, H-5, J = 5.5 Hz), 4.19 (d, 2H, H-1, J = 7.0 Hz), 5.63 (dt, 1H, H-2, J = 14.5 Hz, 7.0 
Hz), 5.79 (dt, 1H, H-3, J = 14.5 Hz, 7.0 Hz); δC (CDCl3, 75 MHz): -4.4 (C-6/7), -4.3 
(C-6/7), 14.3 (C-16), 18.3 (C-8), 22.8 (C-15), 25.5 (C-14), 26.0 (C-9), 29.4 (C-13), 29.9 
(C-12), 32.0 (C-14), 37.1 (C-11), 40.1 (C-4), 45.5 (C-1), 72.0 (C-5), 128.1 (C-2), 132.8 













To a solution of (R,E)-tert-butyl((1-chlorododec-2-en-5-yl)oxy)dimethylsilane 93 
(1.00 g, 3.01 mmol, 1.0 eq.) in anhydrous DMF (10 mL) under argon was added 
potassium phthalimide (837 mg, 4.52 mmol, 1.5 eq.), and the reaction stirred at room 
temperature for 72 h. The mixture was diluted with Et2O (50 mL) and brine (50 mL) and 
the organics separated. The aqueous layer was then extracted with Et2O (2 × 50 mL) and 
the combined organics washed with brine (2 × 50 mL), dried over anhydrous MgSO4 and 
concentrated under reduced pressure. The crude material was purified by silica gel 
chromatography (7 : 93 EtOAc : pet. ether) to afford (R)-94 as a colourless oil (1.29 g, 
97 %). 
 
δH (CDCl3, 300 MHz): -0.01 (s, 6H, H-10–11), 0.82-0.92 (m, 12H, H-13, H-20), 1.17-1.42 
(m, 10H, H-15–19), 1.35-1.47 (m, 2H, H-14), 2.16 (t, 2H, H-8, J = 6.0 Hz), 3.68 (quint, 
1H, H-9, J = 5.5 Hz), 4.19 (d, 2H, H-5, J = 6.0 Hz), 5.54 (dt, 1H, H-6, J = 15.5 Hz, 6.0 
Hz), 5.74 (dt, 1H, H-7, J = 15.5 Hz, 7.0 Hz), 7.71 (dd, 2H, H-1, J = 5.5 Hz, 3.0 Hz), 7.84 
(dd, 2H, H-2, J = 5.5 Hz, 3.0 Hz); δC (CDCl3, 75 MHz): -4.4 (C-10/11), -4.3 (C-10/11), 
14.2 (C-20), 18.2 (C-12), 22.8 (C-19), 25.4 (C-15), 26.0 (C-13), 29.4 (C-17), 29.8 (C-16), 
32.0 (C-18), 37.0 (C-14), 39.7 (C-5), 40.3 (C-8), 72.0 (C-9), 123.4 (C-2), 125.4 (C-6), 
131.8 (C-7), 132.4 (C-3), 134.0 (C-1), 168.1 (C-4); HRMS: Calculated for [M+Na]+ 











Compound (S)-94 was synthesised from (S)-93, following the procedure described for 
(R)-94. Yield: 1.12 g, 87 %. NMR and LRMS data are consistent with those for (R)-94. 
 




To a solution of (R,E)-2-(5-((tert-butyldimethylsilyl)oxy)dodec-2-en-1-yl)isoindoline-
1,3-dione 94 (50.0 mg, 113 µmol, 1.0 eq.) in a 1 : 1 mixture of MeOH : DCM (1.6 mL) 
was added (1S)-(+)-10-camphorsulfonic acid (27.5 mg, 118 µmol, 1.1 eq.) and the 
reaction stirred at room temperature for 1.5 h. The mixture was diluted with Et2O 
(20 mL), quenched with H2O (10 mL) and the organics separated. The aqueous layer was 
then extracted with Et2O (2 × 10 mL) and the combined organics washed with H2O 
(10 mL), brine (10 mL), dried over anhydrous MgSO4 and concentrated under reduced 
pressure. The crude material was purified by silica gel chromatography (1 : 3 EtOAc : 
pet. ether) to afford (R)-95 as a white solid (37.0 mg, 99 %). 
 
m.p.: 52-54 °C; δH (CDCl3, 300 MHz): 0.86 (t, 3H, H-17, J = 7.0 Hz), 1.16-1.34 (m, 10H, 
H-12–16), 1.35-1.47 (m, 2H, H-11), 1.79 (br. s, 1H, H-10), 2.09 (dt, 1H, H-8a, J = 14.0, 
7.5 Hz), 2.24 (dtd, 1H, H-8b, J = 14.0 Hz, 6.0 Hz, 1.0 Hz), 3.57-3.65 (m, 1H, H-9), 4.23 
(dd, 1H, H-5a, J = 15.0 Hz, 6.0 Hz), 4.30 (dd, 1H, H-5b, 2H, H-5, J = 15.0 Hz, 6.0 Hz), 
5.60 (dt, 1H, H-6, J = 15.5 Hz, 6.0 Hz), 5.76 (dt, 1H, H-7, J = 15.5 Hz, 7.5 Hz), 7.71 (dd, 
2H, H-1, J = 5.5 Hz, 3.0 Hz), 7.84 (dd, 2H, H-2, J = 5.5 Hz, 3.0 Hz); δC (CDCl3, 75 MHz): 
14.2 (C-17), 22.8 (C-16), 25.8 (C-12), 29.4 (C-14), 29.7 (C-13), 31.9 (C-15), 36.9 (C-11), 
39.8 (C-5), 40.4 (C-8), 70.8 (C-9), 123.4 (C-2), 126.8 (C-6), 131.3 (C-7), 132.3 (C-3), 













Compound (S)-95 was synthesised from (S)-94, following the procedure described for 
(R)-95. Yield: 292 mg, 95 %. NMR and LRMS data are consistent with those for (R)-95. 
 




To a solution of (R,E)-2-(5-hydroxydodec-2-en-1-yl)isoindoline-1,3-dione 95 (37.0 mg, 
112 µmol, 1.0 eq.) in EtOH (2 mL) was added 40 % aq. MeNH2 (150 µL, excess) and the 
solution stirred at room temperature for 2 h. The reaction was quenched with H2O (2 mL), 
basified with 1 M NaOH (pH > 10) and the product extracted with Et2O (3 × 10 mL). The 
combined organics were washed with H2O (20 mL) and brine (20 mL), dried over 
anhydrous MgSO4 and concentrated under reduced pressure to afford (R)-84 as a white 
solid (21.2 mg, 95 %). 
 
m.p.: 53-56°C; δH (MeOD, 300 MHz): 0.83 (t, 3H, H-14, J = 6.5 Hz), 1.17-1.45 (m, 12H, 
H-8–13), 2.02-2.22 (m, 2H, H-5), 3.15-3.21 (m, 2H, H-2), 3.45-3.46 (m, 1H, H-6), 
5.47-5.77 (m, 2H, H-3–4); δC (MeOD, 75 MHz): 14.5 (C-14), 23.7 (C-13), 26.8 (C-9), 
30.5 (C-11), 30.8 (C-10), 33.0 (C-12), 37.8 (C-8), 41.4 (C-5), 44.0 (C-2), 72.2 (C-6), 
130.1 (C-4), 132.1 (C-3); HRMS: Calculated for [M+H]+ 200.2009, found 200.2014. 
 








Compound (S)-84 was synthesised from (S)-95, following the procedure described for 
(R)-84. Yield: 31.1 mg, 99 %. NMR and LRMS data are consistent with those for (R)-84. 
 




To a stirred solution of (R)-95 (180 mg, 516 mol, 1.0 eq.) in MeOH (2.1 mL) was added 
10 % Pd/C (60.0 mg). The flask was purged with H2 × 5 (1 atm) and stirred at room 
temperature for 5 h. The catalyst was removed by filtration through celite, the solvent 
evaporated and the crude material purified by silica gel chromatography (1 : 3 EtOAc : 
pet. ether) to afford (R)-98 as a white solid (112 mg, 62 %). 
 
m.p.: 62-63 °C; δH (CDCl3, 300 MHz): 0.87 (t, 3H, H-17, J = 7.0 Hz), 1.20-1.57 (m, 16H, 
H-7–8, H-11–16), 1.63-1.77 (m, 2H, H-6), 3.53-3.61 (m, 1H, H-9), 3.69 (t, 2H, H-5, 
J = 7.0 Hz), 7.70 (dd, 2H, H-1, J = 5.0 Hz, 3.0 Hz), 7.84 (dd, 2H, H-2, J = 5.0 Hz, 3.0 
Hz); δC (CDCl3, 75 MHz): 14.2 (C-17), 22.8 (C-16), 23.0 (C-7), 25.8 (C-12), 28.7 (C-6), 
29.4 (C-14), 29.8 (C-13), 32.0 (C-15), 37.0 (C-8), 37.7 (C-11), 38.0 (C-5), 71.8 (C-9), 
123.3 (C-2), 132.3 (C-3), 134.0 (C-1), 168.6 (C-4); HRMS: Calculated for [M+Na]+ 
354.2040, found 354.2043. 
 




Compound (S)-98 was synthesised from (S)-95, following the procedure described for 
(R)-98. Yield: 97.8 mg, 57 %. NMR and LRMS data are consistent with those for (R)-98. 
 
 








To a solution of (R)-2-(5-hydroxydodecyl)isoindoline-1,3-dione 98 (55.0 mg, 166 µmol, 
1.0 eq.) in EtOH (2.8 mL) was added 40 % aq. MeNH2 (223 µL, excess) and the solution 
stirred at room temperature for 3 h. The reaction was quenched with H2O (2 mL), basified 
with 1 M NaOH (pH > 10) and the product extracted with EtOAc (3 × 10 mL). The 
combined organics were washed with H2O (20 mL) and brine (20 mL), dried over 
anhydrous MgSO4 and concentrated under reduced pressure to afford (R)-60 as a white 
solid (30.2 mg, 90 %). 7 mg was purified by analytical HPLC (table 5.10, elution 
time = 8.8 min) for accurate determination of the enantioselectivity of CpkH. 
 
m.p.: 82-85 °C; δH (MeOD, 500 MHz): 0.90 (t, 3H, H-14, J = 7.0 Hz), 1.24-1.39 (m, 10H, 
H-9–13), 1.40-1.59 (m, 8H, H-3–5, H-8), 1.60-1.73 (m, 2H, H-3), 2.92 (t, 2H, H-2, 
J = 7.5 Hz), 3.50-3.56 (m, 1H, H-6); δC (MeOD, 125 MHz): 14.4 (C-14), 23.7 (C-4), 23.7 
(C-13), 26.8 (C-9), 28.7 (C-3), 30.5 (C-11), 30.8 (C-10), 33.0 (C-12), 37.6 (C-5), 38.6 
(C-8), 40.7 (C-2), 72.1 (C-6); HRMS: Calculated for [M+H]+ 202.2165, found 202.2170. 
 




Compound (S)-60 was synthesised from (S)-98, following the procedure described for 

















To a solution of (R,E)-2-(5-hydroxydodec-2-en-1-yl)isoindoline-1,3-dione 95 (20.0 mg, 
60.7 µmol, 1.0 eq.) in DCM (600 µL) was added a solution of (R)-(+)-α-methoxy-α-
trifluoromethylphenylacetic acid (MTPA) (15.6 mg, 66.8 µmol, 1.1 eq.) in DCM 
(200 µL), followed by EDC (12.8 mg, 66.8 µmol, 1.1 eq.) and DMAP (820 µg, 6.07 µmol, 
0.1 eq.). The reaction was stirred at room temperature for 16 h, at which time 2 M HCl 
(1 mL) and H2O (10 mL) were added. The layers were separated and the aqueous 
extracted with DCM (2 × 10 mL). The combined organics were dried over anhydrous 
MgSO4, concentrated under reduced pressure and the crude residue purified by silica gel 
chromatography (1 : 3 EtOAc : pet. ether) to afford (R,R)-96 as a colourless oil (18.0 mg, 
54 %). 
 
δH (CDCl3, 500 MHz): 0.86 (t, 3H, H-24, J = 7.0 Hz), 1.07-1.31 (m, 10H, H-19–23), 
1.47-1.60 (m, 2H, H-18), 2.37 (t, 2H, H-8, J = 6.0 Hz), 3.51 (s, 3H, H-13), 4.23 (d, 2H, 
H-5, J = 5.5 Hz), 5.09 (quint, 1H, H-9, J = 6.0 Hz), 5.61 (dt, 1H, H-6, J = 15.5 Hz, 6.0 Hz), 
5.67 (dt, 1H, H-7, J = 15.5 Hz, 6.5 Hz), 7.37-7.41 (m, 3H, H-15, H-17), 7.49-7.54 (m, 
2H, H-16), 7.71 (dd, 2H, H-1, J = 5.5 Hz, 3.0 Hz), 7.84 (dd, 2H, H-2, J = 5.5 Hz, 3.0 Hz); 
δC (CDCl3, 125 MHz): 14.2 (C-24), 22.7 (C-23), 24.9 (C-21), 29.2 (C-20), 29.3 (C-19), 
31.8 (C-22), 33.3 (C-18), 36.8 (C-8), 39.4 (C-5), 55.6 (C-13), 76.5 (C-9), 84.7 (C-11), 
123.4 (C-2), 124.6 (C-12), 127.3 (C-6), 127.4 (C-16), 128.5 (C-15), 129.2 (C-17), 129.7 
(C-7), 132.3 (C-14), 132.5 (C-3), 134.1 (C-1), 166.3 (C-10), 168.0 (C-4); HRMS: 
Calculated for [M+Na]+ 568.2281, found 568.2286. 
 









Compound (R,S)-96 was synthesised from (R)-95 and (S)-(−)-MTPA, following the 
procedure described for the synthesis of (R,R)-96. Yield: 16.8 mg, 51 %. 
 
δH (CDCl3, 500 MHz): 0.87 (t, 3H, H-24, J = 7.0 Hz), 1.16-1.35 (m, 10H, H-19–23), 
1.50-1.66 (m, 2H, H-18), 2.31 (t, 2H, H-8, J = 6.0 Hz), 3.51 (s, 3H, H-13), 4.16 (d, 2H, 
H-5, J = 5.0 Hz), 5.09 (quint, 1H, H-9, J = 6.0 Hz), 5.50 (dt, 1H, H-6, J = 15.5 Hz, 5.5 Hz), 
5.57 (dt, 1H, H-7, J = 15.5 Hz, 6.5 Hz), 7.30-7.34 (m, 3H, H-15, H-17), 7.42-7.46 (m, 
2H, H-16), 7.64 (m, 2H, H-1, J = 5.5 Hz, 3.0 Hz), 7.77 (dd, 2H, H-2, J = 5.5 Hz, 3.0 Hz); 
δC (CDCl3, 125 MHz): 14.2 (C-24), 22.7 (C-23), 25.3 (C-21), 29.2 (C-20), 29.4 (C-19), 
31.8 (C-22), 33.3 (C-18), 36.4 (C-8), 39.4 (C-5), 55.6 (C-13), 76.6 (C-9), 84.7 (C-11), 
123.4 (C-2), 127.2 (C-6), 127.5 (C-16), 128.5 (C-15), 128.9 (C-17), 129.7 (C-7), 132.3 
(C-14), 132.5 (C-3), 134.1 (C-1), 166.3 (C-10), 168.0 (C-4); HRMS: Calculated for 











Compound (S,R)-96 was synthesised from (S)-95 and (R)-(+)-MTPA, following the 
procedure described for the synthesis of (R,R)-96. Yield: 21.4 mg, 65 %. NMR and LRMS 







Compound (S,S)-96 was synthesised from (S)-95 and (S)-(−)-MTPA, following the 
procedure described for the synthesis of (R,R)-96. Yield: 20.5 mg, 62 %. NMR and LRMS 
data are consistent with those for (R,R)-96. 
 
5.6.5 Synthesis of CpkD substrate 
 




To a stirred suspension of NaH (75.2 mg, 3.13 mmol, 1.2 eq.) in anhydrous THF (5 mL) 
at 0 °C under argon was added triethyl-4-phosphonoacetate (621 µL, 3.13 mmol, 1.2 eq.), 
dropwise. The mixture was stirred for 1 h, at which time a solution of trans,trans-2,4-
hexadienal 100 (288 µL, 2.61 mmol, 1 eq.) in THF (2.5 mL) was added dropwise. The 
reaction was allowed to warm to room temperature and stirred until completion. The 
reaction was then quenched with sat. aq. NH4Cl (10 mL) and the aqueous phase extracted 
with Et2O (3 × 15 mL). The combined organics were washed with H2O (10 mL), brine 
(10 mL) and dried over anhydrous MgSO4. The solvent was removed under reduced 




pressure and the crude residue purified by silica gel chromatography (1 : 9 EtOAc : pet. 
ether) to afford 99 as a white solid (312 mg, 72 %).  
 
Note: compound exists as mixture of geometric isomers (E:Z ≈ 9:1) and m.p. not obtained 
due to polymerisation; δH (CDCl3, 300 MHz): 1.21 (t, 3H, H-1, J = 7.0 Hz), 1.75 (d, 3H, 
H-10, J = 7.0 Hz), 4.12 (q, 2H, H-2, J = 7.0 Hz), 5.76 (d, 1H, H-4, J = 15.5 Hz), 5.77-5.91 
(m, 1H, H-9), 6.00-6.16 (m, 2H, H-6, H-8), 6.45 (dd, 1H, H-7, J = 15.0 Hz, 10.5 Hz), 7.22 
(dd, 1H, H-5, J = 15.5 Hz, 11.5 Hz); δC (CDCl3, 75 MHz): 14.4 (C-1), 16.6 (C-10), 60.3 
(C-2), 120.2 (C-4), 127.7 (C-8), 131.3 (C-6), 135.1 (C-7), 141.1 (C-8), 144.9 (C-5), 167.3 
(C-3); HRMS: Calculated for [M+Na]+ 189.0886; found 189.0888. Data are consistent 
with those reported by Goodreid and coworkers.223  
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Appendix 1  
 
Table 7.1: Proposed functions of proteins encoded within the coelimycin biosynthetic gene cluster in 
Streptomyces coelicolor A3(2).30 Open reading frames (ORFs) are coloured as follows. Red: PKS 




CDS number Proposed function 
ScbC SCO6264 Ketoreductase involved in SCB1 biosynthesis 
ScbR SCO6265 Butyrolactone-responsive repressor protein 
ScbA SCO6266 Butenolide synthase involved in SCB1 biosynthesis 
ScbB SCO6267 Oxidoreductase involved in SCB1 biosynthesis 
CpkM SCO6268 Two-component system histidine kinase 
CpkPβ SCO6269 α-Ketoacid-dependent ferredoxin reductase β-subunit 
CpkPα SCO6270 α-Ketoacid-dependent ferredoxin reductase α-subunit 
AccA1 SCO6271 Acyl-CoA carboxylase α-subunit (biotinylated) 
ScF SCO6272 Secreted flavin-dependent epoxidase/dehydrogenase 
CpkC SCO6273 Polyketide synthase module 5 
CpkB SCO6274 Polyketide synthase modules 3 and 4 
CpkA SCO6275 Polyketide synthase loading module, and modules 1 and 2 
CpkD SCO6276 Flavin-dependent epoxidase/dehydrogenase 
CpkE SCO6277 Isomerase? (α, β-hydrolase fold) 
CpkF SCO6278 Transmembrane efflux protein 
CpkG SCO6279 PLP-dependent ω-transaminase 
CpkO SCO6280 SARP-family transcriptional activator 
CpkH SCO6281 Secreted flavin-dependent epoxidase/dehydrogenase 
CpkI SCO6282 Nicotinamide-dependent dehydrogenase 
CpkJ SCO6283 NmrA-family protein (unknown function) 
CpkK SCO6284 Acyl-CoA carboxylase β-subunit 
CpkL SCO6285 Hypothetical protein (unknown function) 
ScbR2 SCO6286 Repressor protein 
ScoT SCO6287 Type II thioesterase 
CpkN SCO6288 SARP-family transcriptional activator 






Procedures for acquiring X-Ray diffraction data from CpkG crystals, performed by Dr. 
Lona Alkhalaf: 
 
Single crystals of CpkG (PACT premierTM, position F12: 0.2 M sodium malonate dibasic 
monohydrate, 0.1 M bis-tris propane, 20 % w/v PEG 3350, pH 6.5), CpkG_ala and 
Cpk_ala_lactol (0.2 M sodium malonate dibasic monohydrate, 0.15 M bis-tris propane, 
20 % w/v PEG, pH 6.5) were selected and flash frozen in liquid N2. All X-ray 
data sets were collected at 100 K at the microfocus beam line I24 at the Diamond Light 
Source, U.K. All data handling was carried out using the CCP4 software package224. Data 
were indexed, integrated and scaled using mosflm225 and aimless226. The apo structure 
was solved by molecular replacement using the coordinates of 5dds135 using Phaser227 
and refined using alternate cycles of manual refitting using COOT228 and 
REFMAC229. Water molecules were added to the atomic model automatically at the 
positions of large positive peaks in the difference electron density, only at places where 
the resulting water molecule fell into an appropriate hydrogen bonding 
environment. CpkG_ala and CpkG_ala_lactol were then solved by molecular 
replacement using the structure of CpkG and refined similarly. The polypeptide chain 
could be unambiguously traced in all structures between residues 16 and 523. Data 
collection and refinement statistics are presented in table 7.2. 
 
 






Table 7.2: Statistics from data collection and refinement of crystal structures of CpkG, CpkG_ala and 
Cpk_ala_lactol 
 CpkG CpkG_ala CpkG_ala_lactol 
 
Data collection    
Space group P21 21 21 P21 21 21 P21 21 21 
Cell dimensions    
a, b, c (Å) 84.69, 115.10, 126.04 84.30, 114.48, 124.8 84.62, 113.67, 123.99 
() 90, 90, 90 90, 90, 90 90, 90, 90 
Wavelength 0.9763 0.9762 0.9762 
Resolution (Å) 2.85 2.60 2.60 
Rpim 0.092 (0.240) 0.100 (0.487) 0.066 (0.237) 
I / I 7.6 (3.4) 10.3 (4.1) 12.7(6.0) 
Completeness (%) 98.0 (98.5) 100 (100) 99.6 (99.5) 
Redundancy 6.8 (6.6) 12.1 (12.5) 11.5 (11.9) 
Refinement    
Resolution (Å) 2.85 2.60 2.60 
No. reflections 28761 37891 37338 
Rwork / Rfree 0.224 / 0.288 0.192 / 0.253 0.197 / 0.259 
No. atoms    
Protein 7432 7734 7708 
Ligand/ion 32 32 - 
Water 2 125 139 
B-factors    
Protein 45.4 37.5 37.8 
Ligand/ion 55.3 40.6 - 
Water 25.3 36.6 30.0 
R.m.s deviations    
Bond lengths (Å) 0.011 0.013 0.012 
Bond angles () 1.7 1.8 1.7 






Proposed biosyntheses of (A) cyclizidine 39; (B) nigrifactin 36 and streptazone E 42; (C) 
pyrindicin 37; (D) latumcidin 35; and (E) streptazolin 38, from predicted polyketide 
aldehyde intermediates. [O] = Dehydrogenase or oxygenase; [R] = reductase; ω-TA = 
ω-transaminase; isom. = isomerase; cyc. = cyclase. Pathways are based on those provided 
by Ohno, Huang, Peng and their respective coworkers.160,159,230  
 
 









Appendix 5  
 
Table 7.3: Proposed functions of proteins encoded within the putative polyketide alkaloid biosynthetic gene 
cluster in Streptomyces cyaneofuscatus NRRL B-2570. Closest protein homologues are displayed with 
sequence identities given in brackets. Open reading frames (ORFs) are coloured as follows. Red: PKS 
component; blue: post-PKS tailoring; and green: regulatory. 
ORF 
 
Closest protein homologue Proposed function 
IF17_ 
RS0112370 
MerR family transcriptional regulator from 
Streptomyces sp. IB2014 011-1 (99 %) 




PPOX class F420-dependent enzyme from 





Aspartate aminotransferase family protein from 




Polyketide synthase from Streptomyces sp. IB2014 
011-1 (99 %) 
PKS loading module, and 
modules 1 and 2 
IF17_ 
RS0112390 
Polyketide synthase from Streptomyces sp. IB2014 
011-1 (99 %) 
PKS module 3 
IF17_ 
RS0112395 
Polyketide synthase from Streptomyces sp. IB2014 
011-1 (99 %) 
PKS module 4 
IF17_ 
RS0112400 
FAD-binding monooxygenase from Streptomyces sp. 





NAD(P)-dependent oxidoreductase from 





Hypothetical protein from Streptomyces sp. IB2014 
011-1 (99 %); hydrolase from Streptomyces sp. 




HTH-type transcriptional regulator CdhR from 




6-Phosphogluconate dehydrogenase from 




Pseudooxynicotine oxidase from Streptomyces sp. 





Cytochrome P450 from Streptomyces sp. IB2014 




Transcriptional regulator from Streptomyces sp. 











Procedures and data for the whole genome sequencing, assembly and annotation of 
Streptomyces abikoensis DSM 40831, performed by Dr. Emmanuel de los Santos: 
 
Genomic DNA was extracted and purified from Streptomyces abikoensis DSM 40831 
using the phenol-chloroform method. It was used to construct a PacBio library that was 
sequenced on two SMRT cells of a PacBio RSII machine using C4-C6 chemistry. 1-15 kb 
reads were assembled using HGAP3 and PacBio SMRT analysis software, to generate a 
single contig consisting of 7519709 bp, with a GC content of 72.16 %. PROKKA and 
antiSMASH version 4.0 were used for genome annotation and mining, respectively. The 











Table 7.4: Proposed functions of proteins encoded within the putative latumcidin biosynthetic gene cluster 
in Streptomyces abikoensis DSM 40831. Closest protein homologues and those from the coelimycin (cpk)30, 
streptazone E (stz)160 and cyclizidine (cyc)159 gene clusters are displayed. Sequence identities are shown in 
brackets. Open reading frames (ORFs) are coloured as follows. Red: PKS component; blue: post-PKS 
tailoring; green: regulatory; purple: precursor supply; and grey: hypothetical/unknown function. 









Abik_03606 Acyl-CoA dehydrogenase from 









dehydrogenase from Streptomyces 
sp. CNS615 (69 %) 
Short-chain 
dehydrogenase 
- StzI  
(45 %) 
- 
Abik_03608 Mycothiol maleyl pyruvate 
isomerase from Streptomyces sp. 




- - - 
Abik_03609 Transcriptional regulator AfsR 
from Streptomyces sp. IB2014 











transferase from Streptomyces 







Abik_03611 Flavin reductase domain-
containing FMN-binding protein 
from Catenulispora acidiphila 
(55 %) 




Abik_03612 Transposase from Streptomyces sp. 
TLI_105 (50 %) 
Transposase? - - - 
Abik_03613 TetR family transcriptional 
regulator from Streptomyces 







Abik_03614 Hypothetical protein from 












Abik_03615 Short-chain dehydrogenase from 







Abik_03616 Thioester reductase-domain 
containing protein from 
Streptomyces sp. 2114.2 (65 %) 






Abik_03617 Polyketide synthase from 
Streptomyces coelicolor (58 %) 






Abik_03618 Polyketide synthase from 
Streptomyces lushanensis (68 %) 
PKS loading 
module, and 







Abik_03619 Hydrolase from Streptomyces 
griseus (79 %) 




Abik_03620 Monoamine oxidase from 
Streptomyces alboviridis (64 %) 
Monooxygenase - StzK 
(41 %) 
- 
Abik_03621 Hypothetical protein from 
Streptomyces sp. NRRL F-5140 
(75 %) 
Cyclase - StzF  
(52 %) 
- 
Abik_03622 Transcriptional regulator from 
Longispora albida (62 %) 
Transcriptional 
regulator 
- - - 
Abik_03623 Hypothetical protein from 









Abik_03624 Class III aminotransferase from 









Abik_03625 Oleoyl-ACP hydrolase from 








Abik_03626 Hypothetical protein from 
Streptomyces sp. MP131-18 
(53 %) 
Repressor protein ScbR2 
(33 %) 
- - 
Abik_03627 Two-component system histidine 









carboxylase subunit α from 














Procedures and data for the confirmation of latumcidin 35 production in Streptomyces 
abikoensis DSM 40831, performed by Dr. Yousef Dashti and Dr. Daniel Zabala: 
 
ISP2 agar was inoculated with Streptomyces abikoensis DSM 40831 spore stock solution 
(15 µL) and incubated at 30 ºC for 7 days. Metabolites were then extracted with EtOAc 
and redissolved in acetonitrile as described in sections 5.3.6.1 and 5.3.6.3. The samples 
were analysed by high-resolution LC-MS according to the elution profile in table 7.5, and 
the absorbance monitored at 210 and 254 nm. 
 
Table 7.5: Elution conditions used for LC-MS detection of latumcidin 35  
Time / min H2O / %     
 (0.1 % FA) 
Acetonitrile / %  
(0.1 % FA) 
Flow rate / mL/min 
0.0 95 5 0.2 
5.3 95 5 0.2 
17.3 0 100 0.2 
22.3 0 100 0.2 
25.3 95 5 0.2 
33.3 95 5 0.2 
 
 
Figure 7.1: Extracted ion chromatogram at m/z = 162.0913 ± 0.05 (corresponding to the [M+H]+ ion for 
latumcidin 35). The calculated molecular formula (C10H12NO+) is also consistent with that of latumcidin.   
 






MS/MS data and calculated molecular formulae arising from the fragmentation of ions at 
m/z = 324 (top; corresponding to the NAC-derivatised mono-epoxide) and m/z = 340 
(bottom; corresponding to the NAC-derivatised bis-epoxide), following incubation of 
triene ester 99 with His6-CpkD, FMN, NAC and NADH. Performed by Dr. Lijiang Song. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
